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ABSTRACT
TOBACCO SMOKE EXPOSURES AND FERTILITY-RELATED OUTCOMES
AMONG FEMALES SEEKING FERTILITY CARE, AND INTERACTION WITH NACETYLTRANSFERASE 2 (NAT2)
T’shura Ali
April 16th, 2020

Cigarette smoke contains thousands of harmful substances and is one of the
leading preventable causes of mortality and morbidity in the United States. Past studies
examining tobacco smoke exposures on fecundability and pregnancy outcomes are
inconsistent. NAT2 is an important enzyme in the metabolism of xenobiotic substances
found within tobacco smoke. This preconception cohort study examines associations
between active smoking and secondhand smoke exposure (SHSe) on fecundability and
spontaneous abortion (SA), and explores a possible interaction with NAT2 acetylator
status.
A total of 223 women seeking fertility care were followed for up to 2.3 years.
Preconception tobacco smoke exposures were collected by questionnaires and verified by
urinary cotinine. SHSe at home and work was measured using the questionnaire (never,
rarely (once/week), often (1-6 times/week), daily for each location) and then combined
and categorized as low or high SHSe. NAT2 was genotyped to determine acetylator
status (rapid vs slow). Pregnancy outcomes (SA vs live birth) were collected on 72
women. Cox proportional hazards regression was used to estimate fecundability ratios
(FR) and 95% confidence intervals (CI), and logistic regression to estimate odds ratios
(OR) and 95% CIs for the association of active smoking and SHSe on fecundability and
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SA, respectively. Full models were adjusted for age, BMI, assisted conception, gravidity,
marital status, alcohol use and race.
Overall, no significant effect of tobacco smoke exposure on fecundability was
established. Though statistically insignificant, the effect of smoking on fecundability was
stronger among slow NAT2 acetylators. Smokers (OR: 6.28; 95% CI 1.31, 37.9) and
nonsmokers with high SHSe (OR: 3.20; 95% CI 0.87, 12.7) had increased odds of SA
(ptrend= 0.02), compared to nonsmokers with low SHSe. Among nonsmokers, women
with high SHSe had higher odds of SA (OR: 4.30; 95% CI 1.14, 19.1) than women to low
SHSe. No significant interaction with NAT2 was reported. Despite wide CIs, results
suggest that active smoking and high levels of SHSe may increase in the risk of SA
among women seeking fertility care. This dissertation has clinical implications for patient
care, and points to biological mechanisms by which tobacco smoke may affect fertility
and pregnancy outcomes.
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I. INTRODUCTION

Infertility is a growing health problem, in the United States (U.S.) and
worldwide. In the last 10 years, the U.S. has experienced increases in infertility and
impaired fecundity, along with a greater use of infertility services (1,2). Infertility is not
just the absence of children; it is classified as a disease of the reproductive system and
affects all aspects of health. The impact of infertility can start with undiagnosed health
conditions and lead to severe financial, and emotional and psychological burdens (3).
Infertility, defined as the inability to conceive after at least 12 months of trying,
can affect both men and women (3,4). Approximately one third of all infertility cases are
due to male factors and one third due to female factors; unexplained or “idiopathic”
infertility, as well as both male and female factors account for the last third (5). The
dissertation will focus primarily on female factors of infertility. There are several
etiologies/factors of female infertility and which are grouped into ovarian, tubal, uterine,
cervical and other factors such as autoimmune disorders (6).
Infertility treatment depends on the type of infertility diagnosis. Treatments can
range from education on changing lifestyle behaviors, to ovarian induction medications,
to assisted reproductive therapies (ART). Medically assisted reproduction (MAR) is the
term used for all therapies including ovulation induction (OI), intrauterine insemination
(IUI), and ART, which in itself includes in vitro fertilization (IVF) with or without
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intracytoplasmic sperm injection (ICSI). In the U.S., approximately 1.7% of all infants
born in 2017 were conceived through ART services (7). While infertility and the use of
MAR services are increasing, the risk of adverse pregnancy outcomes has been shown to
be higher among assisted compared to natural conceptions. Several studies have found
significantly higher rates of spontaneous abortion (SA) among ART-assisted conceptions,
compared to the general population (8).
There are also several important risk factors that have been associated with
infertility and/or SA. These include older age, genetic factors, menstrual cycle
irregularities, sexually transmitted infections, extreme (very high and very low) levels of
stress, extreme levels of body mass index (BMI), extreme levels of exercise, diet, heavy
caffeine use, heavy alcohol consumption and tobacco smoke exposure (9). Prior
pregnancy loss and certain medication use are included with the previous list as risk
factors for SA (10).
Tobacco smoke exposure is one of the leading preventable causes of mortality and
morbidity in the U.S. and has been found to be associated with longer time to conception,
lower conception rates, and adverse pregnancy outcomes such as SA (11). While the U.S.
Surgeon General report supported the association of active, current smoking on
conception, it stated that there was less evidence of an association among women using
MAR. The report also stated that there was suggestive but insufficient evidence to infer
an association between current smoking and SA (12). In addition, studies examining the
effect of secondhand smoke exposures on fertility and fertility-related outcomes are
inconclusive and inconsistent. Many studies are subject to bias because of their
retrospective design and reliance on self-reported information about smoking. In addition,
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the majority of studies did not take all potential confounding factors into account. Finally,
almost no studies explored possible gene-environmental interactions.
N-acetyltransferase 2 is an enzyme used in the metabolism and detoxification of
xenobiotic substances, including therapeutic drugs and exogenous chemicals such as the
ones found in tobacco smoke (13). Genetic variation in the NAT2 gene results in
different levels of acetylation, commonly grouped into rapid and slow acetylation
phenotypes. NAT2 acetylator status may modify the metabolism of environmental toxins
and therapeutic medicines. NAT2 acetylator status has also been associated with
differences in cancer risk and may modify the effect of smoking on some cancers (14).
Few studies have explored how NAT2 can modify the association of smoking and
fertility. To date, only one study has found a significant interaction between NAT2 and
smoking on female fertility (15), while two studies on idiopathic male infertility showed
contradictory results (16,17). These studies have emphasized the importance of further
exploring gene-environmental interactions on fertility outcomes.
This dissertation explores the effects of active and secondhand tobacco smoke
exposures on fertility-related outcomes and examines the interaction of NAT2 with
tobacco smoke exposure among women seeking fertility counselling and treatment.
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II. OBJECTIVE, SPECIFIC AIMS AND HYPOTHESES

The primary objective of the study was to assess the effect of active smoking (current
and lifetime), secondhand smoke exposure (recent and in the past year) and the combined
effect of both exposures on fecundability and probability of spontaneous abortion. Effect
modification by NAT2 acetylator status on conception and spontaneous abortion was also
examined. The potential for selection bias due to loss to follow-up was investigated.
Analyses were done using (1) all women and their follow-up time, whether or not they
used medically assisted reproduction (MAR); (2) MAR treatment cycles only; and (3) all
other follow-up time, which is termed natural conception (NC) follow-up time, for the
purposes of this dissertation. The populations are not mutually exclusive.
The specific aims of the study are as follows:

Specific Aim 1: Examine the association between tobacco smoke exposures (active and
passive) and fecundability after fertility counselling among three populations: all followup time; medically assisted reproduction (MAR) cycles; and natural conception (NC)
follow-up time.

a.

Examine the effect of active smoking (current and lifetime) on
fecundability for all populations. Hypothesis: Active smoking (current and
lifetime) is associated with reduced fecundability.
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b.

Examine the effect of secondhand smoke exposure (recent and in the
past year) on fecundability for all populations. Hypothesis: Secondhand
smoke exposure (recent and past year) is associated with reduced
fecundability.

c.

Examine the combined effect of active smoking with secondhand
smoke exposure on fecundability for all populations. Hypothesis: There is
a dose-response relationship, in that smokers will have the lowest
fecundability, and non-smokers with high SHS exposure will have reduced
fecundability when compared with non-smokers with low SHS exposure.

d.

Examine the interaction of active smoking with NAT2 acetylator status
for the measures estimated in aims 1a above. Hypothesis: There is a
synergistic effect between active smoking and slow acetylation status, such
that active smokers who are also slow acetylators will have markedly
reduced fecundability.

Specific Aim 2: Examine the association between tobacco smoke exposures (active and
passive) and pregnancy outcomes among individuals who conceived, after fertility
counseling.

a.

Examine the effect of active smoking (current and lifetime) on pregnancy
outcomes (spontaneous abortion vs live birth) among all conceptions.
Hypothesis: Active smoking is associated with higher probability of
spontaneous abortion.
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b.

Examine the effect of secondhand smoke exposure (recent and in the
past year) on pregnancy outcomes (spontaneous abortion vs live birth)
among all conceptions. Hypothesis: Higher exposure to secondhand
smoke exposure (recent and in the past year) is associated with a higher
probability of spontaneous abortion.

c.

Examine the combined effect of active smoking with secondhand
smoke exposure on pregnancy outcomes (miscarriage vs live birth) after
fertility counseling. Hypothesis: There is a dose-response relationship, in
that smokers will have the highest probability of spontaneous abortion;
non-smokers with high SHS exposure will have intermediate probability;
and non-smokers with low SHS exposure will have the lowest probability
of spontaneous abortion.

d.

Examine the interaction of active smoking with NAT2 acetylator status
for the measures estimated in aims 2a and 2b, above. Hypothesis: Active
smokers who are also slow acetylators will have a markedly increased
probability of spontaneous abortion (higher than expected when
examining each risk factor alone).

Specific Aim 3: Evaluate the potential for selection bias due to loss to follow-up in the
LOUSSI Study.
a.

Evaluate the potential for selection bias due to loss to follow-up by
comparing characteristics of participants lost to follow-up to participants

6

with complete follow-up. Hypothesis: Characteristics of those lost to
follow-up are similar to those with complete follow-up.
b.

If there is evidence for selection bias due to loss to follow-up, apply
inverse probability weighting to adjust for selection bias. Hypothesis:
If there is no selection bias due to loss to follow-up, there will be no
differences in the odds/hazard ratio estimates when compared to the initial
analysis.
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III. BACKGROUND AND LITERATURE REVIEW

SECTION A - Infertility

The World Health Organization’s International Committee for Monitoring
Assisted Reproductive Technologies (WHO-ICMART), along with the Center for
Disease Control and Prevention (CDC) describes infertility as a disease of the
reproductive system defined by the inability to attain a clinical pregnancy after 12 months
of regular, unprotected sexual intercourse or due to an impairment of a person's capacity
to reproduce either as an individual or with his/her partner (3,4). Other fertility-related
terms include subfertility, sterility, fecundity, impaired fecundity and fecundability. Most
are used interchangeably, hence the need for more formal and universal definitions to
accurately compare studies.
In 2017, WHO-ICMART revised and expanded their 2009 edition of the
International Glossary on Infertility and Fertility Care, from 87 to 283 terminologies (4).
They define fertility as the capacity to establish a clinical pregnancy, sterility as a
permanent state of infertility and state that subfertility should be used interchangeably
with infertility. However, one article defined subfertility as any form of reduced fertility
in couples unsuccessfully trying to get pregnant, not specifying a time period (18).
Fecundity, on the other hand, is not just the capacity to conceive, but to also carry the
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pregnancy to term, which is also known as the reproductive potential (19). The CDC
states that infertility is specific only to married couples and deals only with issues getting
pregnant; whereas impaired fecundity refers generally to all women regardless of marital
or relationship status, and deals with problems with getting pregnant and carrying a baby
to term (19). Time to pregnancy or conception (TTC) is the number of months or
menstrual cycles taken to establish a pregnancy and fecundability is the probability of
conception per month or menstrual cycle (4).
Infertility is commonly classified into two main groups: primary infertility and
secondary infertility, which can then be sub-divided by gender. Firstly, primary infertility
for females is diagnosed if there has not been a clinical pregnancy and the infertility
criteria is met. For males, primary infertility is defined when there was never initiation of
a clinical pregnancy and by the infertility criteria (3). Female secondary infertility is
defined by the inability to establish a clinical pregnancy following a previous pregnancy
and similarly, male secondary infertility is the inability to initiate a clinical pregnancy
after successfully initiating one before (4).
The highest probability of conception among the general population occurs 2 days
before ovulation of the first cycle of intercourse without contraception use and is
approximately 30% (20). This probability decreases slightly over time/cycles; one article
showed that the cumulative probability of conceiving within the first three cycles of
unprotected intercourse is around 30%, then 75% within six cycles and almost 90%
within 12 months (20). Highly fertile couples will conceive in the first cycles of attempt
and others will still naturally conceive even after 12 months (20).
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Epidemiology
Infertility is known to be a global public health issue; however, global prevalence
rates are very difficult and tedious to calculate due to the inconsistency within the
literature. Studies use different definitions, for example the length of time actively trying
to conceive using either 12 months, 24 months or 5 years. Also, the population included
in the definition varies from including females, couples, individuals or married women.
The lack of population-based studies and differences in definition and methodologies
adds to the difficulty in estimating and comparing global infertility rates (21). However,
in 2010 the WHO published a study on global infertility trends using 277 surveys from
190 different countries.
The prevalence of primary infertility among women aged 20 to 44 years was
calculated at 1.9%; and secondary infertility, which was defined inability to have a
second live birth, was calculated at 10.5% (22). They defined infertility as the inability to
have a live birth over a 5-year period and was based on marriage/union status, desire for
child and no contraception use. Worldwide, a small decrease from 1990 to 2010 in
primary infertility (1.6% to 1.5%) and in secondary infertility (3.9% to 3.0%) was
reported. The absolute number of couples impacted by infertility, though has increased
from 42 million in 1990, to 48.5 million in 2010 due to accelerated population growth
(22). The WHO stated that there was a significant increase to 121 million when the
infertility time period was cut down to 2 years instead of 5. The overall global prevalence
of infertility was calculated to range from 8% to 12% of couples (22). It was also noted
that developing regions and countries such as sub-Saharan Africa, the Middle East, North
Africa, South Asia, Central and South Asia, and Eastern Europe experienced

10

disproportionately higher infertility rates up to 30% (21). This may be due to higher
secondary infertility rates which can result from infections from unsafe abortions and
poor post-partum or maternity care (21). The global infertility prevalence from this study
and other studies that definition of infertility only include married women are highly
underestimated.
Recently in December 2019, authors published estimates of the global burden of
infertility, using results from a 2017 global burden of disease study among 195 countries.
They found that worldwide, there had been a 0.37% increase annually in agestandardized infertility prevalence rates for females and a slightly lower increase, 0.29%
for males (23). These increases were maintained over all sociodemographic index
countries.
In the U.S., the National Center for Health Statistics used data from National
Survey of Family Growth (NSFG) and showed that percentages of married women aged
15 to 44 years with infertility were 7.4%, 6.0%, 6.7% and 8.8 % in 2002, 2006-2010,
2011-2015 and 2015-2017, respectively (1,2). This increasing trend was retained after
women were categorized into four age groups (15-29, 30-34, 35-39, 40-44) (1,2). A
similar trend for impaired fecundity, which takes into account all women into account
regardless of their marital status showed 11.8%, 10.9%, 12.1% and 13.1 % in 2002,
2006-2010, 2011-2015 and 2015-2017, respectively (1,2). A similar increasing trend was
shown with age. In 2013, one study estimated the prevalence of couple infertility from a
male’s perspective using the 2002 NSFG data. Males estimated the prevalence of
couple’s infertility at 12.0% (95% CI: 7.0, 23.2), which was found to be consistent with
female reporting in prospective cohort studies (24).
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Women and men can both endure emotional and psychological stress such as
depression, discrimination and ostracism when dealing with infertility (21,22). The
impact of infertility is all encompassing, ranging from the unexpected medical diagnoses
to the financial burden of medical services and health disparities to access of care.
Infertility has also been shown to be associated with adverse pregnancy outcomes, which
can consequently affect the onset of adult diseases later in life and quality of life for the
individuals (3).

Causes, Risk Factors and Biological Mechanisms
There are a number of well-defined risk factors that have been studied and found
to increase the odds of being infertile among women (9). These factors can be nonmodifiable such as age (25–27), irregular menstrual cycles (28–31), and some genetic
factors (32–34). Then there are several modifiable lifestyle factors that can affect fertility
including diet (35–37), caffeine (38–40), alcohol consumption (29–31), body mass index
(41–43), exercise (41,43,44), sexually transmitted infections (45,46), and stress and
psychological state (47,48). Some of these important risk factors and causes, along with
their biological mechanisms are outlined below. Tobacco smoke specifically, and its
possible biological mechanisms on fertility are presented in the next section.
Conception is a result of a multistep process that has to meet every criteria to be
successful. Firstly, a woman must ovulate which means an egg is released from one of
her ovaries and travels along the fallopian tube to the site of fertilization. A man’s sperm
must also travel up the uterus to fertilize the egg. After successful fertilization, the
fertilized egg known as the zygote then travels down the fallopian tube to the uterus. The
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zygote will proliferate into an embryo, which develops into a blastocyte and will then
implant itself into the uterus lining. Disruptions at any stage can lead to infertility issues
(5).
Among all infertility cases, female factors account for approximately 35% and
male factors account for 35% (5,49). The majority of the remaining 30% of cases do not
meet the criteria for any known causes of infertility and are diagnosed with unexplained
infertility (5). Female infertility has several etiologies that can be grouped into categories:
ovulation dysfunction, tubal obstruction, uterine abnormalities, cervical factors and other
factors such as autoimmune disorders and genetic factors (6). The different
categorizations of etiologies also help to differentiate the specific type of infertility
diagnosis.

Ovulatory Dysfunction
Ovulatory dysfunction is one of the common causes of female infertility,
accounting for over 30% of cases (49). It can manifest in a variety of forms including
anovulation (absence of ovulation), oligoovulation (irregular ovulation), ovarian aging
and diminished ovarian reserve (DOR) (5). Ovarian reserve is the quantity and quality of
the oocytes within the ovaries and is highly correlated to reproductive potential (5). The
main causes of DOR are aging, obesity, cigarette smoking, genetic abnormalities (Fragile
X and other X chromosome abnormalities), aggressive treatments (radiation) and ovarian
surgery (for endometriosis). Other causes of DOR are unknown and are termed idiopathic
(50). Some women with low ovarian reserve may respond to ovarian stimulation with a
poor follicular development and may need more aggressive management; however, some
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women with higher ovarian reserve may experience ovarian hyperstimulation syndrome
(OHSS) that can also lead to adverse fertility outcomes (5,50). One retrospective cohort
study in 2015 showed a significant increase in DOR from 19% in 2004 to 26% in 2011
(51). However, few studies have reported that DOR is not an accurate predictor of poor
ovarian response (51).
Ovarian aging is a term used to describe the natural decline in the quantity and
quality of eggs due to normal aging (5,49). The biological mechanisms behind ovarian
aging are not fully understood, however, it is established that as the follicle pool
diminishes with age, the odds of chromosomal abnormalities increases (49). While
ovarian aging is a natural process, DOR can also affect younger women. Ovarian aging
and DOR are quantified through Antral Follicle Count (AFC) and different reproductive
hormones such as Follicle-Stimulating Hormone (FSH), Antimüllerian Hormone (AMH),
luteinizing hormone (LH) and estradiol (49). One prospective fecundability study showed
the percentage of infertility increased with woman’s age: 8% among 19 through 26-yearolds, 13%-14% for 27 through 34-year-olds and 18% among 35 through 39-year-olds
(26). Lower fecundability rates have also been seen among aging follicles with linear
decline in fecundability and increasing female age (27). Primary Ovary Insufficiency
(POI) is another disorder, where the ovaries stop producing hormones and releasing eggs,
and experience either anovulation or oligoovulation (52). It is a common condition that
increases with age and can induce premature or early menopause (53). One study showed
a 10-fold increase every decade for the prevalence of POI, from 0.01% among women
younger than 20 years to 0.1% in women under 30 years of age and 1% among women
younger than 40 years (54).
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Amenorrhea (absence of bleeding) and oligomenorrhea (irregular or extended
menstrual cycle bleeding) are also related factors in anovulation infertility (49). The
menstrual cycle includes several stages that prepare the body for conception.
Irregularities or disruption at any stage can lead to infertility. Two recent studies have
shown that any deviation from normal or the average menstrual cycle characteristics such
as longer or shorter menstrual cycle lengths, later or earlier onset of menarche and shorter
or longer bleeding duration have been associated with reduced fecundability (30,31).
Other diseases associated with anovulation include thyroid disease, and
hypothalamic and pituitary dysfunction which controls the production of hormones
(5,49). Functional hypothalamic amenorrhea (FHA) is one the most common causes of
secondary amenorrhea and is associated with chronic stress and psychiatric disorders like
depression (55). Studies done both in the general and infertile population have shown that
psychological distress including chronic stress have been shown to increase odds of
DOR, affect menstrual cycle characteristics, lower conception rates and increase adverse
pregnancy outcomes (47,48,56).

Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is the most common cause of anovulation and
affect 6 to 12% (~ 5 million) of reproductive aged women in the U.S. (57). Among
anovulatory infertility, PCOS accounts for 80% to 90% of cases (58). It is characterized
by oligomenorrhea, obesity, insulin-resistance and an overproduction of androgen, which
increases LH and lowers FSH. Hormonal imbalances have been shown to obstruct the
development and maturation of follicles and ovulation, leading to issues with fertility and
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fertility treatments (5). PCOS can also arise from endocrine, genetic, lifestyle and
environmental factors.
Anovulation infertility is commonly found in both overweight (BMI ≥ 30 kg/m2)
and severely underweight women (BMI < 17 kg/m2) (49). One case-control study
compared cases of anovulatory infertility to fertile controls and found that overweight
women had 3.1 times the odds of anovulatory infertility, and severely underweight
women also had increased odds compared to women with a normal BMI (59). Proper
diet, healthy exercise and weight loss management have been shown in studies to help
treat PCOS, increase fecundability and increase odds of natural conception by facilitating
spontaneous ovulation (49). However, a bad “fertility” diet from one study included
higher intake of trans fats and animal protein, lower intake of high-fiber, plant-based iron
and multivitamin use showed to increase the risk of anovulatory infertility (35,36). While
vigorous exercise can improve fertility among overweight and obese women, women
with normal BMI that exercise vigorously everyday including cycling, running and
swimming have increased odds of anovulatory infertility (43,60). Though the research
examining infertility and alcohol consumption is inconsistent and needs to be further
elucidated, heavy alcohol use has been shown to increase estrogen levels through a
decrease in FSH secretion which can then lead to ovulatory dysfunction (9,61).
Caffeine’s association with infertility is also not well-defined, with some studies showing
an increased risk for higher levels of consumption and others showing no association.
The biological mechanisms are unclear; however, some studies theorized that caffeine
may affect ovulation through disruptions in glucose metabolism and insulin production
(9,62,63).
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Structural Dysfunction
Structural or anatomical dysfunction within the fallopian tubes, uterus and cervix
can all obstruct the sperm from joining the egg, block transport of zygote to uterus and
impair implantation of embryo into the endometrium. Tubal factor infertility accounts for
the majority of the structural abnormalities, affecting approximately 30% of female
infertility cases (5,49). Some of the main causes of tubal disease include sexually
transmitted diseases (STD) such as untreated gonorrhea and chlamydia; which can lead to
pelvic inflammatory disease (PID), prior tubal or pelvic surgery, septic abortion and
appendicitis (5,49). One large study showed that women with tubal factor infertility had
higher odds of chlamydia trachomatis antibodies compared to infertile women who did
not have tubal blockage (46). Another study showed that a recurrent PID infection was
significantly associated with twice the odds of tubal infertility (45). In most developed
countries such as North America and Europe, infections affecting tubal infertility mostly
include chlamydia and PID, however, in developing countries like India and Nepal,
tuberculosis is the more common source of infection. Previous history of a ruptured
appendix was also significantly associated with tubal factor infertility, but not
appendicitis (64).
Congenital malformations, cervical trauma, chronic infections of the cervix and
surgical treatments such as loop electrosurgical excision (LEEP) procedure used for
human papillomavirus (HPV) associated cervical lesions can lead to cervical factor
infertility (5,65). Most of these factors impair fertility by affecting the quality and
quantity of cervical mucus (65). The cervical mucus helps to protect the sperm within the
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acidic environment of the vagina and improve motility to cervix (5). One meta-analysis
reviewed six clinical studies and found a significant association between high risk-HPV
infection and female infertility (66).

Uterine Abnormalities
Uterine factor infertility is the term used for abnormalities of the uterus that can
lead to infertility. It includes uterine fibroids, uterine polyps, uterine scarring or
adhesions and endometriosis (5,49). Uterine polyps are formed within the endometrial
lining and can impair the function of the uterus. They typically are noncancerous and can
regress over time. Fibroids, on the other hand, are made up of thick muscle tissue and are
more common, occurring in up to 60% of women. Higher rates of uterine fibroids are
found among older women and women of African American race (43). While most
women with fibroids can get pregnant, uterine fibroids contribute to 5 to 10% of all
female infertility cases (5). They can be found at various locations: within the uterus,
endometrium and around the cervix (67). The fibroids that grow within the uterine cavity
have the most potential to cause infertility by either obstructing the fallopian tubes,
impairing blood supply, altering the shape of the uterus or altering position of the cervix
(5,67,68). Pelvic adhesions also known as scarring are bands of fibrous (scar) tissue that
form within the uterus from a previous surgery, an injury or an infection (5). They can
physically block sperm from traveling to fertilize an egg, as well as, impair blood supply
to the uterus consequently affecting implantation (5,67).
Endometriosis is a disease characterized by the growth of uterine tissue outside
the uterus. Approximately 10 to 15% of reproductive women are diagnosed with
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endometriosis, however, the prevalence rates among infertile women are much higher
ranging from 25% to 50% (5,69). The biological mechanisms behind this association are
still unknown and controversial but there are proposed theories. They include infertility
through pelvic adhesions or scarring which can impair egg release, excessive fluid within
the peritoneum which can disrupt the functions of the sperm, eggs and tubes, and lastly,
chemical changes within the endometriosis which can lead to implantation failure (5,69).

Treatment Options
Evaluation of female infertility starts with extensive medical and reproductive
history and physical examination, along with vital laboratory and imaging tests (6).
Treatment options depend on the evaluation and the type of infertility diagnosed.
Treating the underlying cause of infertility is the first step. This can be as simple as
lifestyle changes such as stopping tobacco use, maintaining a healthy BMI and proper
diet, reducing stress, caffeine and alcohol intake and increasing frequency and proper
timing of intercourse (5,6). Women with anovulatory infertility can use medications to
stimulate ovulation known as ovulation induction (OI). Medications include letrozole,
clomiphene or clomiphene citrate, human chorionic gonatropin (hCG) and gonadotropins
such as FSH (5,6,49). Infertile women with thyroid disease can also take medications to
regulate their hormones and increases chances of conception. Surgery is more effective
for tubal and uterine factor infertility. Blockages can be removed from fallopian tubes
and tubes can be repaired, however, there is a low success rate and high risk of ectopic
pregnancies (5). Uterine scarring from endometriosis, polyps and fibroids can also be
surgically removed to increase the odds of pregnancy.
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Intrauterine insemination (IUI) is a technique involving the preparation of a
semen specimen which is then inserted into the uterus via a catheter (4,5). It is commonly
used among uterine, cervical or male factor infertility. IUIs can also be used in
combination with OI to increase the odds of conception (5,65). The next line of treatment
is ART which per the 2017 International Glossary of Infertility and Fertility Care, does
not include OIs and IUIs that involves the handling of only one gamete (4). The glossary
uses the term MAR to define any and all technologies to treat different types of infertility
diagnoses, including OIs IUI and ART (4). If ART using one’s own eggs or a partner’s
sperm is unsuccessful, couples can use donors, as well as embryo donors, surrogates and
gestational carriers (70).

Assisted Reproductive Technology (ART)
Assisted Reproductive Technology is a medical treatment for infertility that
handles both sperm and egg for conception and do not include treatments such as IUI or
OI (4). ART include but are not limited to include in-vitro fertilization (IVF), IVF with
embryo transfer and IVF with intracytoplasmic sperm injection (IVF-ICSI) (7,71). IVF is
the main form of ART and involves retrieving a woman’s eggs usually after OI,
fertilizing the eggs with a semen specimen in a laboratory, then implanting the most
optimal embryo(s) into the woman’s uterus or a gestational carrier (71). For couples with
a diagnosis of male factor infertility, ICSI is incorporated and involves a single sperm
being injected into the egg for fertilization (72). In the U.S. approximately 60% of IVF
procedures use ICSI (72).
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ART success rates can depend on patients’ characteristics such age, infertility
diagnosis, parity/gravidity, previous miscarriages, lifestyle choices and others factors (7).
These include the number and quality of embryos transferred, the type and numbers of
ART cycles and use of ICSI also affect success rates. There are different ways to measure
ART success rates. The most commonly used rate reported is the percentage of IVF
cycles or embryo transfers that resulted in a live birth (7). IVF success rate can also be
measured as the percentages of IVF cycles or embryo transfers that resulted in a
pregnancy (72).

Epidemiology of MAR
One global report done by the ICMART used a retrospective cross-sectional study
to investigate trends over time during 2011. The study involved both women and men
undergoing ART from 65 different countries, which is around two thirds of global ART
activity (73). Data was imputed for clinics that did not report ART information. There
was a reported total of 1,643,912 cycles that resulted in more than 394,662 live born
infants (73). There was also an increase in the proportion of women aged 40 years and
older undergoing ART from 23.2% in 2010 to 24.0% in 2011 and a slight drop in ICSI
percentages from 67.4% in 2010 to 66.5% in 2011 (73). From 2010 to 2011, results also
showed an increase in cumulative delivery rates per cycle, a decrease in perinatal
mortality rate after fresh IVF/ISCI cycle and even lower drop among perinatal mortality
rates after frozen ET (FET) (73).
In the U.S. the CDC released the 2017 Fertility Clinic Success Rates Report and
estimated that there were 284,385 ART cycles which had increased from 231,936 in
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2015. This resulted in 68,908 live births in 2017, an increase from 60,778 live births in
2015 (7). In the U.S., 1.7% of all infants born in 2017 were conceived through ART
services (7). One article published estimates of trends for infertility services, using the
NSFG data from 1982 to 2010. They found 12% (7.3 million) of 15 to 44-year-old
women reported ever using infertility services from 2006 through 2010 (74). They also
found that women who ever used infertility services were older, nulliparous, of nonHispanic white race, had infertility issues, and were more likely to have higher income
and education (74). Additionally, a recent survey in 2019 using NSFG data, showed an
increase in ever use of infertility services with 12.7% for 15 to 49-year-old women (24).

SECTION B - Adverse Pregnancy Outcomes

Early pregnancy loss (EPL) of an intrauterine pregnancy prior to 20 weeks’
gestation, without the use of elective medical or surgical means to terminate the
pregnancy is known as a spontaneous abortion (SA) or miscarriage (10,75). However, the
2017 International Glossary of Infertility and Fertility Care uses 22 weeks of gestational
age to define SA (4). Previous nomenclature also included blighted ovum and missed
abortion. Spontaneous abortions can be subdivided into several categories such as
incomplete abortion, complete abortion, threatened abortion, inevitable abortion, missed
abortion, septic abortion and recurrent spontaneous abortion (10). These inconsistencies
in the definition and length of gestation make it difficult to compare studies. Early
pregnancy loss is a public health burden in that it can be a traumatic experience for many
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and is shown to have adverse physical and mental effects including anxiety, depression
and grief (10).

Epidemiology of Early Pregnancy Loss
The incidence of EPL is difficult to calculate as many go unrecognized. Most
women are unaware of the onset of pregnancy and may misinterpret a SA for a late or
heavy menstrual cycle (10,75). Early pregnancy losses can occur either between postimplantation and pre-clinical detection or post medical recognition (75). After four to six
weeks of gestational age, the rate of EPL ranges from 10% to 15% and decreases as
gestational age increases (76). An early study found that approximately 20% of all
clinically detected pregnancies resulted in an early loss (77). However, that number
increased to 31%, when women with a biomarker measurement (e.g. hCG) were followed
up (77). A recent study in the U.S. analyzed trends in the risk of EPL and found a rate of
13.5% during 1990 through 2000, with a 1% increase per year adjusted for maternal and
pregnancy factors (78). Spontaneous abortion rates among ART-assisted conceptions
were significantly higher with rates ranging from 8% to 30% compared to the general
population (8). One retrospective cohort study found a significant 20% increased risk of
SA among ART-assisted pregnancies compared to natural conceptions (8). However,
these number may be biased in that ART procedures allow for earlier and more effective
detection of losses, as well as the characteristics of infertile women may also predispose
their risk.

Predictors of Spontaneous Abortion
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There are many common risk factors that can predispose women to have an
increased risk of SA including maternal age, prior pregnancy loss, certain medical
conditions, substance and specific medication use, some lifestyle factors and
environmental exposures (10,79). Etiologies of SAs can be grouped into endocrine
dysfunction, immunological causes, infectious diseases, abnormalities in implantation,
structural dysfunction of the uterus and most commonly, genetic factors (75,79). The
causes and risk factors are discussed below, along with their biological mechanisms.
Up to 90% of EPLs are caused by both numerical and structural chromosomal
abnormalities (10). Aneuploidies are numerical chromosomal mutations that result in less
or more than the usual number of chromosomes such as in Turner’s syndrome.
Polyploidy, on the other hand, is defined as having an extra complete set of chromosomes
(10,79). The risk of aneuploidies increases with advancing age, along with the risk of SA.
One study showed that the risk of EPL varied based on maternal age, for women under
25 years the risk of EPL was around 8.9%, and up to almost 75% among women older
than 45 years of age (80). Another more recent study done in Norway, also showed that
the risk was lowest for women under 25 years but gradually started increasing after the
age of 30, with 53% risk of SA among women older than 45 years (81).
A prior miscarriage is an important risk factor for subsequent losses, after
controlling for maternal age (10). The previously mentioned study also examined the risk
of SA recurrence and found that after adjusting for age, the odds of having another SA
was 60% higher after one prior SA, more than twice the odds after 2 previous SAs and
almost four times the odds after 3 prior SAs (81). Medical conditions specifically viral
and bacterial infections account for over 15% of all cases and include cytomegalovirus
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(CMV), human parvovirus B19, herpes simplex virus, varicella zoster virus and many
other infections (10,79). One study showed that the odds of the presence of CMV
antibodies were 2.5 times higher among SA compared to normal live births (82). Other
maternal diseases such as thyroid dysfunction, PCOS, endometriosis, diabetes, celiac
disease and other autoimmune diseases have also been associated with SA (75,79,83).
Characteristics of PCOS such as obesity, high levels of LH and insulin resistance have
also shown to increase the risk of SA, independent of PCOS (75,83).
One way that immunological factors can cause miscarriage involves the foreign
paternal genes inherited within the zygote (75,79). Certain immunological characteristics
of the maternal environmental helps to prevent attack or rejection of the inherited
paternal genes, thus promoting successful fertilization, implantation and development
(75,83). Lack of expression of antiphospholipid antibodies (APA), human leukocyte
antigens (HLA), antisperm antibodies (ASA), leukemia inhibitory factor (LIF), integrins,
endometrial adhesion factors, cytokines and uterine natural killer cells have all been
associated with both infertility and SA (79).
Uterine abnormalities are not as common but include uterine or pelvic adhesions,
uterine polyps and uterine fibroids (10). Congenital uterine malformations, such as a
septate uterus, have shown to significantly increase the risk of first trimester miscarriage
by almost 3-fold (84). Certain medications such as misoprostol (Cytotec), retinoids,
methotrexate and nonsteroidal anti-inflammatory drugs including ibuprofen have also
been found to increase EPL risk (10). The severity of the risk depends on the drug, the
exposure window and the dose or concentration. Environmental exposures such as
arsenic, lead, carbon disulfide, heavy metals and organic solvents may also increase the
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risk of EPL through apoptosis, impairment of tissue development, or disruptions within
cell division and other processes (75,79). Lastly, lifestyle factors that may increase the
risk of EPLs include moderate alcohol consumption, heavy caffeine use, substance abuse
with methamphetamines, marijuana and cocaine and cigarette smoking, through a doseresponse effect (10,75).

SECTION C - Smoking and Secondhand Smoke Exposure

The WHO reported in May 2017 that over 6 million people die yearly as a direct
result of tobacco use and over 890,000 people solely from exposure to secondhand smoke
(85). Secondhand tobacco smoke (SHS) also known as environmental tobacco smoke
(ETS) is a combination of the smoke produced from the burning of tobacco products such
as cigarettes, cigars, pipes or bidis and the smoke exhaled by the person smoking a
tobacco product (85). There is no safe level of SHS exposure and almost everyone is at
risk (85). Globally the prevalence of smoking and is decreasing; however, the absolute
number of smokers remains significantly high due to accelerated population growth and
an increase in the amount and variety of tobacco products on the market (85).

Epidemiology of Tobacco Use
In 2012, a worldwide study reported that approximately 1 billion men and 250
million women smoked every day, and the prevalence of smoking among women alone
was estimated to increase from 12% in 2010 to 20% in 2025 (86). The CDC reported in
2018 that the prevalence of current cigarette smoking among adults aged 18 years and
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older in the U.S. is 13.7%, equivalent to 34.2 million adults (87). In the same year, the
U.S. reported that 12% of adult females in the U.S. were current smokers (87). A study
using the Pregnancy Risk Assessment and Monitoring Survey (PRAMS) data from 27
different sites estimated the prevalence of smoking before pregnancy in 2010. They
showed approximately 23% of women reported smoking 3 months before pregnancy,
with trends from 2000 through 2010 unchanged for 20% of the women (88). Another
study examined the prevalence of self-reported smoking along with intensity of smoking
three months before pregnancy in 2016. They found that the overall rate of low-intensity
smoking (< 10 cigs/day) was 9.4% and 6.3% for high-intensity smoking (≥ 10 cigs/day)
(89).
While there have been significant decreases in current cigarette smoking rates, the
level of SHS exposure over the past 30 years remains high. The CDC reported over 58
million non-smokers were exposed to SHS in the U.S. during 2011 to 2012 (90). The
total U.S. economic burden directly attributable to smoking for both direct medical care
for adults and lost productivity due to deaths and SHS exposure was over $300 billion a
year (91). In 2018, the CDC reported from the Behavior Risk Factor Surveillance System
(BRFSS) that the percentage of current cigarette use among adults in Kentucky was
23.4%, compared to the national percentage of 16.1% (92). They also reported that the
percentage of women aged 18 to 44 years, who reported smoking at least 100 cigarettes
in their lifetime and currently smoke every or some days was 23.3% (92).

Types of Tobacco Smoke Exposures
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There are several ways to be exposed to tobacco smoke. Mainstream smoke is the
smoke that is inhaled then exhaled by a smoker, while sidestream smoke is the smoke
emitted into the surrounding environment directly from the burning end of the cigarette,
pipe, or cigar (93). The differences in the chemical compositions between mainstream
smoke and sidestream smoke depends on the burning conditions. During inhalation, the
cigarette burns at a higher temperature allowing for complete combustion in mainstream
smoke (93). However, the incomplete combustion from sidestream smoke produces
undiluted chemicals that are more concentrated with harmful and carcinogenic chemicals
compared to mainstream smoke (93). SHS is a mixture of two forms of smoke from
burning tobacco: the exhaled mainstream smoke and sidestream smoke (93). People are
also exposed to SHS in their homes, workplaces, public spaces and cars.
Recently, thirdhand smoke has been recognized as another type of tobacco smoke
exposure and is the result of residual tobacco smoke chemicals accumulating and
attaching to hair, surfaces, clothing, furniture and dusts in the environment (94). These
toxins remain settled for months long after the SHS is cleared and over time can become
increasingly more dangerous (94,95). One study in 2014 examined the effects of
thirdhand smoke using animal models under similar conditions that simulate human
exposures. They found that the mice exposed to thirdhand smoke showed changes in
multiple organ systems, specifically the liver, lung and skin (95). They found higher lipid
levels and non-alcoholic fatty liver disease within the livers of thirdhand smoke exposed
mice. In the lung, there were an excess of collagen and inflammatory cytokines and
lastly, poor healing of wounded skin on mice exposed to thirdhand smoke (95).
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Tobacco Smoke Composition
There are over 7,000 chemicals in tobacco smoke, of which at least 250 are
known to be harmful and over 70 that are carcinogenic (96). Some known human
carcinogens in SHS are benzene, 2-napthylamine, 4-aminobiphenyl, nickel and
polonium-201. Probable human carcinogens in SHS include formaldehyde, hydrazine,
1,3-butadiene, benzo[a]pyrene and cadmium. Some of the toxic substances include
carbon monoxide, acrolein, ammonia and nitrogen gases (93,97). Smoking tobacco can
potentially harm every organ within the human body and there are a plethora of studies
associating tobacco smoke, both active smoking and SHS exposure to a multitude of
diseases and illnesses. Some health effects of tobacco smoke include cardiovascular
disease such as coronary disease and stroke; respiratory disease such as chronic
obstructive pulmonary disease and asthma; several types of cancers such as lung, bladder,
cervix and liver; and infertility and adverse pregnancy outcomes (11).

Measures of Tobacco Smoke Exposures
There are a few methods to assess and measure tobacco smoke exposure, with
varying levels of validity and reliability. The two most commonly used methods are selfreport and biomarkers (97). Self-reported exposures can easily be assessed and measured
through questionnaires or interviews. Questionnaires are the most convenient and
inexpensive method especially for larger observational studies. Unfortunately, there are
limitations with self-reported data such as lack of standardized measurements,
misclassifications, recall bias and under-reporting (98). However, meta-analyses have
showed that self-reported smoking measures can be validated with biochemical
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measurements (99). Some examples of questions asked to assess smoking, for both active
and passive smoking include “Do you currently smoke tobacco on a daily basis, less than
daily, or not at all?”, “Have you smoked tobacco in the past?”, “How many cigarettes or
packs (or list of other tobacco products) do you smoke a day/week?”, “Have you ever
smoked more than 100 cigarettes?”, “How often does anyone smoke inside you home?”
and “Did anyone smoke at your work during the past 30 days?” (100).
A more objective and reliable measurement of tobacco smoke exposure is the use
of biomarkers. The two most widely used are nicotine and cotinine (101). Nicotine is the
primary addictive and major component of tobacco smoke. Its half-life is between 2 and
3 hours within the blood and it is then later excreted through urine (101). However, only
5 to 10 percent of nicotine is excreted in the urine and among the remaining,
approximately 80 percent is metabolized to cotinine in the liver (101). The limitations to
using nicotine include its short half-life, which limits it from assessing long-term
exposures, as well as, the assay used to measure nicotine is costly and must be highly
specific due to low levels present (101). Cotinine is a metabolite of nicotine and is the
preferred biomarker for tobacco exposure (102). Its half-life ranges from 15 to 20 hours
and depend on the type of specimen it is being measured from (102). Cotinine can be
measure from blood, urine, saliva and hair follicles. Published cutoff values by exposure
levels are different for plasma, urine and saliva. For urinary cotinine, levels less than 10
ng/mL to indicate unexposed non-smoker, 10-200 ng/mL for a passive smoker and above
200 ng/mL indicates an active smoker (103). Another example differentiated active
smokers with cotinine levels >14ng/mL, SHS exposed from 0.5-13.9 ng/mL and
nonsmokers a <0.5ng/mL (104). One recent study used urinary cotinine levels >30ng/mL
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to identify current smoking with 94% sensitivity and 98% specificity (105). There are
limitations using biomarkers such as differences in uptake, metabolism and excretion
rates, which can increase inter-subject variation. It is also very difficult to differentiate
SHS exposures because of lower levels of cotinine.
Zenzes and associates examined cotinine levels in follicular fluid among infertile
women by smoking status (106). They enrolled 111 infertile women from a hospital IVF
program and classified them into active, passive and non-smokers, using self-reported
number of cigarettes smoked for both females and their husbands (106). Cotinine was
measured in follicular fluid and was strongly correlated in a dose-dependent manner with
the number of cigarettes smoked per day for both active and passive smokers. The
authors discussed that there were a lot of inter-variation between cases that reported
similar number of cigarettes smoked but suggested it may be due to difference in nicotine
metabolism, unreliability of self-reported data and time before last cigarette smoked
given cotinine’s half-life (106). This was one of the first studies to examine cotinine
levels in passive smokers. Cotinine was also detected in all active smokers, most of the
passive smokers and some nonsmokers, which they deemed as environmentally exposed
passive smokers.

Smoking and Biological Mechanisms
Several mechanisms have been proposed to explain how tobacco smoke exposure
(particularly before conception) may be harmful for reproductive function. Scientists
have used both animal models and clinical data to develop and support these theories.
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Folliculogenesis and Steroidogenesis
Follicular fluid is secreted during folliculogenesis and maintains a healthy
environment to promote granulosa cell and oocyte development (107). Cigarette smoke is
theorized to be associated with folliculogenesis and ovarian steroidogenesis impairment
(107,108). Harmful tobacco smoke constituents can build up within the ovaries resulting
in a deleterious follicle environment, causing increased oxidative stress, abnormal
intercellular crosstalk, meiosis impairment and activation of cell death pathways (107–
111). Chemicals found in tobacco smoke such as cadmium and benzo(A)pyrene (BaP)
can act as endocrine disrupting chemicals and lead to impairment of production of
estradiol and progesterone (107,108). Cigarette smoke components such as nicotine and
cotinine can also inhibit the expansion of the cumulus-oocyte complex (COC) (107,108).
The structural and functional processes involved in the expansion of COC is important in
oocyte maturation, fertilization and embryo development (107,108).
Oxidative stress is the term used to characterize uncontrolled reactive oxygen
species (ROS) production, which is a by-product of oxygen metabolism, or an imbalance
between free radicals (pro-oxidants) and antioxidants (109). Heavy metals and other
harmful substances within tobacco smoke promote oxidative stress, which can lead to
harmful effects on cell membranes, DNA and proteins (107,110). DNA damage can lead
to aneuploidies which in turn adversely affect fertilization and pregnancy outcomes
(109,110). Studies have shown that tobacco smoke contains over 1015 ROS per puff (112)
and that higher levels of ROS were associated with lower oocyte yield (113). Higher
levels of ROS have also been shown to produce immature and poorer quality embryos in
women who were not successful with IVF (114). Khan and associates used a mouse
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model to show that SHS exposure is associated with adverse fertility outcomes in female
mice, which was not prevented by antioxidant use (115). Mai and colleagues examined
cigarette smoke extract on ovulation, oocyte morphology and ovarian gene expression
using an animal mode. They found cigarette smoke exposure to be associated with poorer
quality of oocytes and a shrink size which they believe is due to oxidative stress (116).
Tobacco smoke has been associated with depletion of the follicle pool and earlier
menopause either through apoptosis of maturing follicles or autophagy of primordial
follicles (107,109). Apoptosis is the term used for programmed cell death and may be the
main cause for smoke-induced loss of primordial follicles. Gannon and colleagues
showed that mice that were exposed to cigarette smoke twice a day had a reduction in
primordial follicle pool as well as, a higher number of autophagosomes in granulosa cells
(117). Several studies have also shown accumulation of cotinine and carcinogens within
follicular fluid and granulosa cells, which can induce apoptosis and potentially affect
ovarian function by directly depleting oocytes (118,119). In 2009, Tuttle and associates
tested whether cigarette smoke exposures, representative of human exposure levels would
decrease ovarian follicles by apoptosis using mice (120). They found a significant
reduction in the number of ovarian follicles via an increase in a pro-survival B-cell
lymphoma 2(Bcl 2) marker, which inhibits apoptosis (120). Plante and colleagues studied
the impact of smoking on AMH levels and found that active smoking (not former or
passive smoking) was associated with lower AMH levels, inferring that tobacco smoke
directly affected the antral follicles and not the primordial follicles (121).

Fallopian Tube, Uterine and Placental Effects
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Tobacco smoke components have been shown to impair fertility through fallopian
tube and uterine effects (108,111). Cigarettes smoke targets the oviduct leading to an
increased number of ectopic pregnancies after exposure and with a dose-response effect
(108,111). Toxins in cigarette smoke can also cause tubal dysfunction through decreased
quality and quantity of ciliary cell activity, abnormal ciliary beat frequency and
infundibular smooth muscle contraction, along with lower oocyte retrieval due to
excessive adhesions between the COC and tubal lining that is responsible for transport of
the COC and embryo along the tubes to the uterus lining (73,108).
A healthy and prepared uterus and uterine lining is necessary for successful
embryo implantation. Several studies have shown lower rates of implantation for smokers
compared to nonsmokers among ART users (122–124). The mechanisms behind tobacco
smoke’s effects on the endometrium are still being elucidated. However, several animal
studies have shown that chemicals in cigarette smoke (mostly nicotine, cadmium and
BaP) can decrease the weight of the uterus, suppress the uterine response to
decidualization, decrease mobility of endothelial cells, and inhibit cell proliferation (108).
Early placentation involves growth, differentiation, transport and invasion of the
trophoblast (108,111). Few studies using human trophoblastic cells have shown that
cigarette smoke chemicals--particularly cadmium, which is a known placental toxin, BaP,
and nicotine-- can disrupt proliferation, differentiation and migration (108,111). These
effects are also directly related to the increased risk of SA.

SECTION D - Epidemiological Studies
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Active Smoking and Fertility
There have been many studies investigating whether active current smoking is
associated with TTC or fecundability (26, 117–119), infertility (128–130) and conception
outcomes for both natural conceptions (131) and MAR (132,133). Findings have been
inconsistent, with some studies showing significant associations and some showing no
association (134,135). The following section describes past research on active smoking
by different types of fertility outcomes. These studies are summarized in Table 1.

Fecundability
In 1997, Curtis and colleagues examined the effects of active smoking and other
risk factors on fecundability, using a retrospective cohort study. Couples from the Ontario
Farm Family Health study who were planning to conceive, completed detailed
questionnaires self-reporting the number of pregnancies, TTC, detailed exposure
information and other important covariates (38). The final sample size included 1277
couples that contributed 2607 pregnancies. After adjusting for spouse's smoking, recent
oral contraceptive use, and woman's age, women who smoked had significantly reduced
fecundability compared to nonsmokers (adjusted fecundability ratio (aFR): 0.90; 95%
confidence intervals (CI): 0.82, 0.98). There was also a significant a dose-response effect
for the number of cigarettes per day (aFR: 0.74; 95% Cl: 0.59, 0.92 for >20 cigarettes per
day) (38). Limitations of the study above include the lack of generalizability given the
specific population, the results may be not be generalizable to the general population.
Effects may be overestimated, as smokers who are highly fertile may have been
excluded, given that they are more likely to have unplanned pregnancies (38). Also, data
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was only collected on couples who did conceive, which excluded potentially infertile,
sterile or less fecund couples. And because smoking has been shown to be associated
with infertility and fecundability, the estimates may be biased towards a null association.
In 2014, Radin and colleagues used a prospective cohort study to assess active
smoking on fecundability also using women planning to conceive (126). Current and past
smoking history along with important covariates were collected by questionnaire at
baseline. Outcome data were self-reported twice a month using follow-up questionnaires.
Confirmation of pregnancy by either a home pregnancy test or physician was collected,
along with TTC and last menstrual cycle. The final sample size included 3773 women
who contributed 15,774 cycles with 2,578 confirmed pregnancies (126). After adjusting
for cycle number at risk, age, partner smoking, and passive smoking, women who were
current smokers had lower fecundability than never smokers, but the estimate was not
significant (aFR:0.89; 95% CI: 0.77, 1.03) (126). The authors also found that women who
were regular smokers for ten years and more had a significantly reduced fecundability
than never smokers (aFR:0.85; 95% CI: 0.71, 1.00) (126). No significant dose-response
effect was established. As detailed as the exposure assessment was, heavy smokers have
been shown to under-report their smoking intensity, leading to exposure misclassification
which can lead to a downward bias. The authors also mentioned unmeasured
confounding and overestimated effects, if the smokers who that were more likely to be
lost to follow-up, were also more likely to conceive (126). Similar to the previous study
described, excluding unplanned pregnancies can also lead to an upward bias.
A more recent study in 2019 examined the extent to which cigarette smoking
affected fecundability using a North American internet-based cohort of pregnancy
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planners. Among 5,473 females, active and passive smoking exposures were selfreported at baseline, then followed up bi-monthly to collect current smoking history for
the prior month (135). Conception outcomes were also self-reported and collected at each
follow-up, along with TTC measured in cycles. Smoking intensity using number of
cigarettes smoked per day and duration were analyzed individually and then jointly
among female current smokers. The authors used proportional probabilities regression to
estimate FRs and 95% CIs, adjusted for important covariates (135).
Results showed minor insignificant reductions in fecundability for current, female
smokers (aFR: 0.90; 95% CI: 0.77, 1.07), current occasional smokers (aFR: 0.88; 95%
CI: 0.73, 1.06), and former smokers (aFR: 0.89; 95% CI: 0.81, 0.98) (135). Females who
smoked ≥10 cigarettes/day for ≥10 years had stronger associations with reduced
fecundability, though still not statistically significant (aFR: 0.77; 95% CI: 0.53, 1.10)
(82). The results of this study supported past studies that revealed current smoking is
associated with reduced fecundability; however, this study also had a few limitations.
Firstly, all smoking exposures were self-reported, which are commonly under-reported
and can lead to non-differential misclassification and a downward bias. Results also
showed low agreement between female and male reporting of smoking intensity which
could be further evidence of under-reporting (135). An objective biomarker such as
cotinine could have increased the validity of the estimates and reduce bias. The study
excluded women who had been trying to conceive for 6 or more months prior to
enrollment and restricted the sample to couples planning a pregnancy. It has been
theorized that smokers are more likely to have unplanned pregnancies either because of
contraceptive use or risky behaviors, so in theory, less fertile smokers would be enrolled,
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which would bias the estimate in an upward direction (135). Lastly, the authors stated
that results from additional analyses showed female current smokers were more likely to
be lost to follow-up, which can lead to an upward bias, if female smokers who did not
conceive were disproportionately lost to follow-up.

Infertility
In 1998, Augood and colleagues conducted a systematic review and meta-analysis
on active smoking and female infertility. Twelve studies were used after meeting the
stringent criteria of the meta-analysis. There were 4 case-control studies and 8 cohort
studies: one prospective and seven retrospective (130). The results overall showed a
significant 60% increased odds of infertility among current cigarette smokers when
compared to non-smokers (OR: 1.60; 95% CI: 1.34, 1.91) (130). This statistically
significant result was also seen when the results were stratified by study designs; for
case-control studies (OR:2.27; 95% CI: 1.28, 4.02) and cohort studies (OR:1.42; 95% CI:
1.12, 1.91) (130). Regardless of the limitations of this meta-analysis, the overall precision
and consistency of effects across the different study designs, outcomes, and sample sizes
like past studies, supported the negative effect of smoking on female fertility (130).
However, while some of the individual studies within the meta-analysis were adjusted for
important confounders, the overall estimates were not.
Laurent and colleagues used a retrospective case-control study to investigate the
effect of active smoking on female infertility. Women used in this study were among the
controls of a cancer and steroid hormone study (128). They recruited 482 cases and 2231
controls. Cases of primary female infertility were defined as having 24 months of actively
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trying to get pregnancy (unprotected intercourse) without pregnancy. And controls were
defined as women who did not meet the criteria for a case, and also had documented
fertility (128). Exposure data was self-reported during an interview-administered
questionnaire. After adjusting for age at infertility/conception, age at first intercourse,
education level, race, and history of benign ovarian disease, the odds of primary
infertility were 36% higher for women who smoked a pack a day compared to
nonsmokers (adjusted odds ratio (aOR):1.36; 95% CI: 1.14, 1.36) (128). However, there
were many limitations including the retrospective study design which cannot assess
temporality of the effect to outcome. Also, women who were categorized as infertile may
over-report exposures because of known associations with infertility and lastly, smoking
behaviors can change over time, leading to misclassification and can lead to
overestimated effects. The authors also stated that contraceptive use and treatment of
infertility were important confounders that were not adjusted for and can ultimately bias
the estimates in an upward direction (128).
In 2016, Hyland and others cross-sectionally examined a large prospective cohort
to assess tobacco smoke exposure with infertility. All information including tobacco
smoke exposures, infertility history and other relevant variables were extracted from
questionnaire used in the Women’s Health Initiative observational study (129). Among
the 88,732 women, active smokers overall had significant increased odds of infertility
compared to never smokers (aOR: 1.14; 95% CI: 1.03, 1.26) after adjusting for several
confounders (129). However, there were a few limitations to this study. Firstly, crosssectional studies are a weak design to infer causality, because it does not allow for
temporality, especially given that many women change their smoking behaviors.

39

Exposures and outcome data were self-reported which can be subjected to recall bias or
under-reported leading to misclassification and a downward bias. The authors also stated
that there maybe be bias from the lack of adjustment for important confounders such as
alcohol use, contraceptive use, infertility treatment and male factor infertility (129).

Clinical Outcomes of Medically Assisted Reproduction
With the emergence of MAR, study designs have improved to allow for more
efficient methods in assessing exposures on conception outcomes among infertile women
and couples. Several meta-analyses and more recent studies have examined the effect of
active smoking on MAR outcomes (131,136–138). Feichtinger and colleagues conducted
a meta-analysis to examine the relationship between the clinical pregnancy rate of female
smokers after the first IVF-ET cycle (136). The authors used seven articles and one of
their own studies to calculate pooled odds ratios and 95% CI. Among a total of 2314 first
IVF-ET cycles, it was found that almost twice as many IVF-ET treatment cycles were
needed for smokers to conceive compared to non-smokers (OR:1.79, 95%CI: 1.24, 2.59)
(136). Given the weak methodological designs of the studies used in this meta-analysis,
the authors warned that the accuracy of overall effect estimate should be taken with
careful consideration.
Waylen and colleagues also conducted a meta-analysis examining the clinical
outcomes ART and smoking at the time of treatment. Among the 18 studies used for the
clinical pregnancy rate per cycle outcome, there were 1284 smokers and 3959 matched
controls (137). The results showed a significant decrease in clinical pregnancy rate per
cycle for women smoking at the time of ART treatment compared to women who did not
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(OR: 0.56; 95% CI: 0.43, 0.73) (137). Budani and colleagues updated the above metaanalysis in 2016 to include three additional studies and found similar results for the
clinical pregnancy rate per cycle (OR: 0.53; 95% CI: 0.41, 0.68) (138). Similar
limitations were mentioned for both, including that the results are more likely to be
confounded by age or male smoking status and the lack of external validity (137,138).
Also, most of the studies included in both meta-analyses only took into account selfreported smoking status by questionnaire, while only a few used an objective marker.

Summary
Although there are inconsistencies across studies, the body of literature as a whole
suggests that current smoking may be associated with reduced fecundability, increased
odds of infertility, and lower the odds of both natural and MAR conceptions (Table 1).
The associations are weaker, however, among the larger studies. Of the seven cohort
studies analyzed, three were of prospective designs and of those, two did not find a
significant association. There were only two studies that found significant dose-response
effects with the number of cigarettes. Also, cross-sectional analyses, case-control or even
retrospective study designs are more susceptible to bias which limits inferences on
causality. Lastly, almost all of these studies used self-reported smoking exposures which
can lead to misclassification and underestimated associations because of under-reporting.
Few studies used an objective biomarker to verify smoking status which can help to
increase accuracy of the estimates and reduce bias.
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Table 1. Studies on Active Smoking Exposures and Fertility

Baird &
Wilcox,
1985
(125)

Study
Design
TTC

N

ART

Exposure

Outcome

678
women

No

Selfreported

Time to
conception

Esti
mate
0.72a

95%
CI
0.59 0.87

Hull
et al.,
2000
(134)

CS of
PCS

8515
women

No

Selfreported

Delayed
conception

1.23a

0.98 1.49

Curtis
et al.,
1997
(38)

RCS

1277
women

No

Selfreported

Fecundability

0.90b

0.82 0.98

Radin et
al., 2014
(126)

PCS

3773
women

No

Selfreported

Fecundability

0.85b

0.72 1.00

Sapra et
al., 2016
(127)

PCS

501
women

No

Selfreported

Fecundability

0.53b

0.33 0.85

Wesseli
nk et al.,
2019
(135)

PCS

2962
women

No

Selfreported

Fecundability

0.90b

0.77 1.07

Laurent
et al.,
1992
(128)

CACO

No

Selfreported

Infertility

1.36a

1.14 1.61

Hyland
et al.,
2016
(129)

CS of
PCS

88 732
women

No

Selfreported

Infertility

1.14a

1.03 1.26

Van
Voorhis
et al.,

RCS

499
women

Yes

Selfreported

Ongoing
pregnancy
rate

0.32a

0.13 0.79

482
cases,
2231
controls
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1996
(132)
Freour
et al,.
2008
(133)

RCS

111
women

Yes

Selfreported

Clinical
pregnancy
rate

%
differ
ence

NA (p
value <
0.05)

Hughes
&
Brennan
, 1996
(131)

MA

13
studies

No

Natural
conception

Yes

0.33
to 1.0
*
0.57c
*
1.60c
*

NA

7
studies
12
studies

Mostly
selfreported,
few used
biomarkers
Selfreported

0.42 0.78
1.34 1.91

8
studies

Yes

Selfreported

Clinical
pregnancy
rate

1.79c
*

1.24 2.59

9
studies

Yes

Selfreported

Pregnancies
per IVFtreated cycles

0.66c
*

0.49 0.88

Selfreported
and
biomarkers

Clinical
pregnancy per
cycle

0.56c
*

0.43 0.73

Clinical
pregnancy
rate per cycle

0.53c
*

0.41 0.68

MA
Augood
et al.,
1998
(130)
MA
Feichtin
ger et
al.,1997
(136)

No

Waylen
et al.,
2009
(137)

MA

18
studies

Yes

Budani
et al.,
2018
(138)

MA

21
studies

Yes

Conceptions
per cycle
Infertility

Selfreported
and
biomarkers
TTC - Time to conception, CS - Cross-sectional, RCS - Retrospective cohort study, PCS
- Prospective cohort study, CACO - Case-control, MA - Meta-analysis
a - Adjusted Odds Ratio, b - Adjusted Fecundability Ratio, c - Pooled OR/RR
* - Some individual studies adjusted for confounders
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Secondhand Smoke Exposure and Fertility
Research on SHS exposure with fertility outcomes such as TTC or fecundability
(127,134), infertility (129) and natural or assisted conception outcomes (122,124) are few
and limited with mostly inconclusive or inconsistent results (126,139,140). The following
section describes past research on SHS exposures by different types of fertility outcomes.
These studies are summarized in Table 2.

Fecundability
In 2000, Hull and colleagues investigated passive smoking on TTC by
retrospectively analyzing a prospective cohort study. Using the Avon Longitudinal Study
of Pregnancy and Childhood, exposures, outcome and other relevant variables were selfreported by questionnaire (134). Pregnancies were enrolled at 18 weeks of gestation and
both unplanned pregnancies and planned pregnancies that did not reach 24 weeks of
gestation were excluded. The final sample included 8,515 women who contributed 9,065
pregnancies (134). After adjusting for confounders, passive smoke exposure was found to
significantly delay 6-month conception (aOR: 1.17; 95%CI: 1.02, 1.37) compared to no
SHS exposure (134). Possible limitations to this study included the lack of
generalizability, unmeasured confounders, the study population which was limited to
only fecund women and under-reporting of smoking behaviors, which can lead to
misclassification and null associations. This study also did not use an objective biomarker
to verify current passive or active smoke exposures.
However, as previously described in 2014, Radin and coauthors used a
prospective cohort study to examine passive smoking on fecundability among women
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planning to get pregnant. Among 2,346 never smokers, passive smoking was associated
with reduced fecundability but was not statistically significant (aFR: 0.92; 95% CI: 0.83,
1.03), after adjusting for confounders (126). The authors stated that as of 2014, their
study was the largest prospective study to examine passive smoking and fecundability.

Infertility
Also described earlier, Hyland and colleagues assessed lifetime tobacco smoke
exposure on infertility using a cross-sectional design. After adjusting for age, race,
education, alcohol use, insecticide exposure, oral contraceptive use, BMI, and exercise,
never-smoking women with the highest levels of lifetime SHS exposure had significantly
increased odds of infertility compared to nonsmoking women with no SHS exposure
(aOR:1.18; 95% CI:1.02, 1.35) (129). Some strengths of this study included its large size
which increased statistical power, adjustment of several confounders and thorough
assessment the impact of lifetime tobacco exposure (129). However, limitations included
the cross-sectional study design which limited causality, recall bias as women were all
past reproductive age, social-desirability bias, and not accounting for male factor
infertility.

Clinical Outcomes of Medically Assisted Reproduction
Neal and associates conducted a retrospective study to measure cigarette smoke
effect from mainstream (MS) and sidestream (SS) smoke-exposed women undergoing
IVF on fertility outcomes compared to non-smoking (NS) women (124). Smoking status
was self-reported and categorized into three categories as stated above. The fertility
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outcomes included embryo quality, implantation rates and pregnancy rates. Among 225
women, results showed a significant difference in implantation rate (MS=12.0%,
SS=12.6%, and NS=25.0%, p<0.001) and pregnancy rate per embryo transfer
(MS=19.4%, SS=20.0%, and NS=48.3%, p<0.001), but showed no difference in embryo
quality between the three smoking groups (124). Misclassification errors and recall bias
may have limited the accuracy of the effect, in that women under-reported exposures
which can lead to a downward bias. Other limitations include the lack of an objective
marker for smoking exposure and residual confounding.
In 2007, Meeker and colleagues conducted two retrospective analyses of a
prospective cohort study to analyze SHS exposure on pregnancy outcomes among
women undergoing MAR. The first study used a retrospective cohort study to investigate
adverse pregnancy outcomes and maternal exposure to SHS (139). Adverse pregnancy
outcomes were collected from medical records and included failure of fertilization, failed
implantation and SA. Maternal exposure to SHS was self-reported on questionnaires and
urinary cotinine levels adjusted for creatinine were measured at the time of ART
treatment. After adjusted for confounders, urinary cotinine levels above the median were
not associated with failed implantation (aOR: 0.98; 95% CI: 0.70, 1.37)(139). The second
study was done to analyze women with childhood SHS exposure from their parents and
SA, with self-reported exposure data. Using a larger sample of 1449 non-smoking
women, no significant association was also found between any current self-reported SHS
exposures and failed implantation (aOR: 1.43; 95% CI: 0.97, 2.09)(140).
In 2011, Benedict and associates carried out a retrospective analysis of a
prospective cohort study to assess the association between SHS exposure and
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implantation failure among non-smoking women already in IVF treatment (122). The
study enrolled 1909 couples with 3270 total IVF cycles. Medical and lifestyle histories
were self-reported. SHS exposure status was self-reported and then verified by measuring
cotinine in follicular fluid. After adjusting for confounders, the authors found a
significant increase in risk of failed implantations among SHS exposed women compared
to unexposed women (aOR = 1.52; 95% CI = 1.20, 1.92; adjusted risk ratio (aRR) = 1.17;
95% CI = 1.10, 1.25) (122). They claimed to have the largest study of SHS exposure
using cotinine on fertility outcomes among IVF patients. Some strengths of this study
included the use of odds and risk ratios; both statistically significant indicating a robust
model, adjustment for several potential confounders and use of an objective marker to
verify SHS exposure status. However, the generalizability of the study is limited because
the study population only included couples in IVF treatment, which is a very specific
demographic. The outcome of implantation failure is usually not observed outside MAR
population and choosing the best embryos in a laboratory is not an option in the general
population (122).

Summary
There are only a few studies examining the association of SHS exposure and
conception outcomes and some are summarized in Table 2. However, the available
studies are inconsistent and do not have strong associations. Most of the studies were
cross-sectional in design rather than the ideal prospective cohort, which would allow for
temporality to infer causality. Only one of three cohort studies found significant results,
however, that study was relatively smaller compared to the others. Furthermore, three of
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the eight studies used a biomarker to measure and verify SHS exposure, the others relied
on self-reporting which has been shown to result in null association. Lastly, adjustment of
important confounders and the use of biomarkers such as cotinine are necessary to reduce
bias in the association of SHS exposure on conception.

Table 2: Studies on Secondhand Smoke Exposures and Fertility
Study
Design
Hull et
CS
al., 2000
(134)

N

ART

Exposure

Outcome

8515
women

No

Selfreported

Delayed
conception

Estim
ate
1.17b

95% CI
1.02 1.37

Radin et
al., 2014
(126)

PCS

3773
women

No

Selfreported

Fecundability

0.92c

0.82–
1.03

Sapra et
al., 2016
(127)

PCS

501
women

No

Serum
cotinine

Fecundability

0.64c

0.41 0.98

Wesseli
nk et.
al., 2019
(135)

PCS

2962
women

No

Selfreported

Fecundability

0.93c

0.70 1.25

Hyland
et al.,
2016
(129)

CS
of
PCS

88 732
women

No

Selfreported

Infertility

1.18b

1.02 1.35

Neal et
al., 2005
(124)

RCS

225
women

Yes

Selfreported

Implantation
rate

Differ
ence
in rate

p-value
<0.01

Meeker
et al.,
2007a
(139)

CS
of
PCS

921
women

Yes

Urinary
cotinine

Implantation
failure

0.98b

0.70–
1.37
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Meeker
et al.,
2007b
(140)

CS
of
PCS

1449
women

No

Selfreported

Implantation
failure

1.43b

0.97–
2.09

Benedict CS
1909
Yes
Follicular
Implantation
1.17a,
1.20–
et al.,
of
women
fluid
failure
1.52b
1.92,
2011
PCS
cotinine
1.10–
(122)
1.25
TTC - Time to conception, CS - Cross-sectional, RCS - Retrospective cohort study, PCS
- Prospective cohort study, CACO - Case-control, MA - Meta-analysis
a - Adjusted risk ratio
b - Adjusted odds ratio
c - Adjusted Fecundability Ratio
d - Pooled OR/RR
* - Some individual studies adjusted for confounders

Active Smoking on Spontaneous Abortion
Past studies have shown that active smoking affects early pregnancy loss for both
natural (141–145) and assisted conception (123,146). However, most of these studies
measured tobacco use during pregnancy and only a few took into account exposures
before conception or before MAR procedures (144,147). In 1999, Ness and colleagues
examined active smoking on SA among pregnant adolescents and women aged 14 to 40
years who visited the emergency department at the University of Pennsylvania Hospital
(142). Tobacco use after conception, during the pregnancy was self-reported and verified
by urinary cotinine. Women with urinary cotinine levels great than 500 ng/mL were
defined as heavy smokers. Four hundred pregnant subjects had a SA either within 3 days
of enrollment or during follow-up and 570 women (controls) remained pregnant past 22
weeks of gestation (142). Results showed that heavy smoking was independently
associated with an 80% increased risk in SA (aOR: 1.8 (95%CI: 1.3, 2.6) (142).
However, the authors discussed several limitations including residual confounding from
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unmeasured factors, recall and misclassification bias and urinary cotinine’s half-life
which only measured recent tobacco use.(142).
One study that examined tobacco exposures prior to pregnancy on SA was
conducted in 2006 by Nielsen and associates. Using a nested case-control study from a
population-based cohort comprising of 20 to 29-year-old women established from 1991
to 1993. The authors recruited 343 cases of SA and 1578 women who had live births
(144). Detailed pre-conception tobacco smoke exposures were self-reported during an
interview-administered questionnaire at enrollment. After adjusting for age, marital
status, previous SA, use of oral contraceptives, use of intrauterine devices, current
smoking status, cigarette smoked per day, duration of smoking, and time since quit
smoking; pre-conception smoking was significantly associated with SA (aOR: 1.64; 95%
CI: 1.07, 2.50) (144). A significant dose-response effect was also found among the
number of cigarettes smoked per day and SA (aOR: 1.20; 95% CI: 1.04, 1.39). However,
no association was for duration of smoking (144). While this study warranted the need
for further investigation of pre-pregnancy smoking habits on SA and had many strengths,
there were a few limitations.
The study suggested that pre-conception smoking may be a proxy for smoking
during pregnancy. It has been shown that heavy pre-conception smokers may have a
harder time quitting during pregnancy, which can be relevant in predicting smoking
during pregnancy (144). However, because data on smoking during pregnancy was not
collected, this assumption was not tested which limited the study effect estimates. As it
was unclear whether the effect estimates were truly a result of pre-conception smoking or
if pre-conception smoking acted as a proxy for smoking during pregnancy (144). Other
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limitations included recall bias, unmeasured factors such as SHS exposure from spouse or
work and the lack of differentiation between early and late SA.

Spontaneous Abortion after Medically Assisted Reproduction
The relationship between active smoking and clinical outcomes within MAR
helps to add and improve the research among the specific population, by allowing for
earlier and efficient detection of pregnancy losses. One study done in 2005 assessed the
effects on smoking with the IVF success rates among infertile couples. The authors
retrospectively analyzed data from a large prospective cohort study and used 8457
eligible women with first IVF cycles (146). Exposures, outcome and relevant information
were either extracted from the medical record or self-reported through a mailed
questionnaire. Smokers were defined as having smoked more than one cigarette a day, for
one year or more, at the time of oocyte retrieval. After adjusting for age, BMI, different
infertility diagnoses and duration of subfertility, current smoking was found to
significantly lower of odds of live birth per IVF cycle compared to nonsmokers (aOR:
0.72; 95% CI: 0.61, 0.84) (146). The authors conducted non-responder analysis which
showed that women with live births were more likely to respond and participate than
women with unfavorable outcomes. This may have caused an overestimation of IVFassisted birth rates which can result in biased estimates in upward direction, if nonresponse was associated with the smoking exposure (146).
In 2019, Rockhill and colleagues used a retrospective cohort in the U.S. to
estimate the proportion of ART cycles with self-reported smoking, and its association
with ART related outcomes (147). Women who self-reported any smoking 3 months
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before the treatment cycle were defined as smokers. Using national data from 2009
through 2013, outcome data was collected for every ART cycle and included
cancellations of ART cycles for all cycles, cycles before egg retrieval and cycles before
ET/FET (147). Pregnancy outcomes such as SA, stillbirth and live birth among cycles
with at least one ET were also collected and examined. Logistic regression was used to
estimate ORs and 95% CIs, taking into account clustering by state, clinic and patient for
smoking and intensity of smoking with the previously mentioned outcomes (147).
Results showed that smoking was reported in over 12,000 (1.9%) ART cycles and
that smokers were more likely to be younger, multiparous, of non-Hispanic White race
and be diagnosed with tubal and male factor infertility (147). Smokers had lowered odds
of implantation, IUP and live birth, along with an increase in the odds of SA, however, all
estimates were not statistically significant (147). While this study incorporated a large,
nationally representative sample and found results consistent with past studies,
limitations included recall bias and misclassification, as exposure status was not verified
with a biomarker. The authors also stated that women undergoing ART treatment tend to
under-report their smoking habits, which can lead to exposure misclassification and
consequently, bias estimates toward the null. The study did not address partners’ smoking
history or SHS exposure, which have shown to be important risk factors.

Summary
The 2020 U.S. Surgeon General report stated that there is suggestive but
insufficient evidence of a causal relationship between maternal smoking and SA (12).
However, a number of studies examining the association were not used in the report. As
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shown in Table 3, there is a lack of prospective cohort studies in this area. The majority
are cross sectional, case-control or retrospective designs which are susceptible to
misclassification, and cannot assess temporality, which threaten inferential causality.
There is also a paucity of studies examining pre-conception smoking and among past
smokers. Exploring smoking at different time periods such as before and during
pregnancy, can help further elucidate potential mechanisms.

Table 3: Studies on Active Smoking and Spontaneous Abortion
Study
Design
Armstron
CS
g et al.,
1992
(141)

N

ART

Exposure

Outcome
SA

Esti
mate
1.68a

95%
CI
1.57 1.79

~56000
women

No

Selfreported

Ness et
al., 1999
(142)

CACO

400 cases,
570 controls

No

Urinary
Cotinine

SA

1.80a

1.3 2.6

Mishra et
al., 2000
(143)

CS

2617 women

No

Selfreported

SA

2.00a

1.50 2.80

Winter et
al., 2002
(123)

RCS

1196
pregnancies

Yes

Selfreported

EPL

2.00a

1.27 3.15

Linsten et
al., 2005
(146)

CS of
PCS

8457 women
w/ 1st IVF
cycle

Yes

Selfreported

Live birth
rate after
IVF

0.72a

0.61 0.84

Nested
343 cases,
CACO 1578 controls

No

Selfreported
(preconception)

SA

1.20a

1.04 1.39

No

Selfreported

SA

1.16a

1.08 1.26

Nielsen
et al.,
2006
(144)
Hyland et
al., 2015

CS

77 805
women
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(145)
Rockhill
et al.,
2019
(147)

RCS

175885 ART
cycles

Yes

Selfreported
(pre-ART)

SA

1.05a

0.96 1.15

Hughes
and
Brennan,
1996
(131)

MA

7 studies

No

Mostly
selfreported,
few
biomarkers

SA

0.83 1.8*

NA

Waylen
et al.,
2009
(137)

MA

4 studies
(100 to 6903
cycles)

Yes

Selfreported
and
biomarkers

Live birth
per cycle

0.54b
*

0.30 0.99

7 studies
(211
smokers,
3959
matched
controls)

Yes

Selfreported
and
biomarkers

SA

2.65b
*

1.33 5.30

Selfreported
and
biomarkers
Selfreported
and
biomarkers

SA

1.23b
*

1.16 1.30

Live birth
rate per
cycle

0.59b
*

0.44 0.79

Pineles et
al., 2014
(148)

MA

50 studies

Both

Budani et
al., 2018
(138)

MA

7 studies
(3407
smokers, 738
nonsmokers)

No

8 studies
Yes
SelfSA rate
2.22b 1.10 (226
reported
per
*
4.48
smokers,
and
clinical
1796
biomarker pregnancy
nonsmokers)
CS - Cross-sectional, RCS - Retrospective cohort study, PCS - Prospective cohort study,
CACO - Case-control, MA - Meta-analysis
a - Adjusted odds ratio
b - Pooled OR/RR
* - Some individual studies adjusted for confounders
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Secondhand Smoke Exposure and Spontaneous Abortion
Several individual studies have examined SHS exposure and SA (122,145,149–
151), however, studies are limited and results are inconsistent (139,140,152). Hyland and
colleagues used a large cross-sectional study to examine the effect of lifetime SHS
exposure among 40,850 never-smoking women from the Women’s Health Initiative
observational study. Exposures, outcome and relevant covariate data were self-reported
via questionnaire (145). Nonsmoking women with the highest levels of lifetime SHS
exposure, including childhood SHS exposure greater than 10 years; adult home SHS
exposure greater than 20 years and adult work SHS exposure for more than 10 years, had
a significantly increased odds of SA compared to nonsmoking women with no SHS
exposure (aOR: 1.17; 95% CI: 1.05, 1.30) after adjusting for age, BMI, gravidity, oral
contraceptive use, race, education and alcohol use (145). A significant dose-response
effect was also established among SHS exposure and SA (p value = 0.01) (145).
Limitations included the cross-sectional study design which is a weaker design to infer
causation and under-reporting of tobacco smoke exposures which can lead to
misclassification and a downward bias. The authors stated that home pregnancy tests
were not readily available which limited the outcome to be recognized by the patient or
by physician and could have also driven estimates toward the null (145).
A large clinical prospective cohort study was done in 1991 by Ahlborg and Bodin,
examined passive smoke exposure during pregnancy on pregnancy outcomes. The study
enrolled 4,787 women attending prenatal care centers in Sweden (149). The authors
defined pregnancy outcome as either SA or stillbirth and relied on self-reported exposure
data. The only significant results found were among first-trimester intrauterine deaths,
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which showed an increased risk for passively exposed women at work (aRR:2.16; 95%
CI:1.23, 3.81) (149). They also showed that active smoking was associated with
intrauterine deaths, but not passive smoke exposure in the home. While this was a large
prospective study, results may be biased because of self-reported data and lack of
adjustment of important confounders. The authors also stated that more quantitative
measures of exposure at different time points were another limitation to their study.
In 1992, Windham and colleagues used a large case-control study to examine
maternal SHS exposure during pregnancy and SA (150). Cases were defined as women
who had a SA recorded at local hospitals and exposure information were self-reported via
a telephone interview. Results showed that pregnant women exposed to SHS for an hour
or more a day had significantly increased of odds of SA (aOR:1.5; 95% CI: 1.2, 1.9)
compared to women who reported no SHS exposure (150). However, the same authors
conducted a similar study using a large prospective cohort of 5000 women in 1999 and
found no significant results (aOR1.01; 95% CI: 0.80, 1.27) between maternal SHS
exposure and SA (152). This latter study differentiated SHS exposure from home, work
or either compared to the previous study in 1992. While the prospective cohort was a
larger sample, the authors reported that similar limitations such as reporting bias,
misclassification, unidentified confounders and lack of more objective, quantitative
exposure measure such as cotinine to accurately measure SHS exposure (150,152). These
contradicting results further add to the inconsistencies among estimates from studies
analyzing SHS exposure and SA.
In 2006, George and colleagues used a population-based case-control study to
examine the relationship of SA with SHS exposure using plasma cotinine concentrations
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(151). The authors claimed to have conducted the first study assessing SHS exposure
using plasma cotinine levels and SA. Cases were defined as having a SA at 6 or 12 weeks
of gestation and exposure information was self-reported weekly before and after
conception (151). Plasma cotinine was measured from blood samples taken at time of
miscarriage. Active smokers were defined as having cotinine levels greater than 15
ng/mL and SHS exposure between 0.1 and 15 ng/mL (151). Nonsmokers had plasma
cotinine levels less than 0.1 ng/mL. The results after adjusting for relevant confounders,
showed significant increases in the odds of SA for SHS exposed women (aOR:1.67; 95%
CI: 1.17, 2.38) compared to nonsmokers (151). Some possible limitations included the
study design, using a case-control study does not allow for temporality to be established,
and the authors did not examine dose-response relationships which is also important in
assessing causality.
Meta-analyses conducted have also shown contradicting results (148,153,154). In
2011, Leonardi-Bee and others conducted a systematic review and meta-analysis of 19
studies to assess the risk of adverse fetal outcomes among nonsmoking pregnant women
with SHS exposure (154). They looked at several outcomes including SA which was
defined as death before 20 weeks’ gestation and stillbirth, defined as death between 20
weeks’ gestation and birth. SHS exposures were assessed either through self-report or a
biochemical measure. The authors did not find a significant association among SHS
exposure and SA from 6 studies (pooled OR: 1.17; 95% CI: 0.88, 1.54) (154). The
authors conducted sensitivity analyses with similar findings and reported low
heterogeneity between studies. Also, most of the studies relied on self-ported exposures
and pooled ORs were not adjusted for important confounders. Another significant
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limitation of all the previously mentioned studies is a lack of assessment of infertility
within the association of SHS exposure and SA. As stated before, there is a significant
increased prevalence of SA among the in infertile population and how it may modify the
association is essential in accurately estimating an unbiased effect.

Spontaneous Abortion after Medically Assisted Reproduction
Conception and pregnancy outcome studies can be designed to better explore risk
factors since the emergence of MAR. As previously described, Meeker and colleagues
analyzed adverse pregnancy outcomes and maternal exposure to SHS among women
undergoing ART treatment (139). Maternal exposure to SHS was self-reported on
questionnaires and urinary cotinine levels adjusted for creatinine were measured at the
time of ART treatment. Among all non-smokers, the median cotinine concentration
adjusted for creatinine was 57.1 ng/mL. After adjusting for confounders, no significant
association was found between urinary cotinine and SA (aOR: 0.51; 95% CI: 0.21, 1.24)
(139). The authors then used a larger population of 1449 women to analyze women with
childhood SHS exposure from their parents and SA, using self-reported exposure data.
The authors also found no association with any current SHS exposure and SA (aOR:
0.80; 95% CI: 0.30, 2.14), as well as, no significant dose-response effects (140).
However, childhood SHS exposure was found to have significantly higher odds of SA
compared to women with no childhood SHS exposure (140). Limitations for the latter
study included the lack of external validity and the high levels of discordance between
urinary cotinine and self-reported SHS exposures. The authors stated that other places of
exposures besides at home and at work were not assessed and given cotinine’s half-life,
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one measurement can lead to misclassification (139,140). They also discussed the doseresponse fallacy where the exposure threshold is lower than expected for the lowest
exposed group, leading to underestimated effects (140).
As described earlier, Benedict and associates also examined SHS exposure on
IVF success rates with a retrospective analysis of a prospective cohort study. Cotinine in
follicular fluid was measured at the time of egg retrieval per cycle. Women with levels
greater than 1.11 ng/mL were defined as SHS exposed nonsmokers and levels less than or
equal to 1.11 ng/mL were defined as unexposed nonsmokers (122). Treatment and
outcome information were extracted from subject’s medical record. The final population
included 1909 self-reported non-smoking women undergoing IVF (122). After adjusting
for age, BMI, year of IVF and the type of down-regulation, SHS exposed nonsmokers
were significantly associated with decreased live birth rates after IVF, compared to
unexposed nonsmokers ((OR: 0.75; 95% CI: 0.57, 0.99) and (aRR: 0.81; 95% CI: 0.66,
0.99)) (122). Previously mentioned limitations remained including generalizability of
results given the specific population and the cross-sectional nature which is a weak
design to infer causality.

Summary
There is also suggestive but insufficient evidence to support a causal relationship
between SHS exposure and SA. However, most studies described earlier did not find a
significant association and few that did used designs that are more subject to biases such
as confounding and selection bias. The only two prospective cohort studies done were
inconclusive and did not use an objective biomarker such as cotinine to verify exposure
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status. Of the three studies listed in Table 4 that showed significant associations, two used
self-reported exposure information and only one found a significant dose-response effect.
Self-reported SHS exposure data are subjected to recall bias and under-reporting, which
can create misclassification and null associations. Almost every study measured SHS
exposures during pregnancy on SA; however, pre-conception SHS exposure may also
affect SA through similar mechanisms. Adjusting for important confounders and taking
into account infertility diagnoses among the MAR population is also crucial to
understand the biological mechanism of SHS exposure on SA.

Table 4: Studies on Secondhand Smoke Exposures and Spontaneous Abortion
Study
Design
Ahlborg & PCS
Bodin,
1991
(149)

N

ART

Exposure

Outcome

Estimate

4,687
women

No

Selfreported

Firsttrimester
fetal loss

2.16a

95%
CI
1.23 –
3.81

Windham
et al., 1992
(150)

CAC
O

626
cases
1,300
controls

No

Selfreported

SA

1.50b

1.2 –
1.9

Windham
et al., 1999
(152)

PCS

~ 5000
women

No

Selfreported

SA

1.01b

0.80 –
1.27

George et
al., 2006
(151)

CAC
O

463
cases
and 864
controls

No

Plasma
cotinine

SA

1.67b

1.17 –
2.38

Meeker et
al., 2007a
(139)

CS
of
PCS

1449
women

No

Selfreported

SA

0.80b

0.30 2.14
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Meeker et
al., 2007b
(140)

CS
of
PCS

921
women

Yes

Urinary
cotinine

SA

0.51b

0.21–
1.24

Benedict et
al., 2011
(122)

CS
of
PCS

1909
women

Yes

Follicular
fluid
cotinine

Live Birth

0.81a,
0.75b

Hyland et
al., 2015
(145)

CS

77 805
women

No

Selfreported

SA

1.17b

0.57–
0.99,
0.66–
0.99
1.05 1.30

Salmasi et
al., 2010
(153)

MA

9
studies

Both

Selfreported&
biomarker

SA

1.17c*

0.97 1.41

LeonardiBee et al.,
2011
(154)

MA

6
studies

No

Selfreported
and
biomarker

SA

1.17c*

0.88–
1.54

Pineles et
al., 2014
(148)

MA

17
studies

Both

SelfSA
1.11c*
0.95 reported
1.31
and
biomarker
CS - Cross-sectional, RCS - Retrospective cohort study, PCS - Prospective cohort study,
CACO - Case-control, MA - Meta-analysis
a - Adjusted risk ratio
b - Adjusted odds ratio
c - Pooled OR/RR
* - Some individual studies adjusted for confounders

SECTION E - N-Acetyltransferase 2

As previously mentioned, there are over 7,000 chemicals in tobacco smoke and
over 70 that are carcinogenic (96). Carcinogens such as polycyclic aromatic
hydrocarbons and heterocyclic amines have been found to cause DNA adducts which can
lead to mutations, that can initiate carcinogenesis (13,155). N-Acetyltransferase 2
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(NAT2) is a vital enzyme used in the metabolism and detoxification of xenobiotic
substances, including therapeutic drugs and exogenous chemicals such as the ones found
in tobacco smoke (13). NAT2 is primarily expressed in the liver and gastrointestinal tract,
and catalyzes the transfer of an acetyl group to compounds, either activating or
deactivating it. (13,155).
Single nucleotide polymorphisms (SNPs) within the NAT2 alleles are responsible
for determining NAT2 genotype and phenotype status. Seven most frequent SNPs studied
are rs1801279 (191G>A), rs1041983 (282C>T), rs1801280 (341T>C), rs1799929
(481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 (857G>A) (156). One
study compared the accuracy of using different NAT2 SNP genotyping panels and found
that a four SNP genotype panel of rs1801279 (191G>A), rs1801280 (341T>C),
rs1799930 (590G>A) and rs1799931 (857G>A) produced the highest accuracy in
predicting NAT2 acetylator status (156). NAT2 acetylator status is usually coded by the
number of variants within the four SNP panel. If the subject had no variants among the
four SNPs, they were classified as a rapid acetylator; one variant as an intermediate
acetylator and two or more variants as a slow acetylator (156). NAT2 acetylator status
explains the effectiveness of therapeutic medicines, differences in cancer risk and how
the body metabolizes environmental toxins (14).
In 2011, Sabbagh and colleagues compiled frequency data for the most important
NAT2 variants from 128 population samples, to examine whether different dietary
patterns and lifestyles can account for inter-population differences in NAT2 variation
(14). They grouped together intermediate and rapid acetylators because there had similar
acetylation rates and were compared to slow acetylators. The population was categorized
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into four major continental areas (Africa, America, Asia and Europe). The highest
percentage of genetic variation was found within populations at 87.4% and 8.3% genetic
variation across continents (14). The authors found that the slow acetylators accounted
for 59% of individuals in Europe and higher percentages of slow acetylators in other
places such as the Middle East, Southeast Asia and India (14). On the other hand, the
slow acetylator status was uncommon in Northeast Asia, with a prevalence of 18%,
which also showed higher percentages of the rapid/intermediate acetylator status (14).
Furthermore, the distribution of slow acetylators within Africa and America were highly
heterogenous with notable differences between the populations.
Several studies have investigated the association of NAT2 polymorphisms and
several cancers such as bladder and colorectal cancer and allergic disorders such as
asthma (157) with inconsistent results. A few of those studies further explored effect
modification by smoking status. The research showed significant interactions between
current smoking and slow acetylation status, with increased risk of bladder cancer (158–
161), breast cancer (162,163), colorectal cancer (164,165) and lung cancer (166,167).

NAT2, Smoking, and Fertility-related Outcomes
Some recent studies have examined the relationship between NAT2
polymorphisms and endometriosis: one study found that there was an increased risk of
endometriosis among slow acetylators (168), another found no association (169), one
meta-analysis showed a significant risk only among Asians (170) and lastly, one study
showed that some SNPs may increase risk of endometriosis and others may be protective
(171). There have been few studies to date that have examined the interaction of NAT2
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polymorphisms with tobacco smoke on fertility. In 2011, Taylor and associates showed
that among slow acetylators, current smoking was significantly associated with reduced
fecundability (fecundability odds ratio (FOR): 0.34: 95% CI, 0.22, 0.90) among office
working women after adjusting for significant confounders (15).
More studies on NAT2 polymorphisms and its interaction with smoking were
focused on male infertility. Two recent contradicting case-control studies included Jiang
and colleagues who showed no significant association between NAT2 polymorphisms
and risk of idiopathic male infertility (IMI) (16), while Trang and associates showed that
the rs1799929 and rs1799930 SNPs significantly increased the risk of IMI (17). In 2014,
Yarosh and colleagues found that among men with a slow-acetylation status, cigarette
smoking was significantly associated with an increased risk of IMI (OR 1.71, 95% CI
1.02, 2.87, P = 0.042) (172). These studies have emphasized the importance of further
understanding gene-environmental interactions on fertility outcomes, and the need for
more research.

SECTION F - Selection Bias in Prospective Cohort Studies

Selection bias due to differential loss of follow-up, also known as attrition bias, is
one major source of potential bias in prospective cohort studies and randomized
controlled trials (173). This occurs when loss to follow-up of study participants is jointly
associated with both the outcome and the exposure (173). Figure 1 shows two examples
of selection bias due to loss to follow-up where the main exposure is smoking (A), the
outcome is conception (Y), a set of measured confounders (L) and a set of unmeasured
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confounders (U) are displayed in a casual diagram. When subjects are censored (C) either
because of loss to follow-up or missing outcome data, they are removed from the study at
the time of being censored. This restricts the data to the uncensored observations, which
is why C is conditioned on in Figure 1. Conditioning on a collider C as in the bottom
diagram in Figure 1 or conditioning on a descendent of a collider L in the top diagram in
Figure 1 induces selection bias on the path between exposure A smoking and outcome Y
conception (Figure 1) (174).

Figure 1. Example of Selection Bias Due to Censoring

A

L

C

Y

U
OR
L
A

C

Y

U

Causal diagrams such as directed acyclic graphs are one way to help to identify
potential selection bias. Another method to identify potential selection bias due to
censoring is to compare the prevalence of exposures and covariates of non-responders or
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partial responders to those who remained in the study and identify significant differences.
Sensitivity analyses can also help to assess the potential impact of attrition bias, by
assuming a particular distribution of the outcome among all non-responders for example,
all censored subjects conceived or all censored subjects did not. However, this technique
yields conditional estimates which are difficult to interpret and have shown to be
insufficient in correcting selection bias.
A more robust method used to control for selection bias due to censoring is the
inverse probability weighting (IPW) technique. In an IPW analysis, a pseudo-population
is created by weighting the probability of being followed up in the study given a set of
risk factors associated with being lost to follow-up and the outcome. The inverse of the
probability of being followed up is computed and included in a weighted analysis for
everyone who were lost to follow-up. (173,175). Hence, the subjects who were followed
up, account for themselves and those lost to follow-up up with similar characteristics. For
example, there are five nonsmokers in a cohort study of the same age, BMI, race and
AMH levels, and 4 are lost to follow-up. In this scenario the estimated probability of
being followed up (uncensored) is 1/5 = 0.2 and the nonsmoker who was followed up
received a weight of 5 (1/0.2). This means that in the pseudo-population, there will be 5
copies of the uncensored nonsmoker to account for the 4 who were censored (176).
In IPW, there are assumptions that must be met in order for valid estimation of
casual effect measures. The first assumption of IPW is conditional exchangeability,
which assumes that there are no other factors, L, that contribute to the loss of follow-up
or selection bias. Sensitivity analyses can be done to test the robustness of estimates by
including additional variables, L, that may explain the selection bias (177). The second
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assumption is positivity, which assumes a non-zero probability of being censored within
every unique exposure combination. And lastly, the model used to estimate the weights
must be correctly specified (177). All these assumptions must hold in order to accurately
estimate effect that have been adjusted for selection bias due to lost to follow-up.

Rationale
Tobacco smoke exposure is one of the leading preventable causes of mortality and
morbidity in the U.S. (11), and its effect on natural and assisted conception and adverse
pregnancy outcomes needs to be further examined with more substantial and conclusive
evidence. There is a lack of exposure data validation with biomarkers, assessment of the
cumulative effects of active smoking and SHS exposure, evaluation of dose-response
effects and the use of tobacco smoke exposure at different time points to fully capture the
effect and its biological mechanisms. Many studies in the past have not adjusted for all
important confounders or explored potential effect modifiers. More large-scale,
longitudinal prospective studies are needed with different age groups to fully determine
differences throughout the reproductive lifespan. Lastly, reducing the potential for bias,
and conducting appropriate statistical tests should be taken into consideration.
The objectives of this study will help to address some of the gaps in the literature
and add new, relevant knowledge in regard to the effect of pre-conception tobacco smoke
exposures on fertility and pregnancy outcomes and the interaction with NAT2 acetylator
status. This study will add new evidence of the association between tobacco smoke
exposures and fecundability and SA within in a clinical population. Validation of
exposures using cotinine measurement and adjustment of selection bias due to loss of
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follow-up can also strengthen the accuracy of estimates. Findings from this study has
clinical implications for fertility care and counseling and can help to bring about more
public health policies and interventions to reduce the impact of smoking and SHS
exposures.
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IV. METHODS

Study Design
The data used in this study came from the Louisville Tobacco Smoke Exposure,
Genetic Susceptibility and Infertility (LOUSSI) study (Granting institution- Eunice
Kennedy Shriver National Institute of Child Health and Human Development; grant
number- 1R15HD087911-01; Principal Investigator - Dr. Kira Taylor). Its objective was
to estimate the cumulative impact of tobacco smoke exposure and its interaction with
NAT2 acetylator status on ovarian reserve and IVF-related outcomes. This study had
both cross-sectional and prospective data collection components. The prospective
component of the LOUSSI study, examining conception and pregnancy outcomes, was
used for this dissertation. Institutional Review Board approval for this study was obtained
from the University of Louisville, IRB number: 16.0063.

Study Setting and Subjects
Study participants were recruited from existing and new patients attending the
University of Louisville Reproductive Endocrinology and Infertility (REI) clinic. The
clinic’s clientele included women of reproductive age seeking fertility counselling and/or
treatment and who resided in the Louisville and southern Indiana area. The inclusion
criteria for the LOUSSI study were all women aged 21 years and older seeking fertility
counselling and/or treatment at the University of Louisville REI clinic. Women illiterate
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in the English language or found to be pregnant at the time of enrollment were excluded
from the study.
Participating physicians and fellows assessed a potential subject’s eligibility and
invited her to take part in the study. If the patient expressed interest, a research assistant
present at the clinic would explain the benefits and risks of the research study and obtain
informed consent. Participating subjects were offered compensation with a $25 VISA gift
card. In July 2017, after 99 subjects were enrolled, the informed consent was modified to
include a section requesting permission to recontact the subject. If the subject agreed to
be recontacted, they were asked to leave a phone number, email and mailing address. The
final sample size of 264 women were enrolled from November 2016 through May 2018.

Data Collection and Study Instruments
After informed consent was obtained, each subject was assigned a unique
identification number which was used to label biological samples, questionnaires and
medical report extracts. One patient key recording the subject’s name and their respective
identification number was made and kept in a secured and locked cabinet at the clinic.
Three sources of data were used to retrieve all information from each subject after
informed consent was obtained. A supplemental smoking questionnaire (SSQ; appendix
A) was given to each subject to measure and record active (current and lifetime) and SHS
exposures (recent and the past year). Information from medical records were extracted to
obtain demographic data, medical history and other relevant variables. Laboratory assays
were done on urine samples collected to assess cotinine and NAT2 acetylator status.
Subjects were then followed to determine whether the subject conceived. Among those
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who conceived, pregnancy outcomes were also collected. Patients who gave permission
to be recontacted by email, phone or mailing address, were contacted after a period
greater than 6 months from enrollment to record any fertility treatments/procedures, and
conception and pregnancy outcomes. Medical records were re-reviewed at least 6 months
after the end of enrollment to update fertility treatments/procedures and pregnancy
outcomes. The subjects who gave permission were personally recontacted twice:
September 2018 through January 2019 and July 2019 through September 2019, to obtain
further information on conception and pregnancy outcomes.

Study Instrument – Supplemental Smoking Questionnaire
The SSQ (appendix A) was used to estimate current and the previous years’
tobacco smoke exposure, for both active and SHS exposures. Questions used were
initially adapted from two nationally validated surveys: the National Health and Nutrition
Examination Survey III and the National Health Interview Survey but were revised to
more precisely address the research questions and the population of the LOUSSI study.
There were three questionnaires provided: one each for current smokers, former smokers
(women who quit over a month ago), and non-smokers. The current and former smokers’
questionnaire contained questions regarding the total amount of years smoking and
number of cigarettes or packs smoked per day. The former smoker’s questionnaire also
included the month and year the participant last smoked.
All questionnaires included three questions to assess SHS exposures (recent and
the past year) measured using a four-point scale (never (1), rarely (2), often (3) and every
day (4)). Early childhood SHS exposure was assessed by asking subjects “how often were
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you exposed to secondhand smoke inside your home while growing up?” There were two
questions regarding SHS exposures in the past year, specifically “how often were you
exposed to secondhand smoke inside your home in the past year?” and “how often have
you been exposed to secondhand smoke inside other places besides your home (example:
a friend or relative’s house, your workplace, bars or restaurants, in your car or someone
else’s car) in the past year?” The questionnaires were later modified and approved by the
IRB in July 2017 to include questions asking if the participant is living with smoker/s;
and if so, how many smokers and their relationship to the smokers. Lastly, the revised
version also included a question regarding other sources of nicotine such as nicotine gum
and e-cigarettes, since their use would be reflected by cotinine in the urine sample.

Study Instrument – Medical Record Data
The medical record data collection form (appendix B) was created to document
important risk factors of both fertility-related outcomes and tobacco smoke exposure,
based on the current literature. Research assistants trained by co-investigators and
research physicians extracted the information from the subject’s intake history form and
medical records.
Variables collected from the medical record are listed below:
•

Demographics (date of visit, age at enrollment, ancestry or race);

•

Anthropometrics and physiological characteristics (height, weight, BMI, and blood
pressure);

•

Social history and behavioral variables (occupation, marital status, partner status,
length of time with current partner, routine exercise; hours of exercise per week,
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times per week and type of exercise; routine exposure to chemicals, diet restrictions,
how many meals per day, current tobacco use; packs per day with total amount of
years smoked; ever smoked 100 cigarettes; alcohol consumption; number of alcoholic
drinks per week; caffeine consumption; number of caffeinated drinks per week and
use of other drugs);
•

Obstetrics and gynecology (OB/Gyn) variables (gravidity, regularity of periods,
average menstrual cycle length, age at menarche, consistent ovulation, and history of
sexually transmitted infections);

•

Reproductive measurement variables (AMH values and dates, AFC values and dates,
duration of infertility, type of infertility diagnoses and self-reported PCOS);

•

Medically assisted reproduction variables (any MAR procedures done after
enrollment, date of procedures, and type of treatment (OI/IUI/IVF/FET));

•

Conception (first clinical conception outcome since enrollment, method of the first
conception since enrollment, last menstrual period of first conception or date of
conception (for OI/IUI/IVF/FET), expected due date);

•

Pregnancy outcomes (first pregnancy outcome since enrollment).

Data Source – Cotinine Assays
Each urine sample collected at enrollment, labelled with the corresponding
patient’s identification number was divided into two samples: one for cotinine analysis
and the other for DNA extraction to perform NAT2 genotyping. All urine samples for
cotinine analysis were stored at 4 degrees Celsius for up to 72 hours and then aliquoted
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and frozen at -80 until the day of the cotinine assay. Cotinine assays were done at the
University of Louisville’s Medical Dental Research Building.
Cotinine ELISA kits (Calbiotech, Spring Valley, CA) were used to measure the
patient’s cotinine levels to differentiate active, passive and no exposure to tobacco smoke
in the past 24 to 72 hours. Standard controls and a negative control (water) were done in
triplicate, while patients’ samples were either assayed in triplicate or duplicate. A
spectrophotometer was used to measure the absorbances of the standards, controls and
samples. The mean, standard deviation and relative standard deviation were calculated
for all absorbances. Outliers among triplicate samples were removed, and if the relative
standard deviation was greater than 0.1, the sample was re-assayed in triplicate.
Firstly, a standard curve was constructed by plotting the mean absorbances of the
cotinine standards versus the cotinine standard concentrations on a line graph. Using the
fitted standard curve, cotinine concentrations of each subject was derived from their
corresponding average absorbance. Urinary cotinine concentrations were estimated to the
nearest 0.50ng/mL and the maximum detectable level of cotinine for this assay kit was
100ng/mL. All assay analyses were done by two research assistants and compared to
increase the accuracy and reliability of results.

Data Source – Genotyping Assays
DNA was extracted using the ZR Urine Isolation Kit TM (Irvine, CA, USA). DNA
extractions were done on a weekly basis then stored at -20 degrees Celsius until time of
genotyping. NAT2 genotyping was done at the University of Louisville’s Clinical and
Translational Research building.

74

NAT2 acetylator status was assessed using a four SNP genotype panel with the
assistance of a trained laboratory technician. Twenty percent or more of the samples in
each batch were done in duplicate along with a negative control (blank or water). If the
genotype status was not clear from the four SNPs due to a lack of DNA amplification or
contamination, samples were repeated in duplicate if there were remaining DNA. All
assay analyses were done by two research assistants and compared to increase the
accuracy and reliability of results.
Different alleles of NAT2 have been associated with rapid and slow acetylation.
The four SNPs (rs1801279(191G>A), rs1801280(341T>C), rs1799930(591G>A),
rs1799931(857G>A)) were coded by the number of variants. If the subject had no
variants among the four SNPs, they were classified as a rapid acetylator; one variant
classified them as an intermediate acetylator and two or more variants as a slow
acetylator (Table 5). Intermediate and rapid acetylators were grouped together as they
have been shown in the literature to have similar acetylation characteristics (14).

Table 5. Example of NAT2 Phenotype Status Using Four (4) SNPs
SNP

191

341

590

857

# of variant alleles

Phenotype

Patient A

0

0

0

0

0

Rapid

Patient B

0

0

1

0

1

Intermediate

Patient C

1

0

1

0

2

Slow

Patient D

1

1

0

1

3

Slow
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Study Instrument – Recontact Questionnaire
Subjects who agreed to be recontacted by either phone, email or mailing address
as indicated on their informed consent were contacted at least 6 months after enrollment
to obtain information on fertility treatments/procedures, and conception and pregnancy
outcomes. If an email address was provided, an initial email was sent out to notify
subjects of the recontact and they were given the option to answer the questions by email
or reply with convenient times to call via phone. The next method was phone call, if a
phone number was given and working. Three attempts were made, leaving a brief
voicemail if no one answered. If no contact was made, another email with the questions
was sent. And lastly, if mailing addresses were given and up to date, a letter was mailed
using the U.S. postal service as a final attempt to recontact the patient.
Using the recontact questionnaire (appendix C), they were first asked “Have you
conceived since enrollment in the LOUSSI Study(yes/no)”. If the subject answered yes,
they were then asked whether it was a natural conception or if they used MAR
procedures. The type of MAR procedure used and its date, if conception was attained, the
last menstrual cycle date or conception date, the due date of the first conception, whether
or not they were currently pregnant, and the pregnancy outcome were recorded. If the
subject answered that they had not conceived since enrollment, they were asked whether
or not they were still trying to conceive. If they were no longer trying, they were then
asked how long after enrollment did they stop trying and if they were using any form of
contraception. Subjects were recontacted twice after enrollment ended, firstly from
September 2018 through January 2019 and then from July 2019 through September 2019
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to obtain further information on conception and pregnancy outcomes if they gave
permission.
Data collection and entry, as well as assay analyses for all sources of data were
done by two trained research assistants and compared for accuracy. Discrepancies were
resolved by reviewing the medical records and hard copies of the SSQ.

Outcome Assessment
Conception outcomes were either extracted from medical records or from the
patients who were successfully recontacted. For this study, the first conception and
corresponding pregnancy outcome since enrollment were used in the analysis.
Follow-up time measured in months or TTC, for those who conceived was
prospectively observed and measured by calculating the number of months between
enrollment and first conception, including the month of enrollment and the month of
conception. This was a straightforward calculation for spontaneous conceptions, by
subtracting the month of enrollment from last menstrual cycle and adding 2. For subjects
who had MAR procedure(s), their TTC was calculated in cycles/intervals at risk with
MAR cycles used as a time-varying covariate from enrollment to first conception.
Among those who did not conceive and did not use MAR during the study period,
follow-up time measured in months was calculated from enrollment to either the date of
the last visit at the clinic in the medical record that indicated that the subject was not
pregnant or month of last personal re-contact, if the permission was given. For subjects
who had MAR procedure(s) and did not conceive, their follow-up time was calculated in
intervals at risk with MAR cycles as a time-varying covariate from enrollment to the
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same endpoints stated above based on whether or not they gave permission to recontacted.
If subjects were seen only once at the clinic, were not personally recontacted, and
did not have at-risk follow-up time, they were removed from the TTC analysis. Months
with contraception use and months noted on subject’s medical record that intercourse was
advised against, were excluded from the follow-up time because the subjects were
theoretically not at risk for pregnancy during those months. Same-sex couples who did
not use MAR after enrollment were also excluded from the TTC analysis.
Pregnancy outcomes of the first conception since enrollment were either extracted
from medical records or retrieved from successful recontact. The answers included live
birth, SA, ectopic pregnancy, molar pregnancy and stillbirth or fetal death. Live birth and
SA were used in the analysis due to lack of events in the other categories.

Exposure Assessment - Current, Active Smoking
Current, active smoking was measured and assessed using the SSQ and cotinine
levels. A current, active smoker by the SSQ was defined when the subject self-reported as
a current smoker or if the subject reported quitting smoking under a month ago. Also, if
any subject had a urinary cotinine level of 100ng/mL, they were defined as a current,
active smoker, regardless of which questionnaire was filled out, otherwise were defined
as a nonsmoker.
A cumulative lifetime smoking variable using pack-years was created by
multiplying the number of packs of cigarettes smoked per day by the number of years the
person has smoked. For example, 1 pack-year is equal to smoking 1 pack per day for 1
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year. If the participant reported number of cigarettes per day, that number was initially
divided by 20 to convert it to packs. The pack-years variable was further categorized into
three groups. Subjects with no pack-years (referent) was compared to pack-years of 5 or
less and pack-years greater than 5. Self-reported smokers and former smokers provided
either the number of cigarettes smoked per day or the number of packs smoked per day, if
it were the latter, that number was multiplied by 20. The total number of cigarettes per
day for all subjects was also calculated and grouped into three categories: 0 cigarettes
(referent), 9 cigarettes or less and greater than or equal to 10 cigarettes.

Exposure Assessment – SHS Exposure (Recent and Past Year)
Recent and the past year’s SHS exposure was assessed for only women defined as
nonsmokers, using the objective measure described above. Current, active smokers were
excluded from the SHS analysis. To examine current SHS exposure, cotinine values were
categorized into three groups. Subjects with cotinine values of 0 ng/mL were place in an
unexposed group (referent), values greater than 0 ng/mL and less than 4.0 ng/mL were
considered as low exposure; and cotinine values greater than or equal 4.0 ng/mL and less
than 100 ng/mL were considered highly exposed to SHS.
Using the SSQ, a score was created for adult SHS exposure in the past year. The
two SHS exposure questions on the SSQ “how often were you exposed to secondhand
tobacco smoke in your home in the past year?” and “how often were you exposed to
secondhand tobacco smoke in other places such as work, restaurants, friends and family’s
homes in the past year?” were combined to create the score. The responses to each
question were given a numerical value as follows: never (1), rarely (2), often (3) and

79

every day (4) and summed. The combined score for adult SHS exposure in the past year
variable ranged from 2 to 8 and was grouped into 4 categories. A description of how the
SHS exposure in the past year variable was categorized is presented in Table 6.

Table 6. Description of SHS Exposure in the Past Year Variable from SSQ
Score

4-Level Group

2

Answers to 2 SHS Questions
from SSQ (SHS in the home,
SHS in other places)
(never, never)

3

(never, rarely)

Low (1)

4

(never, often) or (rarely, rarely)

Intermediate (2)

5

(never, everyday) or (rarely, often)

Intermediate (2)

6

(rarely, everyday) or (often, often)

High (3)

7

(rarely, often)

High (3)

8

(everyday, everyday)

High (3)

Final
Grouping

None (0)
Low SHS
exposure

High SHS
exposure

Exposure Assessment – Combined Effect Exposure
A combined effect variable using the objective, current active smoking variable
and the final SHS exposure variable from the SSQ was created. The new combined effect
variable included three groups: non-smokers with low SHS exposure (referent), nonsmokers with high SHS exposure and current, active smokers. Table 7 shows the
treatment of all exposure variables used in this study.
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Table 7: Exposure Variable Definitions and Treatment in Modeling
Variable
Current, active smoking
Dichotomous

Definition
Smoker (1) = Cotinine level of 100 ng/mL or Selfreported as a Current Smoker
Non-Smoker (0) = Cotinine level < 100 ng/mL and
No Self-report of Current Smoker (Referent)

Pack-years
Categorical

0 = 0 pack-years (Referent)
1 = ≤ 5 pack-years
2 = > 5 pack-years

Total Number of cigarettes
Categorical

0 = 0 cigarettes per day
1 = ≤ 9 cigarettes per day
2 = ≥10 cigarettes per day

Cotinine*
Categorical

0 = 0 ng/mL (Referent)
1 = 0 < cotinine ≤ 4 ng/mL
2 = ≥ 5 ng/mL

Adult SHS exposure in the
past year*
Categorical
Adult SHS Score ≤ 3 (Referent)
No/Low Adult SHS Score  4
Intermediate/High
Combined effect exposure
(Current, Active Smoking and
Adult SHS Score)
Categorical

Non-smoker with Low Adult SHS exposure
(Referent)
Non-smoker with High Adult SHS exposure
Current, Active Smokers
* - Among objectively defined non-smokers

Important Covariates
Relevant covariates were chosen based on a theorized directed acyclic graph
(DAG) developed from a priori knowledge and were either collected at time of
enrollment if it was the patient’s first visit or extracted from the medical record at time of
the first clinic visit. These included age at the time of enrollment, BMI recorded by the
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clinic at time of enrollment, ethnicity/race, gravidity, age of menarche, average cycle
length, menstrual cycle regularity, history of previously diagnosed sexually transmitted
diseases, marital status, current routine exercise, alcohol consumption, caffeine
consumption, AMH level, self-reported length of infertility, ART treatment cycles, type
of ART treatment, and infertility diagnoses.
Age at enrollment, BMI at enrollment, gravidity, average cycle length, age of
menarche, self-reported length of infertility and AMH levels were recorded continuously.
Menstrual cycle regularity, history of past diagnosed sexually transmitted diseases,
marital status, routine exercise, alcohol consumption, caffeine consumption and MAR
cycle were dichotomized no or yes. Ethnicity was recorded as Caucasian, African
American, Asian/Pacific Islander, American Indian/Alaska Native, Middle Eastern,
Hispanic/Latin American and other. Lastly, the type of infertility diagnosis was collected
and included unexplained, tubal, uterine, ovarian, male factor, PCOS, other, unknown
and none. The infertility diagnoses were not mutually exclusive, and many women had
more than one diagnosis.

Data Analysis
Descriptive Statistics
All statistical analyses were performed using R Studio version 1.2.5 (Boston, MA,
USA). Descriptive statistics were calculated for covariates to examine their distributions.
Univariate analyses were conducted to examine the crude association between covariates
and exposure variables from Table 7 within three different populations (all individuals,
MAR users, and non-MAR users). This was done using Chi-square/Fisher exact test for
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categorical variables and Student’s T-test for normally distributed, continuous variables
or Wilcoxon rank-sum for non-normally distributed, continuous variables. Significant
differences were defined with p-value <0.05.
Covariates in the final multivariable logistic regression and survival analysis
models were initially chosen using both theory and data-based methods. Covariates
associated with the exposure with a p-value of less than 0.2 from univariate analyses
were included. However, age and BMI were retained in all models regardless of p-value
given their well-established associations with fertility or birth outcomes. Table 8 shows
the description and treatment of all chosen covariates used in the final models. Age was
dichotomized at the median, which demonstrated a shift in fecundability in this
population; BMI was dichotomized at the WHO’s obesity threshold (30 kg/m2). Age and
BMI had been previously shown to have a non-linear association with fecundability in
past studies. Race was dichotomized into African American and other races because it
showed the most significant association with pregnancy within the dataset compared to
other categorizations.

Table 8: Covariate Definitions and Treatment in Modeling
Variable
Age (years)

Type of variable
Dichotomous (at median)

Definition
0 =  33 1 = > 33

BMI (kg/m2)

Dichotomous
Continuous (Aim 2)

0 =  30

1 = > 30

MAR cycle

Dichotomous

0 = No

1 = Yes

Gravidity

Dichotomous (Aim 2)

0 = no prior pregnancies
1 = ≥ 1 prior pregnancy

Categorical (Aim 1)

0 = no prior pregnancies
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1 = 1 prior pregnancy
2 = ≥ 2 prior pregnancies
Marital Status

Dichotomous

0 = No

1 = Yes

Race

Dichotomous

0 = Other races
1 = African American

Alcohol Use

Dichotomous (Aim 2)

0 = No

NAT2 Acetylator
Status

Dichotomous

0 = Fast/Intermediate
1 = Slow

1 = Yes

MAR Type*
Dichotomous
0 = OI/IUI 1 = IVF/FET
* - Used only when modeling MAR cycles only population

Multivariable Models
Survival Analyses - Cox Proportional Hazard Regression Models
The dataset for survival analyses was constructed in a counting process structure
to include MAR cycle as a time-varying covariate. Each row in the dataset indicated a
time interval in months at risk for conception, categorized by whether or not the month
was a MAR cycle. The coxph and surv function in the survival package was used to run
Cox models. A cluster term for participant’s ID was included in the model to show that
participants may have multiple rows of data and produced estimates with robust standard
errors to address non-independence. Start time was defined as the month of enrollment
(time 0) and the stop time referred to either the month the subject had the event
(conception) or the month the subject was censored. Month of censorship was defined by
either the date of last re-contact, the date of last medical record visit, or the date the
subject reported last actively trying to conceive.
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A statistical test using the cox.zph function was used to assess the proportional
hazards assumption on all variables in the full models. The test examined the correlation
between survival time (or ranked survival times) and Schoenfeld residuals. A p-value less
than 0.05 indicated that the proportional hazards assumption was violated and the
Schoenfeld residuals were dependent on survival time. If this were the case, the
appropriate models were adjusted for an interaction term of the variable in violation and
time.
All models were evaluated for multicollinearity using variance inflation factors
using the vif function in the rms package, before and after confounding assessment.
Confounders were assessed using a combination of theory and data-based approaches.
The full models were initially fitted and variables that changed the estimate of the main
exposure by 10% when removed from the model were defined as data-based
confounders, and hence remained in the model. Age and BMI, however, were retained in
all models because of the consistent and strong evidence of associations with fertility in
the literature. Statistically significant variables were defined by a p-value less than 0.05.
There were six different exposure variables, and each were examined within the
following sub-populations: all follow-up time, MAR cycles only, and natural conception
(NC) follow-up time only. Women in the natural conception follow-up sub-population
contributed intervals of at-risk follow-up time for natural conception and did not use
MAR procedures during these intervals. The number of NC follow-up was estimated
using calendar months, as there was not data on ovulation available.
Among all follow-up time models, the time-varying MAR cycle variable (yes/no)
was included as a covariate. In the model that included MAR cycles only, the MAR type
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in the MAR cycle (IVF/FET vs. OI/IUI) was included as a time-varying covariate, as it
changed over intervals. Within these two sub-populations, models were analyzed using
Extended Cox regression because they included a time-varying covariate; whereas, the
NC follow-up time models used Cox proportional hazards regression. Hazard ratios of
fecundability also called fecundability ratios (FR) and 95 % confidence intervals were
estimated and reported. Main exposure variables with two or more categories such as
cotinine levels among non-smokers and the combined effect variable were further
examined ordinally for a dose-response effect, and their respective p-values for trend
were reported.

Specific Aim 1a: Current, Active Smoking and Fecundability
The effect of current, active smoking on fecundability was assessed using survival
analysis. The objectively measured smoking variable was used to compare current, active
smokers to non-smokers. The effect of cumulative lifetime smoking on TTC was also
analyzed, using pack-years as exposure. Fecundability ratios and 95% CI’s were
calculated and adjusted for potential confounders.

Specific Aim 1b: Recent and Past Year’s SHS Exposure and Fecundability
The effect of recent and past year’s SHS exposure on fecundability was assessed
using survival analysis among non-smokers. Firstly, current SHS exposure was assessed
using urinary cotinine levels collected at enrollment. Secondly, the SHS exposure scores
from the SSQ was used to compare low and high SHS exposure in the past year.
Fecundability ratios and 95% CI’s were calculated, adjusted for potential confounders.
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Specific Aim 1c: Combined Effect of Active Smoking With SHS Exposure and
Fecundability
The combined effect variable using current, active smoking and SHS score in the
past year on fecundability was assessed using survival analysis. Current smokers and
nonsmokers with high SHS exposure was compared to nonsmokers with low SHS
exposure. A dose-response effect or trend test was estimated by modelling the 3-level
categorical variable, ordinally. Fecundability ratios and 95% CI’s for were calculated,
adjusted for potential confounders.

Specific Aim 1d: Interaction of Active Smoking With NAT2 Acetylator Status and
Fecundability
Effect modification by NAT2 acetylator status on current smoking and
fecundability was examined by adding an interaction term for current, active smoking
and NAT2 acetylator status to the full model from the survival analysis in specific aim
1a. Fecundability ratios and 95% CI’s were calculated, adjusted for potential
confounders. Significant interaction was defined with a p-value <0.05 for the interaction
term.

Multivariable Logistic Regression Models
The effect of tobacco smoke exposures on spontaneous abortion versus live birth
was examined using multivariable logistic regression, among women who conceived.
Pregnancy outcomes variable was defined as either a live birth (0) or spontaneous
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abortion (SA)/miscarriage (1). The different tobacco smoke exposures from Table 7,
were analyzed with the pregnancy outcomes among all women who conceived.
Variables chosen for the full models included age, BMI, gravidity, marital status,
race and alcohol consumption, because of its known association with spontaneous
abortion. All models were evaluated for multicollinearity using variance inflation factors
with the vif function in the rms package, before and after confounding assessment.
Similar to Aim 1, age and BMI were retained in all models. Dose-response relationships
were assessed for exposure variables with more than 2 categories, by treating the variable
ordinally and their respective p-values for trend were reported.

Specific Aim 2a: Current, Active Smoking and Spontaneous Abortion
The effect of current, active smoking on the probability of SA was assessed using
multivariable logistic regression, comparing current active smokers to non-smokers. A
dose-response relationship was also assessed, using the total number of cigarettes per
day. The cumulative lifetime smoking on probability of pregnancy outcome was analyzed
using pack-years. Odds ratios and 95% CI’s were calculated, adjusted for potential
confounders.

Specific Aim 2b: Recent and Past Year’s SHS Exposure and Spontaneous Abortion
The effect of recent and past year’s SHS exposure among nonsmokers on
probability of SA was assessed using multivariable logistic regression. Firstly, current
SHS exposure was assessed using urinary cotinine collected at enrollment, grouped into 3
categories. Secondly, SHS exposure in the past year variable from the SSQ was assessed
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comparing high SHS exposure to low SHS exposure in the past year. Odds ratios and
95% CI’s were calculated, adjusted for potential confounders.

Specific Aim 2c: Interaction of Active Smoking With NAT2 Acetylator Status and
Spontaneous Abortion
Effect modification by NAT2 acetylator status on probability of SA was
examined by adding an interaction term for current, active smoking and NAT2 acetylator
status to the full multivariable logistic regression model from Aim 2a. Odds ratios and
95% CI’s were calculated, adjusted for potential confounders.

Specific Aim 2d: Combined Effect of Active Smoking and SHS Exposure and
Spontaneous Abortion
The combined effect variable using current, active smoking and SHS score in the
past year on probability of SA was assessed using multivariable logistic regression.
Current smokers and nonsmokers with high SHS exposure was compared to nonsmokers
with low SHS exposure. A dose-response effect or trend test was estimated by modelling
the 3-level categorical variable, ordinally. Odds ratios and 95% CI’s were calculated,
adjusted for potential confounders.

Selection Bias
Specific Aim 3a: Evaluation of Selection Bias due to Loss to Follow-up
The full dataset included women that contributed no follow-up time (n=257). The
dataset was divided into two groups: Group 1 contained women that were not asked
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permission to be personally followed up and Group 2 contained the remaining women
who were asked permission for personal follow-up. The groups were then each stratified
by the type of follow-up they received: either no follow-up, follow-up through medical
record only or personal follow-up by phone, email or mailing address only.
Characteristics of women in each group were then compared by the type of follow
up they received to evaluate the potential for selection bias due to loss to follow-up also
known as attrition bias or differential loss to follow-up. Group 1 compared women with
no follow-up data (n=21) to those with only medical record follow-up (n=74), whereas
group two compared no follow-up (n=7) to medical record follow-up only (n=35) and to
personal follow-up only (n=120). Differences between types of follow-up within each
group were assessed using Chi-square/Fisher exact test for categorical variables and
Student’s T-test for normally distributed, continuous variables or Wilcoxon rank-sum for
non-normally distributed, continuous variables. Significant differences were defined with
p-value <0.05. If there were no significant differences among Group 2 between medical
record follow-up only and to personal follow-up only, then Group 1 and Group 2 would
be combined and women with no follow-up would be compared to women with followup.

Specific Aim 3b: Inverse Probability Weighting
Current smoking was significantly associated with attrition, in that smokers were
more likely to be censored (lost to follow-up). Inverse probability weighting (IPW) was
used to account for differential loss to follow-up and for the aforementioned confounding
variables to examine the associations between current smoking status and the
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development of two outcomes: conception as a dichotomous variable (yes/no) and
fecundability as the probability of conception over the entire follow-up period.

IPW: Conception Outcome - Dichotomously
To adjust for confounding using IPW, a pseudo-population was made by
weighting each subject by the reciprocal (inverse) of the conditional probability of being
a smoker conditional on MAR cycle, age, BMI, gravidity, marital status and race, such
that in the pseudo-population there is no relationship between smoking and the
aforementioned confounders. The denominator of the stabilized inverse probability
weights was estimated fitting a logistic regression of being a smoker, conditioned on
MAR cycle, age, BMI, gravidity, marital status and race. While the numerator of the
stabilized inverse probability weights was estimated by fitting a logistic regression model
for the probability of being a smoker with only the intercept.
The geeglm function in the geepack package in R was used to fit a generalized
estimating equations (GEE) model using a robust variance estimator to allow for
correlated observations created by weighting. The GEE model was fitted to examine the
association of smoking on conception in the weighted pseudo-population adjusted for
confounding. The inverse-probability weighted ORs adjusted for confounding, along with
95% CIs were reported and compared to the estimates from the original aims.
Selection bias due to loss to follow-up was also adjusted for using IPW. A
pseudo-population was made by weighting each subject by the reciprocal (inverse) of the
probability of being uncensored conditional on age, BMI, gravidity, race and current
smoking. The denominator of the stabilized inverse probability weights was estimated by
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fitting a logistic regression model for the probability of being uncensored, conditional on
current smoking, age, BMI, gravidity and race. While the numerator of the inverse
probability weights was estimating using a logistic regression model for the probability of
being uncensored, conditioned on only smoking.
The stabilized inverse probability weights estimated from confounding and
selection bias due to loss of follow-up were multiplied, to adjust for them simultaneously.
The GEE model was fitted to examine the association of smoking on conception in the
weighted pseudo-population adjusted for both confounding and selection bias. The
weighted ORs adjusted for both confounding and selection bias to loss of follow-up,
along with 95% CIs were reported and compared to the estimates from previous aims.
These steps were then repeated to adjust for confounding and selection bias due to loss to
follow-up among non-MAR users and estimates were documented and compared.

IPW: Fecundability
Confounding and selection due to loss of follow-up within the fecundability data
were adjusted for separately and jointly using IPW, with the ipwtm function in the ipw
package in R. The function was used to estimate stabilized inversed probability weights
at each time interval at-risk during follow-up, taking into account fixed and time-varying
confounders. The longitudinal data was coded in the counting process format and was
used to fit Cox proportional hazard models.
Stabilized inverse probability weights to adjust for confounding only were
estimated by fitting two Cox proportional hazard models. The denominator of the
stabilized inverse probability weights was estimated from a model that examined
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probability of smoking at each time-interval, given MAR cycle, age, BMI, gravidity,
marital status and race. While, the numerator of the stabilized inverse probability weights
was estimated by fitting a logistic regression model for the probability of being a smoker
with only the intercept at each time-interval. The stabilized time-interval-specific weights
were then used to fit a marginal structured model (MSM) that assessed the effect of
smoking on fecundability, to estimate measures of association adjusted for confounding
only. Inverse-probability weighted FRs adjusted for confounding, along with 95% CIs
were reported and compared to the estimates from original aims.
Selection bias due to loss of follow-up was adjusted for using stabilized inverse
probability of censoring weights similarly to the weights used for confounding
adjustment. The denominator of the stabilized inverse probability weights was estimated
by fitting the regression model for the probability of being uncensored at each timeinterval, conditional on current smoking, age, BMI, gravidity and race. While the
numerator of the inverse probability weights was estimating using a regression model for
the probability of being uncensored, conditioned on only smoking at each time-interval.
Stabilized inverse probability of censoring weights were then used to fit a MSM that
assessed the effect of smoking on fecundability.
The stabilized inverse probability weights from confounding and selection bias
due to loss of follow-up were multiplied to adjust for them simultaneously. The stabilized
time-interval-specific weights were then used to fit a MSM that assessed the effect of
smoking on conception, to estimate measures of association adjusted for confounding and
selection bias due to loss of follow-up. Inverse-probability weighted FRs adjusted for
both confounding and selection bias to loss of follow-up along with 95% CIs were
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reported and compared to the estimates from previous aims. These steps were then
repeated to adjust for confounding and selection bias due to loss to follow-up among NC
follow-up time and estimates were documented and compared.
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V. RESULTS

Among 264 participants enrolled in the LOUSSI study, seven women were
excluded: three were under the age of 21 and four were found to be pregnant at the time
of enrollment. Out of the remaining 257 women, 229 (89.1%) were successfully followed
up after baseline either through information extracted from medical records and/or if they
gave permission through personal re-contact via phone, email or postal mail. Figure 2
illustrates the follow-up methods of participants with and without permission to
recontact.

Figure 2: Study Flow Diagram Showing Follow-Up Data among Participants
All participants enrolled in the LOUSSI study
264
7 excluded
(Under 21 years of age or
pregnant at enrollment)

N = 257
GROUP 2
Participants who were asked to be
personally recontacted (#100 – 264)
162 (3 were excluded above)

GROUP 1
Participants who were not asked to be
personally recontacted (#1-99)
95 (4 were excluded above)

6 lost to follow-up
7 declined permission

Lost to follow-up
(did not return to clinic)
21

Successful follow-up
(using medical records)
74

6 of the7 that declined
permission were followed
up through medical
records

Successful follow-up (only
personal recontact)
120

95

Successful follow-up
(only medical records)
35

Of the 120 women who were personally recontacted from Group 2, five women
reported that they did not continue to pursue conception since enrollment and one women
did not provide TTC data at recontact, hence these 6 women did not contribute at-risk
months and were removed. These 114 women in addition to the women followed up by
medical record only (74 women from the Group 1 and 35 women Group 2), brought the
final sample size for the fecundability analyses to 223 women. These 223 women were
followed up to 28 months and contributed a total of 1,967 at-risk months (median: 7
months; Q1-Q3: 3 - 15 months).
Figure 3 shows the distribution of conception and pregnancy outcomes by MAR.
Among the 223 women with TTC data, 83 (37.2%) had a documented and/or selfreported pregnancy since enrollment. Among the total 83 pregnancies reported, there
were documented or self-reported pregnancy outcomes for 72 pregnancies. Of the eleven
women with missing pregnancy outcomes, 5 were still pregnant at the end of follow-up
from Group 2 and 6 were from Group 1 that did not return to the clinic. These eleven
women were excluded from the SA analysis. Forty-one (56.9%) of the documented
pregnancy outcomes were live births, and 31 (43.1%) were SAs. Among the 130 (58.3%)
women who did not use any MAR treatment since enrollment, 29 (22.3%) had
spontaneous pregnancies. Of the 93 women who had at least one MAR treatment since
enrollment, 47 (50.5%) had successful MAR treatments resulting in a pregnancy and 7
(7.53%) had a spontaneous pregnancy after unsuccessful MAR treatments.
Within the study population (n=223), fifty-four (24.2 %) were verified as current,
active smokers, 112 (50.2%) were nonsmokers with low SHS exposure, and 57 (25.6%)
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were nonsmokers with high SHS exposure. Cotinine levels were correlated with selfreported SHS exposure (r = 0.39, p < 0.001) among all women.

Figure 3: Flow Diagram of Conception and Pregnancy Outcomes
All women with >0 follow-up
N = 223
83 (37.3%) had a pregnancy

Women who did not use MAR
since enrollment
N = 130
29 (22.3%) spontaneous
pregnancies

5 missing
outcomes

Live
births
15 (62.5%)

Women who used MAR since
enrollment
N = 93
47 (50.5%) pregnancies using MAR
7 (7.53%)spontaneous pregnancies
after unsuccessful MAR
Spontaneous
MAR
Pregnancy
5 missing
outcomes

Spontaneous
Abortions
9 (37.5%)

1 missing
outcome

Live births
22 (52.4%)

Live births
4 (66.7%)

Spontaneous
Abortions
20 (47.6%)

Spontaneous
Abortions
2 (33.3%)

Descriptives Statistics
Descriptive analyses were conducted for four different tobacco smoke
comparisons of active and second-hand smoke exposures within the full study population
(n=223). The four different smoking status comparisons included: 1) current smokers (n=
54) versus former or never-smokers (n=169 ); 2) current SHS exposure via urinary
cotinine among nonsmokers with any exposure (cotinine >0 ng/mL) (n=78) vs.
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unexposed (cotinine=0 ng/mL, n=82);3) self-reported SHS exposure in the past year via
the SSQ score among nonsmokers: high SHS exposure = score ≥ 4 (n=57) compared to
low SHS exposure = score ≤ 3 (referent, n=112); and 4) nonsmokers with low SHS
exposure score (referent, n=112) were compared to nonsmokers with high SHS exposure
score (n=57) and current smokers (n=54). We additionally stratified analyses by MAR to
examine women that used MAR after enrollment (n=130) and women who did not use
MAR prior enrollment (n=93) (Appendix D Table S1-8).
In all descriptive tables, categorical variables are presented with N(%), normally
distributed continuous variables are presented with their mean ± standard deviations (SD)
and continuous variables that did not follow a normal distribution are presented with their
median and interquartile range(Q1-Q3).

1)

Current Active Smokers Compared to Current Nonsmokers
Table 9 shows the characteristics of all 223 women with follow-up time, stratified

by current active smoking. Smokers were defined as women with a cotinine level of
>=100 ng/mL or who had self-reported as a current smoker. A nonsmoker was defined as
anyone with a cotinine level < 100 ng/mL and did not self-report as a current smoker.
Current smokers had longer average menstrual cycle lengths (P = 0.01), were
more likely to have a previous STD (P = 0.07), less likely to be married (P <0.001), less
likely to exercise (P = 0.10), more likely to be of African American race (P <0.001),
more likely to not use MAR (P <0.001) and more likely to have a SA (P = 0.03)
compared to nonsmokers. Cotinine levels were also significantly correlated with current
active smoking (r=0.98, p-value <0.001). Descriptive statistics comparing current

98

smokers and nonsmokers stratified by MAR can be found in the Appendix D (Table S12).

Table 9 : Characteristics among Women with Follow-up Data Stratified by Current
Smoking (N=223)

Cotinine Levels, mg/dL
median (Q1-Q3)
Cotinine Categories, n (%)
0 mg/dL
<100 mg/dL
100mg/dL
Age in years,
median (Q1-Q3)

Nonsmoker
N = 169
0.00(0.00-4.00)

Current Smoker
N = 54
100(100-100)

P - value
<0.001

<0.001
82(51.25)
78(48.75)
0(0.00)

0(0.00)
2(3.85)
50(96.15)

33.00(28.00-37.00)

32.50(27.25-36.00)

Age in years, n (%)

0.48

0.59
≤33
>33

BMI, median (Q1-Q3),
(kg/m2)
BMI Category kg/m2, n
(%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

91(53.85)
78(46.15)

32(59.26)
22(40.74)

28.54(24.82-35.17)

30.36(26.77-34.46)

0.22
0.31

46(27.22)

11(20.37)

49(28.99)
74(43.79)

13(24.07)
30(55.56)

BMI kg/m2, n (%)

0.18
≤30
>30

95(56.21)
74(43.79)

24(44.44)
30(55.56)

Gravidity, n (%)

0.44
0
1
>=2

74(43.79)
38(22.49)
57(33.73)

Regular Period, n (%)

19(35.19)
12(22.22)
23(42.59)
1.00
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No
Yes

58(34.32)
111(65.68)

18(33.33)
36(66.67)

Average Cycle Length
(days), median (Q1-Q3)

28.00(27.50-30.00)

29.50(28.00-30.00)

0.01

Age of Menarche, in years,
median (Q1-Q3)

13.00(12.00-14.00)

12.00(11.00-13.00)

0.11

Previous STD, n (%)

0.07
No
Yes

107(63.69)
61(36.31)

25(48.08)
27(51.92)

Marital Status, n (%)
No
Yes
Routine Exercise, n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Other
Black

<0.001
46(27.22)
123(72.78)

37(68.52)
17(31.48)
0.10

67(41.36)
95(58.64)

28(56.00)
22(44.00)
0.75

97(57.40)
72(42.60)

29(53.70)
25(46.30)
0.52

34(20.36)
133(79.64)

8(15.09)
45(84.91)
<0.001

128(75.74)
41(24.26)

27(50.00)
27(50.00)

AMH
(ng/mL), median (Q1-Q3)

2.49(1.11-5.01)

2.48(1.52-5.66)

0.55

Length of Infertility
(years), median (Q1-Q3)

2.00(1.00-4.46)

2.50(1.33-5.50)

0.16

Treatment Cycles, n (%)
0
1
2 and more
NAT2 Acetylator Status,
n (%)
Rapid
Slow

<0.001
87(51.48)
35(20.71)
47(27.81)

43(79.63)
3(5.56)
8(14.81)
0.32

84(57.93)
61(42.07)
100

33(67.35)
16(32.65)

Pregnant, n (%)

0.14
No
Yes

Pregnancy Outcome,
n (%)
Live Birth
SA
Total Follow-up Time
(years), median (Q1-Q3)

2)

101(59.76)
68(40.24)

39(72.22)
15(27.78)
0.03

37(63.79)
21(36.21)

4(28.57)
10(71.43)

6.00(3.00-14.00)

7.00(2.25-15.00)

0.94

Secondhand Smoke Exposure – Recent SHS Exposure (Urinary Cotinine)
among Nonsmokers
Of the 169 nonsmoking women, 9 did not provide urine samples which left a final

sample size of 160 nonsmoking women for this analysis. Recent SHS exposure as defined
using urinary cotinine levels. A level of 0 ng/mL was used as the referent group (n=82).
Those with cotinine levels less than and equal to 4 ng/mL were classified as low recent
SHS exposure (n=42), and those with cotinine levels greater than 4 ng/mL were classified
as high recent SHS exposure (n=36). Women with urinary cotinine values of 100 ng/mL
or self-reported as a current smoker or that quit smoking less than a month ago were
excluded from this analysis. Table 10 presents the characteristics of 160 nonsmoking
women stratified by their amount of SHS exposure measured through urinary cotinine
levels.
As shown in Table 10, nonsmoking women with highest recent SHS exposure
(urinary cotinine levels greater than 4 ng/mL) were younger in age (P = 0.06), more
likely to be obese (P = 0.04), more likely to have children (P = 0.002), less likely to
exercise (P = 0.10), less likely to use MAR (P = 0.07), more likely to have a SA (P =
0.17), more likely to be slow acetylators (P = 0.072) and have less follow-up time (P =
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0.03) compared to nonsmoking women with no recent SHS exposure (urinary cotinine
level of 0 ng/mL). Descriptive statistics comparing urinary cotinine levels stratified by
MAR can be found in the Appendix D (Table S3-4).

Table 10: Characteristics of Nonsmoking Women Stratified by Recent SHS
Exposure Using Urinary Cotinine (N=160)
Cotinine = 0
mg/dL
N=82
34.0
(30.00-37.75)

Age in years,
median (Q1-Q3)

0 < Cotinine ≤
4mg/dL
N=42
31.50
(27.25-35.75)

4 < Cotinine
≤ 47 mg/dL
N=36
31.00
(26.00-35.25)

Age in years, n (%)

Pvalue
0.06

0.08
≤33
>33

BMI (kg/m2),
median (Q1-Q3)
BMI Category kg/m2,
n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

37(45.12)
45(54.88)

26(61.90)
16(38.10)

23(63.89)
13(36.11)

27.18
(23.76-32.07)

31.49
(27.73-37.66)

31.14
(25.46-36.41)

0.003

0.13
26(31.71)

7(16.67)

9(25.00)

27(32.93)
29(35.37)

11(26.19)
24(57.14)

8(22.22)
19(52.78)

BMI kg/m2, n (%)

0.04
≤30
>30

53(64.63)
29(35.37)

18(42.86)
24(57.14)

17(47.22)
19(52.78)

Gravidity, n (%)
0
1
>=2
Regular Period, n (%)
No
Yes
Average Cycle Length
(days), median (Q1-Q3)

0.002
30(36.59)
19(23.17)
33(40.24)

29(69.05)
7(16.67)
6(14.29)

10(27.78)
10(27.78)
16(44.44)
0.26

25(30.49)
57(69.51)

19(45.24)
23(54.76)

12(33.33)
24(66.67)

28.00
(27.25-30.00)

28.00
(27.50-29.25)

29.00
(26.50-30.00)
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0.85

Age of Menarche, in
years, median (Q1-Q3)

13(12-14)

12(11-14)

12(12-14)

Previous STD, n (%)

0.50

0.91

No
Yes
Marital Status, n (%)
No
Yes
Routine Exercise, n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Other
Black

52(63.41)
30(36.59)

27(65.85)
14(34.15)

22(61.11)
14(38.89)

66(80.49)
16(19.51)

30(71.43)
12(28.57)

25(69.44)
11(30.56)

AMH (ng/mL),
median (Q1-Q3)

2.17
(0.86-3.95)

3.23
(1.09-5.56)

2.60
(1.59-5.61)

0.33

Length of Infertility
years, median (Q1-Q3)

2.00
(1.00-4.00)

2.00
(1.31-4.25)

2.21
(1.00-5.81)

0.54

0.20
21(25.61)
61(74.39)

9(21.43)
33(78.57)

14(38.89)
22(61.11)
0.10

27(34.18)
52(65.82)

16(40.00)
24(60.00)

19(55.88)
15(44.12)
0.94

73(90.12)
8(9.88)

37(90.24)
4(9.76)

31(88.57)
4(11.43)
0.75

45(54.88)
37(45.12)

26(61.90)
16(38.10)

21(58.33)
15(41.67)
0.33

Treatment Cycles,
n (%)

0.07

0
1
2
3 and more

38(46.34)
17(20.73)
12(14.63)
15(18.29)

23(54.76)
7(16.67)
4(9.52)
8(19.05)

21(58.33)
10(27.78)
5(13.89)
0(0.00)

NAT2 Acetylator
Status, n (%)

0.07
Rapid
Slow

47(64.38)
26(32.62)

23(60.53)
15(39.47)

14(41.18)
20(58.82)

Pregnant, n (%)

0.82
No

49(59.76)

23(54.76)
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22(61.11)

Yes
Pregnancy Outcome, n
(%)
Live Birth
SA

33(40.24)

21(72.41)
8(27.59)

9(60.00)
6(40.00)

5(41.67)
7(58.33)

Total Follow-up Time
(years), median (Q1-Q3)

8.00
(4.00-16.00)

5.00
(3.00-14.00)

5.00
(2.75-9.75)

3)

19(45.24)

14(38.89)
0.17

0.03

Secondhand Smoke Exposure – Past Year’s SHS Exposure (SSQ) among

Nonsmokers
Self-reported SHS exposure in the past year was measured using two questions
from the SSQ. Each question was scored never (1), rarely (2), often (3) and every day (4)
and then summed. High SHS exposure was defined with a combined SSQ score ≥ 4
(n=57) and compared to low SHS exposure with a combined SSQ score ≤ 3 (n=112).
Women with urinary cotinine values of 100 ng/mL or self-reported as a current smoker or
that quit smoking less than a month ago were excluded from this analysis. Table 11
presents the characteristics of 169 nonsmoking women stratified by SHS exposure in the
past year measured from the SSQ.
Nonsmoking women who self-reported high SHS exposure (combined SSQ score
of ≥ 4) in the past year (n=57) were less likely to be married (P=0.01), more likely to be
of African American race (P = 0.03), reported longer lengths of infertility (P = 0.02),
were less likely to use MAR (P = 0.04) and less likely to conceive (P = 0.14), and were
more likely to have a SA (P = 0.16), compared to nonsmoking women who self-reported
low SHS exposure (combined SSQ score ≤ 3) in the past year. Descriptive statistics for
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SHS exposure via the SSQ, stratified by MAR can be found in the Appendix D (Table
S5-6).

Table 11: Characteristics of Nonsmoking Women Stratified by SHS Exposure in the
Past Year Using the SSQ (N=169)
No and Low
exposure (score=2,3)
N=112
0.00
(0.00-1.00)

Cotinine Levels, mg/dL
median (Q1-Q3)
Cotinine Categories,
n (%)
0 mg/dL
<4 mg/dL
>= 4 mg/dL
Age in years
median (Q1-Q3)

Med and High
exposure (score ≥4)
N=57
2.50
(0.00-10.40)

P-value

<0.001

<0.001
65(61.90)
26(24.76)
14(13.33)

17(30.91)
11(20.00)
27(49.09)

33.00
(29.00-37.00)

32.00
(27.00-35.00)

Age in years, n (%)

0.36

0.56
≤33
>33

BMI, kg/m2
median (Q1-Q3)
BMI Category, kg/m2,
n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

58(51.79)
54(48.21)

33(57.89)
24(42.11)

28.43
(24.81-32.39)

24.95
(24.95-37.25)

0.23

0.65
30(26.79)

16(28.07)

35(31.25)
47(41.96)

14(24.56)
27(47.37)

BMI kg/m2, n (%)

0.52
≤30
>30

65(58.04)
47(41.96)

30(52.63)
27(47.37)

Gravidity, n (%)

0.90
0
1

48(42.86)
26(23.21)
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26(45.61)
12(21.05)

>=2
Regular Period, n (%)
No
Yes

38(33.93)

19(33.33)
0.51

36(32.14)
76(67.86)

22(38.60)
35(61.40)

Average Cycle Length,
(days), median (Q1-Q3)

28.00
(28.00-30.00)

28.00
(27.00-23000)

0.82

Age of Menarche
in years, median (Q1-Q3)

13.00
(12.00-14.00)

12.00
(12.00-13.75)

0.39

Previous STD, n (%)

0.79
No
Yes

72(64.86)
39(35.14)

35(61.40)
22(38.60)

Marital Status, n (%)

0.01

No
Yes
Routine Exercise, n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Other
Black

23(20.54)
89(79.46)

23(40.35)
34(59.65)

91(81.25)
21(18.75)

37(64.91)
20(35.09)

AMH, ng/mL
median (Q1-Q3)

2.46
(1.13-4.96)

2.51
(1.14-6.28)

0.62

Length of Infertility, in
years, median (Q1-Q3)

1.75
(1.00-3.17)

3.00
(1.25-6.42)

0.02

0.21
40(37.38)
67(62.62)

27(49.09)
28(50.91)
0.21

60(53.57)
52(46.43)

37(64.91)
20(35.09)
0.97

22(19.82)
89(80.18)

12(21.43)
44(78.57)
0.03

Treatment Cycles, n (%)
0
1
2 and more

0.04
50(44.64)
25(22.32)
37(33.04)

NAT2 Acetylator Status,
n (%)

37(64.91)
10(17.54)
10(17.54)
0.83
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Rapid
Slow

55(59.14)
38(40.86)

29(55.77)
23(44.23)

Pregnant, n (%)

0.14
No
Yes

Pregnancy Outcome,
n (%)
Live Birth
SA
Total Follow-up Time,
(years), median (Q1-Q3)

4)

62(55.36)
50(44.64)

39(68.42)
18(31.58)
0.16

29(70.73)
12(29.27)

8(47.06)
9(52.94)

7.00(3.00-15.00)

5.00(3.00-13.00)

0.60

Combined Exposure – Active Smoking and SHS Exposure
The combined exposure variable compared nonsmokers with low SHS exposure

in the past year (n=112) to nonsmokers with high SHS exposure (n-=57) and then to
current smokers (n=54). The characteristics of 223 women using the combined effect
exposure variable are shown in Table 12. Current smokers were more likely to have a
previous STD (P = 0.12), less likely to be married (P<0.001), less likely to exercise (P =
0.07), more likely to be of African American race (P<0.001), less likely to use MAR
(P<0.001), less likely to conceive (P = 0.07) and more likely to have a SA/miscarriage (P
= 0.014), when compared nonsmokers with high SHS exposure (n=57) then to
nonsmokers with low SHS exposure (n=112). Descriptive statistics for the combined
exposure, stratified by MAR can be found in the Appendix D (Table S7-8).
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Table 12: Characteristics of Women Using the Combined Effect Variable (N=223)

Cotinine Levels,
mg/dL,
median (Q1-Q3)
Cotinine Categories,
n (%)
0 mg/dL
<100 mg/dL
100mg/dL
Age in years,
median (Q1-Q3)
Age in years, n (%)
≤33
>33
BMI, kg/m2,
median (Q1-Q3)
BMI Category
kg/m2, n (%)
<25 (Underweight
and Normal)
25 - 29.9
(Overweight)
≥ 30 (Obese)
BMI kg/m2, n (%)
≤30
>30

Nonsmokers
with low SHS
N=112
0.00
(0.00-1.00)

Nonsmokers
with high SHS
N=57
2.50
(0.00-10.40)

Smokers

Pvalue

N=54
100.00
(100.0-100.0)

65(61.90)
40(38.10)
0(0.00)

17(30.91)
38(69.09)
0(0.00)

0(0.00)
2(3.85)
50(96.15)

< 0.001

33.00
(29.00-32.76)

32.00
(27.00-35.00)

32.50
(27.25-36.00)

0.51

< 0.001

0.59
58(51.79)
54(48.21)

33(57.89)
24(42.11)

32(59.26)
22(40.74)

28.43
(24.81-32.39)

29.04
(24.95-37.25)

30.36
(26.77-34.46)

0.21

0.53
30(26.79)

16(28.07)

11(20.37)

35(31.25)

14(24.56)

13(24.07)

47(41.96)

27(47.37)

30(55.56)
0.26

65(58.04)
47(41.96)

30(52.63)
27(47.37)

24(44.44)
30(55.56)

Gravidity, n (%)

0.78
0
1
>=2

48(42.86)
26(23.21)
38(33.33)

26(45.61)
12(21.05)
19(33.33)

19(35.19)
12(22.22)
23(42.59)

Regular Period,
n (%)

0.70
No

36(32.14)

22(38.60)
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18(33.33)

Yes

76(67.86)

35(61.40)

36(66.67)

Average Cycle
Length, (days),
median (Q1-Q3)

28.00
(28.00-30.00)

28.00
(27.00-30.00)

29.50
(28.00-30.00)

0.03

Age of Menarche, in
years, median (Q1Q3)

13.00
(12.00-14.00)

12.00
(12.00-13.75)

12.00
(11.00-13.00)

0.19

Previous STD,
n (%)

0.12
No
Yes

72(64.86)
39(35.14)

35(61.40)
22(38.60)

25(48.08)
27(51.92)

Marital Status,
n (%)

<0.0001
No
Yes

23(20.54)
89(79.46)

23(40.35)
34(59.65)

37(68.52)
17(31.48)

Routine Exercise,
n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes

0.07
40(37.38)
67(62.62)

27(49.09)
28(50.91)

28(56.00)
22(44.00)
0.33

60(53.57)
52(46.43)

37(64.91)
20(35.09)

29(53.70)
25(46.30)
0.68

22(19.82)
89(80.18)

12(21.43)
44(78.57)

8(15.09)
45(84.91)

Race, n (%)

<0.001
Other
Black

91(81.25)
21(18.75)

20(35.09)
37(64.91)

27(50.00)
27(50.00)

AMH, ng/mL
median (Q1-Q3)

2.46
(1.13-4.96)

2.51
(1.14-6.28)

2.48
(1.52-5.66)

0.73

Length of Infertility,
years, median (Q1Q3)

1.75
(1.00-3.17)

3.00
(1.25-6.42)

2.50
(1.33-5.50)

0.02

Treatment Cycles,

<0.001
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n (%)
0
1
2 and more
NAT2 Acetylator
Status, n (%)
Rapid
Slow

50(44.64)
25(22.32)
37(33.04)

37(64.91)
10(17.54)
10(17.54)

43(79.63)
3(5.56)
8(14.81)
0.47

55(59.14)
38(40.86)

29(55.77)
23(44.23)

33(67.35)
16(32.65)

Pregnant, n (%)

0.07
No
Yes

Pregnancy
Outcome, n (%)
Live Birth
SA
Total Follow-up
Time, years, median
(Q1-Q3)

62(55.36)
50(44.64)

39(68.42)
18(31.58)

39(72.22)
15(27.78)
0.02

29(70.73)
12(29.27)

8(47.06)
9(52.94)

4(28.57)
10(71.43)

7.00
(3.00-15.00)

5.00
(3.00-13.00)

7.00
(2.25-15.00)

0.88

Descriptive statistics comparing the characteristics of all 223 women stratified by
MAR use is displayed in Table 13. Overall, MAR users since enrollment were
significantly older (P = 0.04), less likely to be obese (P = 0.06), more likely to be married
(P = 0.01), more likely to drink alcohol (P = 0.03), more likely to get pregnant (P
<0.001), less likely to be a current smoker (P <0.001), and less likely to have high urinary
cotinine levels (P <0.001), compared to women who did not use MAR since enrollment.
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Table 13 : Characteristics of Women Stratified by MAR Use
No MAR
N = 130
31.50
(27.00-36.00)

Age in years
median (Q1-Q3)

MAR
N = 93
34.00
(30.00-38.00)

Age in years, n(%)

P value
0.04

0.06
≤33
>33

BMI (kg/m2)

BMI Category kg/m2, n(%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

79(60.77)
51(39.23)

44(47.31)
49(52.69)

30.45
(24.85-36.33)

28.53
(25.16-32.71)

0.10

0.04
34(26.15)

23(24.73)

28(21.54)
68(52.31)

34(36.56)
36(38.71)

BMI kg/m2, n(%)

0.06
≤30
>30

62(47.69)
68(52.31)

57(61.29)
36(38.71)

Gravidity, n(%)

0.46
0
1
≥2

51(39.23)
28(21.54)
51(39.23)

42(45.16)
22(23.66)
29(31.18)

Regular Period, n(%)

0.53
No
Yes

47(36.15)
83(63.85)

29(31.18)
64(68.82)

Average Cycle Length
(days) median (Q1-Q3)

28.50
(28.00-30.00)

29.00
(28.00-30.00)

0.87

Age of Menarche (in years)
median (Q1-Q3)

12.00
(11.00-14.00)

13.00
(12.00-13.75)

0.62

Previous STD, n(%)

0.72
No
Yes

75(58.59)
53(41.41)

57(61.96)
35(38.04)

Marital Status, n(%)

0.01
No

58(44.62)
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25(26.88)

Yes

72(55.38)

68(73.12)

Routine exercise, n(%)

0.23
No
Yes

59(48.76)
62(51.24)

36(39.56)
55(60.44)

Alcohol Use, n(%)

0.03
No
Yes

82(63.08)
48(36.92)

44(47.31)
49(51.69)

Caffeine Use, n(%)

1.00
No
Yes

24(18.90)
103(81.10)

18(19.35)
75(80.65)

Race, n(%)

0.004
Black
Other

50(38.46)
80(61.54)

18(19.35)
75(80.65)

AMH (ng/mL)
median (Q1-Q3)

2.54
(1.06-5.60)

2.40
(1.37-4.99)

0.78

Length of Infertility (in
years) median (Q1-Q3)

2.00
(1.50-2.00)

1.50
(1.00-5.00)

0.02

NAT2 Acetylator Status,
n(%)
Rapid
Slow
Pregnant, n(%)
No
Yes
Pregnancy Outcome, n(%)
Live Birth
SA

0.82
70(61.40)
44(38.60)

47(58.75)
33(41.25)
<0.001

101(77.69)
29(22.31)

39(41.94)
54(58.06)
0.67

15(62.50)
9(37.50)

26(54.17)
22(45.83)

Total Follow-up Time in
years, median (Q1-Q3)

8.00
(3.00-15.00)

5.00
(3.00-12.00)

0.13

Cotinine Levels mg/dL,
median (Q1-Q3)

4.75
(0.00-100.00)

0.20
(0.00-5.13)

<0.001

Cotinine mg/dL, n(%)

<0.001
0
<100
10

38(30.64)
46(37.10)
40(32.26)
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44(50.00)
34(38.64)
10(11.36)

Current Active Smoker,
n(%)

<0.001
No
Yes

87(66.92)
43(33.08)

82(88.17)
11(11.83)

Self-reported SHS
Exposure among
Nonsmokers, n(%)
No/Low
Intermediate/High

0.28

93(71.54)
37(28.46)

73(78.49)
20(21.51)

Self-reported SHS
Exposure among All,
n(%)
No
Low
Intermediate
High

0.05

24(24.74)
30(30.93)
29(29.90)
14(14.43)

27(30.68)
37(42.05)
20(22.73)
4(4.55)

Specific Aim 1a: The Effect of Active Smoking on Fecundability
The association of active smoking (current and lifetime) on fecundability was
modelled among three populations which included all follow-up time, MAR cycles and
NC follow-up time. Full models were adjusted for MAR cycle, age, BMI, marital status,
gravidity and race, as described in Table 8. Age and BMI were retained in all models,
along with confounders that changed the effect of smoking by at least 10%. Doseresponse relationships were assessed by treating the exposure variable ordinally and pvalues and 95% confidence intervals were reported. The proportional hazards assumption
was met for all variables in each model. The results for active smoking on fecundability
are presented in Table 14.
Among all 223 women, current active smoking was not significantly associated
with fecundability. Smokers had a 27% higher rate of fecundability compared to
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nonsmokers, minimally adjusted for age, BMI and marital status (aFR: 1.27; 95% CI:
0.68, 2.38; p = 0.46). Compared to nonsmokers, women with 6 or more pack-years
showed a 17% lower rate of fecundability (95% CI: 0.40, 1.70) and those with 1-5 packyears had a 17% higher rate of fecundability (95% CI: 0.58, 2.38), after adjusting for age
and BMI. The estimates and the test for trend, however, were also not statistically
significant (p-trend = 0.83). The total number of cigarettes per day was not associated
with fecundability, nor was a dose-response established (p-trend = 0.99).
The sub-population that analyzed MAR cycles only included 93 women. The full
model included the same variables as the previous, but MAR type was included as the
time-varying covariate instead of MAR cycle. The results among MAR cycles were
similar to the all follow-up time models, in that current, active smoking was not
significantly associated with fecundability. Smokers showed an insignificant 88% higher
rate of fecundability (95% CI: 0.73, 4.85) compared to nonsmokers with adjustment for
age, BMI and marital status. Among MAR cycles, women with 6 or more pack-years and
1-5 pack-years had a 20% (95% CI: 0.42, 3.46) and 31% higher rate of fecundability
(95% CI: 0.65, 2.65) compared to women with no pack-years, respectively. The test for
trend was not significant (p-trend = 0.44). Total number of cigarettes per day was not
associated with fecundability, nor was a dose-response effect established (p-trend = 0.22).
The sub-population that analyzed NC follow-up time only included 212 women.
The full models included age, BMI, gravidity, marital status and race. In this group,
smoking was generally associated with a non-significant reduction in fecundability.
Among NC follow-up time, current, active smokers showed a 22% reduction in
fecundability (95% CI: 0.34, 1.79) compared to nonsmokers after adjusting for age, BMI
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and marital status, but the estimate was not significant (p = 0.56). Women with NC
follow-up time that had 6 or more pack-years and 1-5 pack-years had a 24% and 9%
decrease in fecundability compared to women with no pack-years, respectively. The
estimates were adjusted for age and BMI and were not statistically significant, along with
the test for trend (p-trend=0.54). After adjusting for age, BMI and marital status, women
who smoked a total of 10 or more cigarettes a day had a 33% (95% CI: 0.28, 1.58)
reduction in fecundability and women who smoke 1 to 9 cigarettes a day had a 4% (95%
CI: 0.32, 2.89) reduction in fecundability, compared to nonsmokers. The test for trend
were also not statistically significant (p-trend = 0.37).

Table 14: Multivariable Cox Regression Models for Active Smoking (Current and
Lifetime) on Fecundability among Three Populations
FULL MODEL*
N
(#events)

Fecundability
Ratio
(95% CI)

Pvalue

MINIMALLY
ADJUSTED MODELa
Fecundability
PRatio
value
95% CI

ALL FOLLOW-UP TIME
Current Active Smoking
Nonsmoker
169(68)
Current active
54(15)
smoker
Total Cigarettes Smoked
per Day
Nonsmokers
156(59)
≤9
30(12)
≥ 10
37(12)
Pack-years
Nonsmokers
≤5
≥6

156(59)
37(15)
30(9)

1.00 (Referent)
1.26 (0.66, 2.41)

0.48

1.00 (Referent)
1.27b (0.68, 2.38)

0.46

p-trend = 0.99
1.00 (Referent)
1.08 (0.49, 2.36)
1.03 (0.52, 2.05)

1.00 (Referent)
1.21 (0.60, 2.45)
0.85 (0.40, 1.78)
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0.85
0.92

1.00 (Referent)
1.17 (0.58, 2.38)
0.83 (0.40, 1.70)

0.66
0.61

0.59
0.66

p-trend = 0.83
1.00 (Referent)
1.17 (0.58, 2.38)
0.83 (0.40, 1.70)

0.66
0.61

MAR CYCLES
Current Active Smoking
Nonsmoker
82(41)
Current active
11(6)
smoker
Total Cigarettes Smoked
per Day
Nonsmokers
71(34)
≤9
11(8)
≥ 10
11(5)

1.00 (Referent)
1.97 (0.72, 5.37)

0.19

1.00 (Referent)
1.88b (0.73, 4.85)

0.19

p-trend = 0.22
1.00 (Referent)
1.11 (0.50, 2.45)
1.78 (0.75, 4.23)

Pack-years
Nonsmokers

71(34)

1.00 (Referent)

≤5
≥6

13(10)
9(3)

1.36 (0.63, 2.96)
1.09 (0.37, 3.19)

0.80
0.19

1.00 (Referent)
1.09b (0.52, 2.29)
1.87b (0.85, 4.11)

0.82
0.12

p-trend = 0.44
1.00 (Referent)
0.44
0.88

1.31b (0.65, 2.65)
1.20b (0.42, 3.46)

0.45
0.73

1.00 (Referent)
0.78b (0.34, 1.79)

0.56

NC FOLLOW-UP TIME
Current Active Smoking
Nonsmoker
160(27)
Current active
52(9)
smoker
Total Cigarettes Smoked
per Day
Nonsmokers
148(25)
≤9
28(4)
≥ 10
36(7)

1.00 (Referent)
0.73 (0.31, 1.68)

0.45

p-trend = 0.37
1.00 (Referent)
0.91 (0.31, 2.68)
0.64 (0.26, 1.54)

0.86
0.32

1.00 (Referent)
0.96b (0.32, 2.89)
0.67b (0.28, 1.58)

0.94
0.36

Pack-years
p-trend = 0.54
Nonsmokers
148(25)
1.00 (Referent)
1.00 (Referent)
≤5
36(5)
0.82 (0.31, 2.17)
0.68
0.91 (0.33, 2.48)
0.85
≥6
28(6)
0.65 (0.25, 1.69)
0.38
0.76 (0.31, 1.83)
0.54
* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status
and Race
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital
status and Race
Full models for All follow-up time models adjusted for MAR cycle, Age, BMI,
Gravidity, Marital status and Race
a - Adjusted for Age and BMI
b - Adjusted for Age, BMI and Marital Status
Abbreviations: MAR - Medically Assisted Reproduction, NC - Natural Conception
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Specific Aim 1b: The Effect of SHS Exposure on Fecundability among Nonsmokers
The association of SHS exposure (recent and past) on fecundability was modelled
for the same three populations among nonsmokers: all follow-up time, MAR cycles, and
NC follow-up time. Recent SHS exposure was measured using urinary cotinine levels
and past SHS exposure using the SSQ. All models under this aim excluded current, active
smokers. The proportional hazards assumption was met for all variables in the models.
The results for SHS exposure (recent and past year) on fecundability are presented in
Table 15.
In general, SHS exposure was not significantly associated with fecundability.
Among all nonsmokers (n = 169), women with high SHS exposure in the past year
reported in the SSQ had a 17% higher rate of fecundability (95% CI: 0.69, 1.99)
compared to low SHS exposure, adjusted for age, BMI and marital status. However, the
estimate did not reach statistical significance (p = 0.56). Similarly, nonsmoking women
with high recent SHS exposure (urinary cotinine levels 5-99 mg/dL) (FR: 2.12; 95%
CI:1.08, 4.15) and low recent SHS exposure (urinary cotinine levels from 1-4 mg/dL)
(FR: 1.04; 95% CI: 0.57, 1.91) had a higher rate of fecundability than unexposed women
(urinary cotinine levels = 0 mg/dL), adjusted for age and BMI. The test for trend with
urinary cotinine was also not significant (p-trend = 0.08).
Among nonsmoking women with MAR cycles, the full models included the same
covariates as the previous models, but MAR type was used as the time-varying covariate
instead of MAR cycle. In these women, high SHS exposure from the past year showed an
insignificant 45% increase in fecundability (95% CI: 0.74, 2.87) compared to low SHS
exposure from the past year, adjusted for age, BMI and marital status. Nonsmoking
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women with high urinary cotinine and low urinary cotinine had an 84% increase and 28%
decrease in fecundability compared to unexposed women, respectively. These estimates
were adjusted for age, BMI, gravidity, marital status and race; and were not statistically
significant, along with the test for trend (p-trend = 0.59).
Among NC follow-up time, the full models were adjusted for age, BMI, gravidity,
marital status and race. Nonsmoking women with high SHS exposure from the past year
had a 4% insignificant reduction in fecundability adjusted for age and BMI (95% CI:
0.32, 1.51), compared to low SHS exposure from the past year. However, in the same
population, nonsmoking women who had high and low levels urinary cotinine levels had
a 36% (95% CI: 0.49, 3.74) and 22% (95% CI: 0.50, 3.01) higher rate of fecundability
compared to unexposed women, respectively. The test for trend (p-trend = 0.53) was not
significant.

Table 15: Multivariable Cox Regression Models for SHS Exposure (Recent and Past
Year) and Fecundability among Nonsmokers
N
(#events)

FULL MODEL*
Fecundability
Ratio
(95% CI)

Pvalue

MINIMALLY
ADJUSTED MODELa
Fecundability
PRatio
value
(95% CI)

ALL FOLLOW-UP TIME
SHS Exposure in the Past
Year From SSQ
Low 112(50)
High 57(18)
Cotinine mg/dL
0 mg/dL
≤ 4 mg/dL

82(33)
42(19)

1.00 (Referent)
1.33 (0.78, 2.28)

1.00 (Referent)
1.08 (0.57, 2.05)
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0.29

1.00 (Referent)
1.17b (0.69, 1.99)

0.81

p-trend = 0.08
1.00 (Referent)
1.04 (0.57, 1.91)
0.90

0.56

5 - 99 mg/dL

36(14)

2.31 (1.15, 4.64)

0.02

2.12 (1.08, 4.15)

0.03

0.29

1.00 (Referent)
1.45b (0.74, 2.87)

0.28

0.52
0.24

p-trend = 0.59
1.00 (Referent)
0.72c (0.26, 1.96) 0.52
1.84c (0.67, 5.03) 0.24

MAR CYCLES
SHS Exposure in the Past
Year From SSQ
Low
High
Cotinine mg/dL
0 mg/dL
≤ 4 mg/dL
5 - 99 mg/dL

62(33)
20(8)

43(20)
8(3)
15(8)

1.00 (Referent)
1.51 (0.71, 3.19)

1.00 (Referent)
0.72 (0.26, 1.96)
1.84 (0.67, 5.03)

NC FOLLOW-UP TIME
SHS Exposure in the Past
Year From SSQ
Low 104(17)
High 56(10)

1.00 (Referent)
1.01 (0.41, 2.46)

0.99

1.00 (Referent)
0.96b (0.43, 2.15)

0.92

Cotinine mg/dL
p trend = 0.53
0 mg/dL 77(13)
1.00 (Referent)
1.00 (Referent)
≤ 4 mg/dL 38(7)
1.41 (0.55, 3.62) 0.48
1.22 (0.50, 3.01)
0.66
5 - 99 mg/dL 35(6)
1.23 (0.36, 4.16) 0.74
1.36 (0.49, 3.74)
0.56
* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status
and Race
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital
status and Race
Full models for All follow-up time models adjusted for MAR cycle, Age, BMI,
Gravidity, Marital status and Race
a - Models adjusted for Age and BMI
b - Models adjusted for Age, BMI and Marital status
c - Models adjusted for Age, BMI, Gravidity, Marital status and Race
Abbreviations: MAR - Medically Assisted Reproduction, NC - Natural Conception
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Specific Aim 1c: The Effect of the Combined Exposure Effect on Fecundability
The association of the combined effect of current, active smoking and SHS
exposure on fecundability was modelled for the same three populations: all follow-up
time, MAR cycles, and NC follow-up time. The same set of covariates in the active
smoking and SHS exposure models were used in the full models. The proportional
hazards assumption was not violated for any variables. The results for combined effect of
active smoking and SHS on fecundability are presented in Table 16.
Similar to the previous models, tobacco smoke exposure was not associated with
fecundability in these models. In the MAR cycles, tobacco smoke exposure was
associated with a non-significant increase in fecundability; whereas in the NC follow-up
time, it was associated with a non-significant decrease in fecundability.
Among all women, current smokers and nonsmokers with high SHS had a 39%
(95% CI: 0.70, 2.64) and 29% (95% CI: 0.75, 2.13) increase in fecundability compared to
nonsmokers with low SHS exposure, respectively. The estimates were adjusted for age,
BMI and marital status and were not significant, along with the trend test (p-trend =
0.27).
Among 93 women who contributed MAR cycles, it was found that current
smokers (aFR: 2.08; 95% CI: 0.79, 5.49) and nonsmokers with high SHS exposure (aFR:
1.31; 95% CI: 0.63, 2.73) had increased fecundability compared to nonsmokers with low
SHS exposure, adjusted for age, BMI and marital status. These estimates, along with the
test for dose-response effect (p-trend = 0.12) were insignificant.
Among the 212 women that contributed NC follow-up time, current smokers and
nonsmokers with high SHS exposure showed a 22% (95% CI: 0.32, 1.91) and 1% (95%
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CI: 0.45, 2.17) reduction in fecundability compared to nonsmokers with low SHS
exposure, respectively. The estimates were adjusted for age, BMI and marital status; the
test for trend was not significant (p = 0.60).

Table 16: Multivariable Cox Regression Model for Combined Effect of Active
Smoking and SHS Exposure on Fecundability among Three Populations
N
(#events)

FULL MODEL*
Fecundability
Ratio
(95% CI)

Pvalue

MINIMALLY
ADJUSTED MODELa
Fecundability
PRatio
value
(95% CI)

ALL FOLLOW-UP TIME
Combined Effect

p-trend = 0.27

NS w/low SHS 112(50)

1.00 (Referent)

1.00 (Referent)

NS w/high SHS

57(18)

1.31 (0.78, 2.20)

0.30

1.29 (0.75, 2.13)

0.34

Current smokers

54(15)

1.39 (0.71, 2.75)

0.34

1.39 (0.70, 2.64)

0.33

MAR CYCLES
Combined Effect

p-trend = 0.12

NS w/low SHS

62(33)

1.00 (Referent)

1.00 (Referent)

NS w/high SHS

20(8)

1.23 (0.59, 2.57)

0.59

1.31 (0.63, 2.73)

0.47

Current smokers

11(6)

2.10 (0.76, 5.77)

0.15

2.08 (0.79, 5.49)

0.14

NC FOLLOW-UP TIME
Combined Effect

p-trend = 0.60

NS w/low SHS 103(17)

1.00 (Referent)

1.00 (Referent)

NS w/high SHS

57(10)

0.96 (0.40, 2.28)

0.93

0.99 (0.45, 2.17)

0.98

Current smokers

52(9)

0.71 (0.28, 1.81)

0.47

0.78 (0.32, 1.91)

0.58

* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status
and Race
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital
status and Race
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Full models for All follow-up time models adjusted for MAR cycle, Age, BMI,
Gravidity, Marital status and Race
Abbreviations: NS - Nonsmokers, MAR - Medically Assisted Reproduction, NC Natural Conception
a - Models adjusted for Age, BMI and Marital status

Specific Aim 1d: Interaction of Current, Active Smoking and NAT2 Acetylator
Status on Fecundability
Effect modification of NAT2 acetylator status on the effect of smoking on
fecundability was examined by adding an interaction term into the models used from Aim
1a, among the three populations. NAT2 acetylator status compared slow and rapid
acetylators. A total of 29 women did not have NAT2 acetylator status, either because they
did not provide a urine sample or had issues with DNA amplification/contamination,
reducing the total sample to 194. All full models were adjusted for age, BMI, gravidity,
marital status, race and NAT2 acetylator status. No statistically significant interactions
were detected among any of the populations (Table 17). In the NC follow-up time model,
current smokers with a slow acetylation status had a 41% reduction in fecundability
compared to nonsmoking women with rapid acetylation status. The estimate was adjusted
for age and BMI but was not statistically significant (95% CI:0.11, 3.27). Among the
MAR cycles only model, current smokers with a slow acetylation status had 6.85 times
the increase in fecundability compared to nonsmoking women with rapid acetylation
status. However, this association may have been due to the fact that there were only 3
women in the highest risk group and all 3 conceived.
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Table 17: Interaction of Current Active Smoking and NAT2 Acetylator Status on
Fecundability
NAT2
Status/
Smoking
Exposure

FULL MODEL*

MINIMALLY ADJUSTED
MODELa
Fecundability
P-value
P-value for
Ratio
for
interaction
(95% CI)
interaction

N
Fecundability
(#events)
Ratio
(95% CI)

ALL FOLLOW-UP TIME
Rapid/
Nonsmoker
Rapid/
Smoker
Slow/
Nonsmoker
Slow/
Smoker

84(38)

(Referent)

0.55

(Referent)

33(9)

0.97 (0.45, 2.12)

1.28 (0.58, 2.82)

61(21)

0.73 (0.42, 1.27)

0.75 (0.44, 5.14)

16(5)

1.42 (0.53, 3.80)

0.52

1.92 (0.70, 5.25)

MAR CYCLES
Rapid/
Nonsmoker
Rapid/
Smoker
Slow/
Nonsmoker
Slow/
Smoker

30(22)

(Referent)

0.007

(Referent)

5(3)

1.09 (0.37, 3.23)

1.38 (0.34, 5.58)

21(13)

1.10 (0.49, 2.46)

1.10 (0.50, 2.39)

3(3)

6.85 (2.72, 17.14)

8.22 (2.54, 26.74 )

0.04

NC FOLLOW-UP TIME
Rapid/
54(16)
(Referent)
0.64
(Referent)
0.63
Nonsmoker
Rapid/
28(6)
0.95 (0.37, 2.45)
0.89 (0.33, 2.38)
Smoker
Slow/
40(8)
0.82 (0.36, 1.87)
0.80 (0.34, 1.88)
Nonsmoker
Slow/
13(2)
0.59 (0.11, 3.27 )
0.54 (0.09, 3.33)
Smoker
* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status
and Race
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital
status and Race
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Full models for All follow-up time models adjusted for MAR cycle, Age, BMI,
Gravidity, Marital status and Race
a – Models adjusted for age and BMI for all cycles

Specific Aim 2a (Active Smoking), Specific Aim 2b (SHS Exposure)
and Specific Aim 2c (Combined Effect Exposure) on Probability of
Spontaneous Abortion
The association of active smoking (current and lifetime) and SHS exposure
(recent and past year) and the combined effect exposure on SA were assessed using
multivariable logistic regression. It should be reiterated that all tobacco smoke exposures
were assessed pre-conception. The main outcome was SA, which was compared to live
birth. Current active smoking compared smokers to nonsmokers, and a dose-response
effect was examined using total cigarettes smoked per day. Lifetime smoking exposure
was assessed using pack-years. Recent SHS exposure was measured using urinary
cotinine levels and SHS exposure in the past year was measured using the SSQ score.
Full models were adjusted for MAR, age, BMI, gravidity, marital status, race and alcohol
use. Age and BMI were retained in all minimally adjusted models, along with
confounders that changed smoking estimates more than 10%. Dose-response
relationships were assessed using a test for trend and p-values were reported. Results are
displayed in Table 18.
In general, tobacco smoke exposure (both active smoking and secondhand) was
associated with an increase in the odds of spontaneous abortion. Among the 72 women
with known pregnancy outcome data, fully adjusted models had similar estimate effects
to the minimally adjusted models. Current, active smokers (aOR:4.14; 95% CI:0.99,
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21.25) had a marginally significant increase in the odds of SA compared to nonsmokers,
adjusted for age, BMI and marital status. Women with 6 or more pack-years (aOR:1.77;
95% CI: 0.48, 6.66) and 1-5 pack-years (aOR: 3.18; 95% CI: 0.58, 20.00) had increased
odds of SA compared to nonsmokers. These estimate were adjusted for age, BMI,
gravidity and marital status, and the test for trend was not significant (p = 0.10). Women
who smoked 10 or more cigarettes a day (aOR: 2.03; 95% CI: 0.43, 9.29) and women
who smoked 9 or fewer cigarettes a day (aOR: 1.93; 95% CI: 0.47, 9.38) had an
insignificant increase in odds of SA compared to nonsmokers. These estimates were
adjusted for age, BMI, gravidity, marital status and alcohol use and also, no doseresponse effect was found (p-trend = 0.28).
Nonsmoking women with high SHS exposure in the past year had a significant
increase in the odds of SA (aOR: 4.30; 95% CI: 1.14, 19.06) compared to low SHS
exposure in the past year, adjusted for age and BMI. Among nonsmokers, high levels
(aOR: 5.77; 95% CI: 1.09, 38.65, p = 0.05) and low levels (aOR: 2.67; 95% CI: 0.52,
16.23) of urinary cotinine showed an increased odds of SA compared to unexposed
women, adjusted for age, BMI, gravidity and race. The test for trend revealed a
significant dose-response (p-trend = 0.04).
Using the combined effect of active smoking and SHS exposure, current smokers
(aOR: 6.28; 95% CI: 1.31, 37.92) and nonsmokers with high SHS exposure (aOR:3.20;
95% CI: 0.87, 12.70) also had a significantly increased odds of SA compared to
nonsmokers with low SHS exposure. These estimates were adjusted for age, BMI,
gravidity and marital status; and produced a significant dose-response effect (p-trend =
0.02).
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Table 18: Multivariable Logistic Regression Models of Smoking Exposures and
Spontaneous Abortion among All Conceptions
N
(#events)

FULL MODEL*
Odds Ratio
(95% CI)

Current Active
72
Smoking
Nonsmoker 58(21)
Current, Active 14(10)
Smoker
Total Cigarettes Smoked
per Day
Nonsmokers 49(17)
≤ 9 11(7)
≥ 10 12(7)
Pack-years
Nonsmokers
≤5
≥6

Pvalue

1.00 (Referent)
3.94 (0.85, 24.07)

0.10

MINIMALLY
ADJUSTED MODEL
Odds Ratio
P(95% CI)
value

1.00 (Referent)
4.14b (0.99, 21.25)

0.06

p-trend = 0.28
1.00 (Referent)
1.92 (0.43, 9.26)
2.07 (0.47, 9.66)

0.40
0.34

1.00 (Referent)
1.93e (0.43, 9.29)
2.03e (0.47, 9.38)

0.39
0.35

1.00 (Referent)
1.62 (0.42, 6.45)
0.48
2.93 (0.52, 18.88) 0.23

p trend = 0.10
1.00 (Referent)
1.77c (0.48, 6.66)
0.39
3.18c (0.58, 20.0)
0.19

SHS Exposure in the Past Year •
Low 41(12)
1.00 (Referent)
High 17(7)
4.24 (1.05, 20.61) 0.05

1.00 (Referent)
4.30a (1.14, 19.06) 0.04

49(17)
14(8)
9(6)

Cotinine mg/dL •
0 mg/dL 29(8)
≤ 4 mg/dL

15(6)

5 - 99 mg/dL

12(7)

p trend = 0.04
1.00 (Referent)

1.00 (Referent)
2.58
(0.50, 15.82)
5.26
(0.98, 35.51)

0.27
0.06

Combined Effect
NS w/Low SHS 41(12)
1.00 (Referent)
Exposure
NS w/High 17(9)
3.17 (0.86, 12.58) 0.09
SHS Exposure
Smokers 14(10) 6.56 (1.24, 46.54) 0.04
• - Models exclude current, active smokers
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2.67d
(0.52, 16.23)
5.77d
(1.09, 38.65)

0.25
0.05

p trend = 0.019
1.00 (Referent)
3.20c (0.87, 12.7)

0.09

6.28c (1.31, 37.92)

0.03

* - Full models adjusted for MAR conception, Age, BMI, Gravidity, Marital status, Race
and Alcohol use
a - Models adjusted for MAR conception, Age and BMI
b - Models adjusted for MAR conception, Age, BMI, Marital status
c - Models adjusted for MAR conception, Age, BMI, Marital status and Gravidity
d - Models adjusted for MAR conception, Age, BMI (continuous), Gravidity and Alcohol
use
e - Models adjusted for MAR conception, Age, BMI, Gravidity, Marital status and
Alcohol use
Abbreviations: NS - Nonsmoker

Specific Aim 2d: Interaction of Current, Active Smoking and NAT2 Acetylator
Status on Spontaneous Abortion
Effect modification between current active smoking and NAT2 acetylator status
on SA was examined by adding an interaction term into the models used from Aim 2a,
among the three populations. NAT2 acetylator status was defined as rapid or slow.
However, 10 participants from this analysis were missing NAT2 acetylator status, either
because they did not provide a urine sample, or had issues with DNA
amplification/contamination, making a final sample of 62. All models were adjusted for
age, BMI, gravidity, marital status, race, alcohol use and NAT2 acetylator status. Results
showed no statistically significant interaction (Table 19). Current smokers with a slow
acetylator status had a 69% increase (95% CI: 0.08, 37.6) in the odds of SA compared to
nonsmoking women with rapid acetylator status. The estimate was adjusted for age, BMI
and MAR conception but was not statistically significant (P = 0.28). This analysis was
not stratified by MAR use because the samples became unreasonably small after
stratification.
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Table 19: Interaction of Current Active Smoking and NAT2 Acetylator Status with
Spontaneous Abortion
NAT2
Status/
Smoking
Exposure

FULL MODEL*
N

Fecundability
Ratio
(95% CI)

P-value for
Interaction

MINIMALLY ADJUSTED
MODELa
Fecundability
P-value for
Ratio
Interaction
(95% CI)

ALL Conceptions (72)
Rapid/
Nonsmoker

32(8)

Rapid/
Smoker

8(6)

Slow/
Nonsmoker
Slow/
Smoker

(Referent)

0.28

9.36 (1.65, 79.5)

0.14

8.91 (0.92, 136.3)

17(12) 5.95 (1.61, 25.02)

5(4)

(Referent)

1.69 (0.08, 37.6)

9.07 (1.98, 55.39)

0.55 (0.03, 11.56)

a – Models adjusted for Age and BMI
b – Models adjusted for MAR conception, Age, BMI, Gravidity, Marital status, Race,
Alcohol use and NAT2 Acetylator status

Specific Aim 3a: Assessment of Selection Bias Due to Loss to Follow-up
The full dataset including women that contributed no follow-up time (n=257) was
divided into two groups. Group 1 contained women that were not asked permission to be
followed up (n=95) and Group 2 contained those who were asked (n=162). The
population was then each stratified by the type of follow-up they received: either no
follow-up, follow-up through medical record only; or personal follow-up by phone, email
or mailing address. The characteristics of women from Group 1 and Group 2 can be
found in the Appendix D (Table S9-10).
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Characteristics of women in Group 2 were stratified by the type of follow-up: no
follow-up, medical record follow-up only, and personal follow-up only. No significant
differences were found between medical record follow-up and personal follow-up;
therefore, these groups were combined for subsequent analyses.. This left “any followup” to be compared with “no follow-up” (Table 20).
Women lost to follow-up were more likely to have a higher BMI (P = 0.15), more
likely to be of African American race (P = 0.02), more likely to be a current smoker (P =
0.01), more likely to have higher urinary cotinine levels (P = 0.004) and more likely to
report higher SHS exposure in the past year (P = 0.09).

Table 20: Characteristics of Women Stratified by Follow-up Type(None vs. Any)
(N=257)

Age in years,
median (Q1-Q3)
Age in years, n (%)
≤33
>33
BMI, kg/m2
median (Q1-Q3)

Lost to
Follow-up
N=28
30.00
(25.50-35.00)

P-value

0.21

0.36
18(66.67)
9(33.33)

127(55.46)
102(44.54)

31.32
(24.43-42.54)

29.04
(24.82-34.85)

BMI Category, kg/m2, n (%)
<25 (Underweight
7(26.92)
and Normal)
25 - 29.9
5(19.23)
(Overweight)
≥ 30 (Obese)
14(53.85)
BMI kg/m2, n (%)
≤30

Medical Record or
Personal
N=229
33.00
(28.00-37.00)

0.15

0.70
61(26.64)
63(27.51)
105(45.85)
0.57

12(66.67)

124(55.46)
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>30
Gravidity, n (%)
0
1
>=2
Regular Period,
n (%)
No
Yes

14(33.33)

105(44.54)
0.26

7(25.93)
8(29.63)
12(44.44)

97(42.36)
51(22.27)
81(35.37)
0.11

14(51.85)
13(48.15)

78(34.06)
151(65.94)

Average Cycle
Length, days,
median (Q1-Q3)

28.00
(27.50-29.50)

29.00
(28.00-30.00)

0.36

Age of Menarche in
years, median
(Q1-Q3)

12.00
(11.00-13.00)

12.00
(11.00-14.00)

0.11

Previous STD,
n (%)

0.78
No
Yes

17(65.30)
9(34.62)

136(60.44)
89(39.56)

Marital Status,
n (%)

0.76

No
Yes
Routine Exercise,
n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Other
Black

11(42.31)
15(57.69)

85(37.12)
144(62.88)

12(44.44)
15(55.56)

158(69.00)
71(31.00)

AMH (ng/mL),
median (Q1-Q3)

2.03
(0.76-4.82)

2.49
(1.30-5.03)

0.37
13(56.52)
10(43.48)

96(44.24)
121(55.76)
0.93

16(59.26)
11(40.74)

129(56.33)
100(43.67)
0.43

3(11.54)
23(88.46)

45(19.91)
181(80.09)
0.02
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0.49

Length of
Infertility, years
median (Q1-Q3)

1.75
(0.79-4.00)

2.00
(0.92-4.25)

NAT2 Acetylator Status, n (%)
Rapid
15(60.00)
Slow
10(40.00)

119(60.41)
78(39.59)

Cotinine (mg/dL),
median (Q1-Q3)

1.50
(0.00-38.00)

1.00

100.00
(2.25-100.00)

Cotinine mg/dL, n
(%)
0
<100
100

0.82

0.004

0.01
5(18.52)
8(29.63)
14(51.85)

84(38.71)
81(37.33)
52(23.96)

Current Active Smoker, n (%)
No
14(50.00)
Yes
14(50.00)

173(75.55)
56(24.45)

Self-reported SHS Exposure, n (%)
Low
9(32.14)
High
19(67.86)

0.01

0.09
117(51.09)
112(48.91)

Specific Aim 3b: Inverse Probability Weighting
Table 21 shows the weighted ORs and weighted FRs estimates adjusting for
confounding and selection bias due to loss to follow-up, separately and jointly for
conception as a dichotomous variable and fecundability. Results showed that there was
little difference between adjusting for confounding only and adjusting for both
confounding and selection bias due to loss of follow-up in all models. This may suggest
that the results are not biased to loss to follow-up. These estimates were also compared to
the estimates from the original analysis (Table 14). The original results from Table 14
showed an adjusted effect estimate in the opposite (anticipated) direction (aFR=1.26 95%
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CI 0.66, 2.41); however, compared to the effect estimate from Table 21 that was adjusted
for both confounding and selection bias due to loss of follow-up (aFR=0.87 95% CI 0.45,
1.68), the effect was in the anticipated direction. Overall, the conclusions remained
consistent with no association between current smoking and fecundability.

Table 21: Weighted Estimates Using Inverse Probability Weighting
Model
Logistic Regression - Conception (All Women)
Unadjusted and Unweighted
Adjusted for Confounding Only
Adjusting for Both Confounding and Selection Bias Due to
Loss of Follow-up

Estimate
OR
0.57
0.99a
0.98

95% CI
0.29, 1.10
0.79, 1.23
0.80, 1.21

Logistic Regression - Conception (NC Follow-up Months)
Unadjusted and Unweighted
Adjusted for Confounding Only
Adjusting for Both Confounding and Selection Bias Due to
Loss of Follow-up

OR
0.74
0.89b
0.90

0.30, 1.69
0.77, 1.03
0.78, 1.05

Survival Analysis - Fecundability (All Follow-up Time)
Unadjusted and Unweighted
Adjusted for Confounding Only
Adjusting for Both Confounding and Selection Bias Due to
Loss of Follow-up

FR
0.69
0.90a
0.87

0.38, 1.23
0.46, 1.76
0.45, 1.68

Survival Analysis - Fecundability (NC Follow-up Months)
FR
Unadjusted and Unweighted
0.95
0.44, 2.05
Adjusted for Confounding Only
0.70b
0.29, 1.70
Adjusting for Both Confounding and Selection Bias Due to
0.73
0.31, 1.74
Loss of Follow-up
a - Adjusted for MAR cycle, Age, BMI, Gravidity, Marital status and Race
b - Adjusted for Age, BMI, Gravidity, Marital status and Race
Abbreviation: MAR - Medically Assisted Reproduction, NC- Natural Conception
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VI. DISCUSSION

This preconception cohort study was done to examine the association of tobacco
smoke exposures on fertility and fertility-related outcomes, among women of
reproductive age seeking fertility counselling and treatment. Overall, smoking and SHS
exposure were not appreciably associated with fecundability, but the directions of
associations were opposite for women who used MAR vs. those who conceived naturally.
Smoking and high SHS exposure were associated with increased odds of spontaneous
abortion among women who conceived.

Active Smoking and Fecundability
Although no significant associations between tobacco smoke exposure and
fecundability were observed in this study, the difference in the direction of association in
those using MAR techniques vs. those who conceived naturally indicates that the effects
of smoking in these two groups may be fundamentally different. Different biological
mechanisms may be at play, which are discussed in more detail below. Additionally, the
population who used MAR was different in that they were significantly older, less likely
to be obese, more likely to be married, less likely to be a current smoker, and had lower
urinary cotinine levels. Some of these factors may be modifying or attenuating the effect
of smoking on the probability of conception using MAR. For example, the women using
MAR may be ‘healthier’ in terms of their ability to conceive, due their lower BMI and
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lower stress, because of a presumably better support system. Women using MAR were
more likely to be married, which can act as a proxy for sexual intercourse frequency,
emotional support or the seriousness of intention to become pregnant. These factors may
directly or indirectly modify the effect of smoking on conception.
Our results did not show an effect of active smoking on probability of conception
using MAR, which is consistent with other studies (178–181). However, there have been
many studies that show associations with smoking and lower success among MAR,
specifically using IVF (131,132,182,183). A recent meta-analysis in 2018, examined 26
studies with samples ranging from 40 to 834, found a significant overall association
between active smoking on ART outcomes (Pooled OR: 0.53, 95%CI: 0.41, 0.68).
Associations remained significant when the analysis was restricted to IVF cycles (16
studies, Pooled OR:0.52, 95%CI:0.39, 0.68). While, the authors did report a moderate
amount of heterogeneity between studies, and heavy reliance on self-reported exposure
data, there is strong evidence to suggest an association between smoking and conception
among women using MAR. Our results are still consistent with a possible harmful effect;
inference is difficult due to the small number of smokers (11) who ever used MAR,
leading to wide confidence intervals.
For natural conceptions, there is a plethora of studies supporting the association of
active smoking with longer time to conception and increased risk of infertility
(38,125,127,130). However, the magnitude of the associations is not overwhelming, with
the majority of studies producing weak effect sizes. Few studies have found significant
dose-response effects for female cigarette use with infertility and fecundability
(38,125,128). Curtis and colleagues found a significant dose-response effect among
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heavier smokers when examining the effect of smoking on fecundability. Women
smoking 11–20 cigarettes (aFR:0.87; 95%CI: 0.77, 0.99) and more than 20 cigarettes per
day (aFR:0.74; 95%CI: 0.59, 0.92) had reduced fecundability (38). Wesselink and
colleagues found similar weak associations and noted that the dose-response effect on
fecundability may only be among heavy smokers (135). Other studies also found
associations at higher intensities (25,126,184). Our study also found stronger reductions
in fecundability with increasing smoking intensity and cumulative lifetime exposure.
Although approximately 25% of our study population were active smokers, consistent
with what is seen in Kentucky (92), we had few heavy smokers, and our estimates were
not statistically significant. Overall, the evidence suggests that the effect of smoking on
fecundability may be limited to the heavy smokers.

Secondhand Smoke Exposure and Fecundability
Overall, our results showed no effect of recent or past year’s SHS exposure on
fecundability among nonsmokers. The difference in the direction of association between
women using MAR and women who conceived naturally can be explained similarly to
the active smoking exposure. Within this population, nonsmoking women using MAR
were significantly different, in that they had characteristics that have been shown to help
increase fertility. These nonsmoking women using MAR were less likely to be obese,
more likely to be married and had lower urinary cotinine levels, meaning they are
healthier in some ways than women who did not use MAR, and had lower levels of
exposure
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For women who conceived naturally, a small but insignificant reduction in
fecundability was reported for high SHS exposure compared to low SHS exposure.
These results are consistent with the previous literature showing either weak associations
(122,127) or no effect (126,139,140). Authors Radin and Wesselink both used
prospective cohort studies to examine self-reported SHS exposure on fecundability with
weak, insignificant findings (aFR: 0.92; 95% CI: 0.83,1.03) and (aFR: 0.93; 95%CI:
0.70,1.25), respectively(126,135). Benedict and colleagues retrospectively analyzed a
cohort study among verified nonsmoking women undergoing IVF treatment and found
that women with follicular fluid cotinine concentrations between 1.11 and 10 ng/ml had
increased risk of implantation failure (aRR: 1.17;95%CI: 1.20,1.92) (122). Sapra and
associates used prospective cohort study to examine heavy metals and serum cotinine
concentrations on TTC. Authors found a significant association for serum cotinine levels
greater than 10 ng/mL and longer TTC in females (aFR:0.64; 95%CI:0.41,.0.98) (127).
However, the association was greatly attenuated after adjusting for cadmium levels,
suggesting that cadmium may be responsible for some of the association between tobacco
use and longer TTC.
There are several proposed mechanisms to explain how tobacco smoke exposure
may affect fecundability. Studies have shown tobacco smoke toxins accumulate within
follicular fluid and surrounding tissues (106,110). The harmful substances within tobacco
smoke can affect gametogenesis, which can increase the risk of aneuploidies within
embryos and affect folliculogenesis by lowering ovarian reserve through impaired follicle
growth or development of oocytes (107,114). Some of the mechanisms include meiosis
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impairment, abnormal intercellular crosstalk, DNA damage, high levels of oxidative
stress, and activation of cell death pathways (107,108,110,114).
Heavy metals and toxins in tobacco smoke promote oxidative stress which can
lead to deleterious effects on cell membranes, DNA and proteins (107,110). DNA
damage can then lead to chromosomal abnormalities which in turn adversely affect
fertilization (114). Cadmium and benzo(A)pyrene, which are commonly found in tobacco
smoke, can also impair steroidogenesis, resulting in hormonal imbalances that can affect
both fertilization and implantation (107,108). Nicotine is a well-known strong
vasoconstrictor that can impair blood flow to the uterus. The structural function within
the fallopian tubes, uterus and cervix is also compromised, as the toxins act as adhesions
to lower ciliary cell activity, impair smooth muscle contraction and lower oocyte retrieval
rates (108,111).
This study examined active smoking and SHS exposure from preconception in
both natural and assisted conception, which allowed for detailed biological mechanisms
to be hypothesized. Among natural conceptions, the observed effect of tobacco smoke
exposures on reduced fecundability supported the mechanisms described earlier.
However, for women using MAR, fecundability may not be affected by tobacco smoke
exposure after OI or oocyte retrieval for IVF. This suggests that the toxins from cigarette
smoke may only affect fecundability via folliculogenesis through impaired follicle
growth or development of oocytes and steroidogenesis through hormonal imbalances that
impair ovulation. However, after OI and oocyte retrieval for IVF-ET, smoking may not
affect to a large extent other aspects such as implantation and/or development of the
trophoblast.
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This study is the first to analyze effect modification by NAT2 acetylator status on
active smoking and fecundability among a clinical population. While no statistically
significant interactions were detected among any of the populations, results may suggest
lower fecundability for current smokers who are slow NAT2 acetylators for natural
conceptions. However, the lack of significant associations may have been due to small
sample sizes among subgroups of smokers within this study. One other study that found
similar results examined the interaction of NAT2 and current smoking on fecundability
among women office workers. They found significantly reduced fecundability among
currents smokers with a slow acetylation status (15). The possible mechanism of effect
modification may be through polycyclic aromatic hydrocarbons and heterocyclic amines,
that are known constituents of tobacco smoke and are also metabolized by NAT2. Slow
acetylators may experience greater accumulation of these constituents within the ovarian
tissue and follicular fluid inducing higher levels of ovarian toxicity. Fecundability may be
also affect by several mechanisms, including increased oxidative stress and DNA
damage.

Active Smoking and Spontaneous Abortion
Among 72 conceptions with documented pregnancy outcomes, a marginally
significant association between current active smoking and SA was observed. Results
also showed increasing odds of SA with increasing intensity of smoking and cumulative
lifetime exposure. However, no significant dose-response effect was established for
either. Our results are consistent with Nielsen and colleagues, who also used
preconception smoking exposure on SA in a nested case-control study. However, their

138

results showed a significant dose-response effect for every 5 cigarettes smoker per day
(aOR: 1.20; 95%CI: 1.04,1.39) (144). Another recent case-control study also found a
significant dose-response effect but for maternal smoking ≥20 cigarettes a day and SA
(aOR: 2.39; 95%CI:1.26, 4.25) (185). While, there are a few studies that found
significant dose-response effects, other studies reported no significant effect for smoking
intensity and SA (143,186).
Studies among women undergoing ART have shown an association between
maternal smoking and adverse ART outcomes, particularly SA. Budani and colleagues
conducted a meta-analysis using 8 studies and found significantly increased odds of SA
per clinical pregnancy rate and maternal smoking (Pooled OR: 2.22; 95%CI: 1.10,4.48).
However, the authors did report a substantial amount of heterogeneity between the
studies. The majority of studies within the literature used self-reported information about
smoking, which can result in misclassification as women can either under-report their
exposures or change their behaviors throughout the pregnancy. Variation in the accuracy
of smoking exposures may explain some of the heterogeneity across studies. In our study,
we verified recent smoking using urinary cotinine; however, we did not ask or verify
whether the women continued to smoke during pregnancy. In addition, we were unable to
stratify the SA analysis by MAR, due to small numbers. Nonetheless, our findings are
consistent with the previous studies for both medically assisted and natural conceptions
and demonstrate a harmful effect of smoking on ongoing conceptions, leading to
spontaneous abortion.
The rate of spontaneous abortion in this study (43%) was noticeably higher than
in the general population, commonly estimated to be 15-20%. However, these
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pregnancies were closely followed, allowing for detection of early losses that might
usually go unnoticed, especially for women who use MAR. Preconception tobacco
smoke exposure captures a critical exposure period that can help elucidate potential
biological mechanisms. It may be that through its proximal effects on the uterine
environment, preconception smoking is more likely to cause early pregnancy losses (loss
of ‘biochemical pregnancies’), as opposed to later, clinical pregnancy losses. More
studies examining preconception smoking exposures on both planned natural conceptions
and MAR/ART outcomes are needed to understand the biological mechanisms of this
critical exposure period.

Secondhand Smoke Exposure and Spontaneous Abortion
Among verified nonsmokers, high SHS exposure in the past year was
significantly associated with increased odds of SA, with a significant dose-response
effect for preconception urinary cotinine. The combined effect exposure also showed
increased odds of SA for nonsmokers with high SHS exposure and even greater increased
odds of SA for current smokers compared to nonsmokers with low SHS exposure,
supporting the association with a significant test for trend.
It is possible that the effect of preconception maternal SHS exposure may be
confounded by paternal smoking, whereby the observed effect of maternal SHS on SA is
actually mediated by damaged sperm from the father. We investigated this possibility.
We did not find evidence that the association of preconception maternal SHS was
confounded by paternal smoking; of the women whose spouses smoked, the spouses were
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not diagnosed with male factor infertility. This suggests that the estimate was not biased
by confounding from spousal smoking or male factor infertility.
Several previous studies examined maternal exposure to SHS on SA found
significant associations; however, there is lack of studies examining preconception SHS
exposures on pregnancy outcomes. Many of the studies that found significant effects for
maternal smoking on SA used weaker study designs and relied on unverified selfreported exposure data (145,149,150), likely attenuating any associations. One casecontrol study used plasma cotinine levels to examine SHS exposure on SA. The authors
found a significant association for plasma cotinine levels between 0.1 and 15 ng/mL and
increased odds of SA (aOR:1.67; 95%CI: 1.17,2.38) (151). There are, however, several
studies that reported no association between SHS exposure during pregnancy and SA
(139,140,152). Pineles and colleagues conducted a meta-analysis examining SHS
exposure during pregnancy and SA using 17 studies. Researchers found no significant
association between SHS exposure during pregnancy and SA (148). Sensitivity analyses
retained insignificant estimates when studies among nonsmokers only were used. This
study may have been able to detect small effects due to the sensitive measures of SHS
from both urinary cotinine and a questionnaire; the ability to adjust for more relevant
confounders than previous studies; and the ability to detect very early pregnancy losses.
It is difficult to make inferences regarding whether NAT2 acetylator status
modified the effect of smoking on SA, because there were very few women in some of
the subgroups. For example, there were only 3 smokers who were slow acetylators and all
3 conceived.

141

Several mechanisms by which tobacco smoke exposure affects spontaneous
abortions have been hypothesized. These include DNA damage, apoptosis, impairment of
tissue development, or disruptions within cell division and other processes (75,79).
Aneuploidies can also form from DNA damage and increase the odds of chromosomal
abnormalities which is the most common cause of SA (10,79). Cadmium and nicotine
directly constrict blow flow to the uterus, impairing development of the placenta and
consequently resulting in EPL (108). Other mechanisms include impairment of
trophoblast growth, impairment of adhesions cells for embryo post-implantation and
apoptosis of placental cells (108,111). A detailed exploration of tobacco smoke exposures
during different critical periods of development will be important in elucidating potential
biological mechanisms and much needed to infer causality.
This study examined active smoking and SHS exposure on SA within a
population that is composed of infertile or subfertile women/couples. The majority of SA
occurred among women who conceived using MAR (64.5%). Some potential
mechanisms behind tobacco smoke exposure and SA among MAR users include
accumulation of cotinine or other harmful toxins within the uterus, affecting processes
after implantation such as restricting blood flow to the uterus and impairing placental
development.

Strengths and Limitations
This study has several strengths. Firstly, its prospective cohort design allowed for
assessment of preconception tobacco smoke exposures; and prospectively following the
subjects from enrollment to pregnancy and pregnancy outcomes establishes temporality,
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boosting the evidence for a causal association. Conception and pregnancy outcome data
were either extracted from medical records in duplicate which increased their accuracy,
or self-reported by women at follow-up intervals. Women who gave permission were
personally contacted in approximately 6-month intervals after their enrollment to collect
data. This allowed an ample amount of time for pregnancy, but short enough to minimize
recall bias. Also, using a prospective cohort allows for time to conception analysis and
adjustment for time-varying exposures and confounders. The analytic approach allowed
for use of time-to-event data, as opposed to simply modeling the probability of a
dichotomous outcome. Survival analyses therefore yield ratio estimates that are more
robust and meaningful, compared to binary regression such as logistic regression.
A second strength of this study includes the high retention rate. Out of all 257
women, 229 (89.1%) were successfully followed up, either through information extracted
from medical records and/or through personal re-contact if they gave permission. Female
smoking was found to be related to attrition in that current smokers were more likely to
be lost to follow-up. If the smokers who were lost to follow-up had a lower chance of
conceiving than the smokers who remained in the study, the probability of conception
among the smokers would be overestimated. However, after investigating the potential
effects of selection bias due to loss of follow-up using IPW, the results showed little
difference between adjusting for confounding only and adjusting for both confounding
and selection bias due to loss of follow-up for both outcomes. This may suggest that the
results are not biased due to loss to follow-up.
A third important strength of the study is the use of an objective biomarker to
verify smoking status. As shown in this study, women tend to under-report their smoking

143

behaviors, which can cause misclassification and may cause bias towards the null, as it
adds smokers to a presumably non-smoking group. In this study, 16 women reported
being a nonsmoker or a former smoker, but their high cotinine levels indicated that they
were currently smoking (>100 ng/mL). These women were grouped with verified current
smokers based on their urinary cotinine levels at the time of enrollment.
Lastly, to the best of our knowledge, this is the only study to explore effect
modification by NAT2 acetylator status on the relationship between smoking and
fecundability, as well as spontaneous abortion in a clinical population. Investigating
possible gene-environmental interactions can help to uncover potential biological
mechanisms and also can help to explain heterogeneity in results of prior studies.
There are a few limitations that should be acknowledged. Firstly, external validity
may be limited, given the specific clinical population used for this study. The results may
not be generalizable to the public, as they may have significantly different characteristics
compared women seeking fertility care. Secondly, the results were limited by the small
sample size of heavy/intense smokers (≥10 cigarettes per day, n=37). Also, after
stratifying the results for fecundability by MAR cycles only (n=70) and NC follow-up
time only (n=153), there were even smaller samples within sub-groups, especially the
MAR-cycles-only models. The analysis for SA was also a small subset of the original
population (n=72 conceptions). This reduced the power to detect any possible interactions
with NAT2 acetylator status on smoking with fecundability and SA. Small sample sizes
within sub-groups affected the precision of the estimates, resulting in wide confidence
intervals. Furthermore, given the small numbers there is a possibility that the associations
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for tobacco smoke exposure on SA reported were due to chance, though this association
is biologically plausible and has other support in the literature.
Preconception smoking is a critical exposure period that has not been fully
explored especially with regard to SA. However, most women change or under-report
their smoking behaviors when they become pregnant. Given that smoking was measured
at one point in this study, it is not clear whether the effect of preconception smoking on
SA is truly a lasting result of smoking prior to pregnancy, or if the effect is seen because
the women kept smoking during pregnancy.
A fourth limitation of the study includes the restriction to women planning a
pregnancy. Women seeking fertility care and treatment, with the intention of conceiving
were eligible for the study. Theoretically, less fertile smokers would have been enrolled,
given that smokers are more likely to have unplanned pregnancies either because of lack
of contraceptive use or risky behaviors.
There is also the possibility of residual confounding from both measured and
unmeasured confounders. To create a parsimonious model, many variables were treated
continuously or simply dichotomized. The estimates for tobacco smoke exposure and SA
were larger compared to past studies. This may reflect residual confounding from
unmeasured variables. While the results were likely not confounded by spousal smoking
or male factor infertility, there may have been other unmeasured confounders; high
secondhand smoke exposure may reflect other adverse environmental exposures, or
unhealthy social or behavioral exposures.
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The rate of SA was significantly higher than expected at 43%. This is likely
because it included early biochemical pregnancy losses. Information was not collected to
separate early from late SA, which could have provided more insight into mechanism.
Time to conception was measured in months and not by menstrual cycles. Women
with irregular menstrual cycles which is common among anovulatory infertility may not
ovulate every month. Hence, using months may have overestimated time to conception
and not accurately reflect cycles-at-risk.

Suggestions for Future Research
The 2020 U.S. Surgeon General report is still stating that there is insufficient
evidence to infer an association between tobacco smoke exposure and SA because of
many methodological concerns. Future studies should consider using more large-scale,
longitudinal prospective studies to help infer causality and biomarkers to validate selfreported exposures. Dose-response effects and measuring tobacco smoke exposures at
critical exposure periods and developmental windows, and at multiple intervals can help
to fully capture the effects and elucidate biological mechanisms. Additionally, many of
the studies that examined MAR procedures only took IVF into account; however, more
research is needed to address whether the effects of smoking are observed across all
treatment procedures including OI, IUI and FET.
When examining natural follow-up time, ovulation kits should be used so that the
number of cycles of follow-up can be accurately determined. Careful consideration
should also be taken when adjusting for all important confounders and examining
potential effect modifiers, such as genetic variants and types of infertility diagnosis.
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Information on paternal smoking should be collected. Lastly, cohort studies study should
be designed to maximize retention and reduce potential selection bias and appropriate
statistical analyses should also be done to assess and adjust for bias, such as selection and
attrition bias, before reporting estimates that may reflect spurious associations.

Conclusion
Infertility and adverse pregnancy outcomes remain growing public health
problems. There are several studies supporting the association of active smoking on
lowered fecundability, increased infertility, and increased risk of adverse pregnancy
outcomes. However, according to the latest U.S. Surgeon General’s report, the literature
is still insufficient with regard to SHS exposures. This study used a prospective cohort
study design, along with objective markers of exposure assessment, adjusted for potential
biases and explored a gene-environment interaction, to further clarify the effect of active
smoking on both assisted and natural conceptions, and added to the small body of
literature regarding the effect of SHS exposure on fecundability and SA.
Results from this study did not show an association for active smoking or SHS
exposure on fecundability, but there was suggestive evidence that the effect of active
smoking may be more pronounced among slow acetylators. Significant associations were
found for preconception active smoking and SHS exposure with a significant doseresponse effect for urinary cotinine on SA. These findings suggest that current smokers
and nonsmokers with high levels of SHS exposure may have increased risk of adverse
birth outcomes. Data from this dissertation can ultimately be used to support public
policies that discourage smoking and limit the public’s exposure to secondhand smoke.

147

REFERENCES

1. Martinez GM, Daniels K, Febo-Vazquez I. Fertility of Men and Women Aged 15-44
in the United States: National Survey of Family Growth, 2011-2015. Natl Health
Stat Rep. 2018 Jul;(113):1–17.
2. Centers for Disease Control and Prevention and National Center for Health Statistics.
National Survey of Family Growth: Key Statistics from the National Survey of
Family and Growth-I Listing. Last reviewed: November 8, 2019; Available from:
https://www.cdc.gov/nchs/nsfg/key_statistics/i_2015-2017.htm#impaired.
3. Centers for Disease Control and Prevention. National Public Health Action Plan for
the Detection, Prevention, and Management of Infertility, Atlanta, Georgia:
Centers for Disease Control and Prevention; June 2014.
4. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et
al. The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod
Oxf Engl. 2017 Sep 1;32(9):1786–801.
5. Barbieri R. Yen & Jaffe’s Reproductive Endocrinology. Chapter 22. Female
Infertility [Internet]. 8th Edition. 2018. 1008 p. Available from:
http://herbex.tn/pdf/68/47_PCOS13.pdf
6. Lindsay TJ, Vitrikas KR. Evaluation and treatment of infertility. Am Fam Physician.
2015 Mar 1;91(5):308–14.
7. Centers for Disease Control and Prevention, American Society for Reproductive
Medicine, Society for Assisted Reproductive Technology. 2016 Assisted
Reproductive Technology National Summary Report. Atlanta (GA): US Dept of
Health and Human Services; 2018.
8. Wang JX. Incidence of spontaneous abortion among pregnancies produced by
assisted reproductive technology. Hum Reprod. 2004 Feb 1;19(2):272–7.
9. Rossi BV, Abusief M, Missmer SA. Modifiable Risk Factors and Infertility: What are
the Connections? Am J Lifestyle Med. 2014;10(4):220–31.
10. Griebel CP, Halvorsen J, Golemon TB, Day AA. Management of spontaneous
abortion. Am Fam Physician. 2005 Oct 1;72(7):1243–50.
11. U.S. Department of Health and Human Services. The Health Consequences of
Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA:
148

U.S. Department of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and Health Promotion,
Office on Smoking and Health, 2014. Printed with corrections, January 2014
[accessed 2019 Jan 11].
12. U.S. Department of Health and Human Services. Smoking Cessation. A Report of the
Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention, National Center for Chronic Disease
Prevention and Health Promotion, Office on Smoking and Health, 2020.
13. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular
genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am
Soc Prev Oncol. 2000 Jan;9(1):29–42.
14. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2
(NAT2) genetic diversity and traditional subsistence: a worldwide population
survey. PloS One. 2011 Apr 6;6(4):e18507.
15. Taylor KC, Small CM, Dominguez CE, Murray LE, Tang W, Wilson MM, et al.
alcohol, smoking, and caffeine in relation to fecundability, with effect modification
by NAT2. Ann Epidemiol. 2011 Nov;21(11):864–72.
16. Jiang W, Liu S, Cao F, Zhang J, Ni M, Zhou Q, et al. [Single nucleotide
polymorphisms of the N-acetyltransferase 2 gene not correlated with male
infertility]. Zhonghua Nan Ke Xue Natl J Androl. 2016 Apr;22(4):320–4.
17. Trang NT, Huyen VT, Tuan NT, Phan TD. Association of N-acetyltransferase-2 and
glutathione S-transferase polymorphisms with idiopathic male infertility in
Vietnam male subjects. Chem Biol Interact. 2018 Apr 25;286:11–6.
18. Vander Borght M, Wyns C. Fertility and infertility: Definition and epidemiology.
Clin Biochem. 2018 Dec;62:2–10.
19. Chandra A, Copen CE, Stephen EH. Infertility and impaired fecundity in the United
States, 1982-2010: data from the National Survey of Family Growth. Natl Health
Stat Rep. 2013 Aug 14;(67):1–18, 1 p following 19.
20. Taylor A. ABC of subfertility: extent of the problem. BMJ. 2003 Aug
23;327(7412):434–6.
21. Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender,
reproductive technologies and global movements in the 21st century. Hum Reprod
Update. 2015 Aug;21(4):411–26.
22. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National,
regional, and global trends in infertility prevalence since 1990: a systematic
analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356.
149

23. Sun H, Gong T-T, Jiang Y-T, Zhang S, Zhao Y-H, Wu Q-J. Global, regional, and
national prevalence and disability-adjusted life-years for infertility in 195 countries
and territories, 1990-2017: results from a global burden of disease study, 2017.
Aging. 2019 Dec 2;11(23):10952–91.
24. Louis JF, Thoma ME, Sørensen DN, McLain AC, King RB, Sundaram R, et al. The
prevalence of couple infertility in the United States from a male perspective:
evidence from a nationally representative sample. Andrology. 2013 Sep;1(5):741–
8.
25. Howe G, Westhoff C, Vessey M, Yeates D. Effects of age, cigarette smoking, and
other factors on fertility: findings in a large prospective study. Br Med J Clin Res
Ed. 1985 Jun 8;290(6483):1697–700.
26. Dunson DB, Baird DD, Colombo B. Increased Infertility With Age in Men and
Women: Obstet Gynecol. 2004 Jan;103(1):51–6.
27. Wesselink AK, Rothman KJ, Hatch EE, Mikkelsen EM, Sorensen HT, Wise LA. Age
and fecundability in a North American preconception cohort study. Am J Obstet
Gynecol. 2017 Dec;217(6):667.e1-667.e8.
28. Bradley D, Landau E, Jesani N, Mowry B, Chui K, Baron A, et al. Time to
conception and the menstrual cycle: an observational study of fertility app users
who conceived. Hum Fertil. 2019 May 16;1–9.
29. Steiner AZ. Menstrual cycle characteristics are associated with fecundability. BJOG
Int J Obstet Gynaecol. 2017 Oct;124(11):1663.
30. Wesselink AK, Wise LA, Hatch EE, Rothman KJ, Mikkelsen EM, Stanford JB, et al.
Menstrual cycle characteristics and fecundability in a North American
preconception cohort. Ann Epidemiol. 2016 Jul;26(7):482-487.e1.
31. Zhang Q, Wang YY, Zhang Y, Zhang HG, Yang Y, He Y, et al. The influence of age
at menarche, menstrual cycle length and bleeding duration on time to pregnancy: a
large prospective cohort study among rural Chinese women. BJOG Int J Obstet
Gynaecol. 2017 Oct;124(11):1654–62.
32. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA.
Genetic variants and environmental factors associated with hormonal markers of
ovarian reserve in Caucasian and African American women. Hum Reprod Oxf
Engl. 2012 Feb;27(2):594–608.
33. Zorrilla M, Yatsenko AN. The Genetics of Infertility: Current Status of the Field.
Curr Genet Med Rep. 2013 Dec 1;1(4).
34. Venkatesh T, Suresh PS, Tsutsumi R. New insights into the genetic basis of
infertility. Appl Clin Genet. 2014;7:235–43.

150

35. Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Diet and lifestyle in the
prevention of ovulatory disorder infertility. Obstet Gynecol. 2007
Nov;110(5):1050–8.
36. Gaskins AJ, Chavarro JE. Diet and fertility: a review. Am J Obstet Gynecol. 2018
Apr;218(4):379–89.
37. Hatch EE, Wesselink AK, Hahn KA, Michiel JJ, Mikkelsen EM, Sorensen HT, et al.
Intake of Sugar-sweetened Beverages and Fecundability in a North American
Preconception Cohort. Epidemiol Camb Mass. 2018 May;29(3):369–78.
38. Curtis KM, Savitz DA, Arbuckle TE. Effects of cigarette smoking, caffeine
consumption, and alcohol intake on fecundability. Am J Epidemiol. 1997 Jul
1;146(1):32–41.
39. Wilcox A, Weinberg C, Baird D. Caffeinated beverages and decreased fertility.
Lancet Lond Engl. 1988 Dec 24;2(8626–8627):1453–6.
40. Lassi ZS, Imam AM, Dean SV, Bhutta ZA. Preconception care: caffeine, smoking,
alcohol, drugs and other environmental chemical/radiation exposure. Reprod
Health. 2014 Sep 26;11 Suppl 3:S6.
41. McKinnon CJ, Hatch EE, Rothman KJ, Mikkelsen EM, Wesselink AK, Hahn KA, et
al. Body mass index, physical activity and fecundability in a North American
preconception cohort study. Fertil Steril. 2016 Aug;106(2):451–9.
42. Zain MM, Norman RJ. Impact of Obesity on Female Fertility and Fertility Treatment.
Womens Health. 2008 Mar;4(2):183–94.
43. Rich-Edwards JW, Spiegelman D, Garland M, Hertzmark E, Hunter DJ, Colditz GA,
et al. Physical activity, body mass index, and ovulatory disorder infertility.
Epidemiol Camb Mass. 2002 Mar;13(2):184–90.
44. Russo LM, Whitcomb BW, Mumford SL, Hawkins M, Radin RG, Schliep KC, et al.
A prospective study of physical activity and fecundability in women with a history
of pregnancy loss. Hum Reprod Oxf Engl. 2018 Jul 1;33(7):1291–8.
45. Trent M, Bass D, Ness RB, Haggerty C. Recurrent PID, subsequent STI, and
reproductive health outcomes: findings from the PID evaluation and clinical health
(PEACH) study. Sex Transm Dis. 2011 Sep;38(9):879–81.
46. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R.
Use of copper intrauterine devices and the risk of tubal infertility among
nulligravid women. N Engl J Med. 2001 Aug 23;345(8):561–7.
47. Hjollund NH, Jensen TK, Bonde JP, Henriksen TB, Andersson AM, Kolstad HA, et
al. Distress and reduced fertility: a follow-up study of first-pregnancy planners.
Fertil Steril. 1999 Jul;72(1):47–53.

151

48. Louis GMB, Lum KJ, Sundaram R, Chen Z, Kim S, Lynch CD, et al. Stress reduces
conception probabilities across the fertile window: evidence in support of
relaxation. Fertil Steril. 2011 Jun;95(7):2184–9.
49. Broekmans FJ, Fauser BCJM. Female Infertility. In: Endocrinology: Adult and
Pediatric [Internet]. Elsevier; 2016 [cited 2020 Mar 11]. p. 2260-2274.e4.
Available from:
https://linkinghub.elsevier.com/retrieve/pii/B9780323189071001323
50. Jirge PR. Poor ovarian reserve. J Hum Reprod Sci. 2016 Jun;9(2):63–9.
51. Hvidman HW, Bang AK, Priskorn L, Scheike T, Birch Petersen K, Nordkap L, et al.
Anti-Mullerian hormone levels and fecundability in women with a natural
conception. Eur J Obstet Gynecol Reprod Biol. 2017 Oct;217:44–52.
52. De Vos M, Devroey P, Fauser BCJM. Primary ovarian insufficiency. Lancet Lond
Engl. 2010 Sep 11;376(9744):911–21.
53. Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Womens Health.
2014;6:235–43.
54. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure.
Obstet Gynecol. 1986 Apr;67(4):604–6.
55. Meczekalski B, Katulski K, Czyzyk A, Podfigurna-Stopa A, Maciejewska-Jeske M.
Functional hypothalamic amenorrhea and its influence on women’s health. J
Endocrinol Invest. 2014 Nov;37(11):1049–56.
56. Homan GF, Davies M, Norman R. The impact of lifestyle factors on reproductive
performance in the general population and those undergoing infertility treatment: a
review. Hum Reprod Update. 2007 May 1;13(3):209–23.
57. Centers for Disease Control and Prevention and National Center for Health Statistics.
PCOS (Polycystic Ovary Syndrome) and Diabetes Last reviewed: August 12,
2019; Available from: https://www.cdc.gov/diabetes/basics/pcos.html.
58. Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with
polycystic ovary syndrome: approach to clinical practice. Clin Sao Paulo Braz.
2015 Nov;70(11):765–9.
59. Grodstein F, Goldman MB, Cramer DW. Body mass index and ovulatory infertility.
Epidemiol Camb Mass. 1994 Mar;5(2):247–50.
60. Green BB, Daling JR, Weiss NS, Liff JM, Koepsell T. Exercise as a risk factor for
infertility with ovulatory dysfunction. Am J Public Health. 1986 Dec;76(12):1432–
6.

152

61. Gill J. The effects of moderate alcohol consumption on female hormone levels and
reproductive function. Alcohol Alcohol Oxf Oxfs. 2000 Oct;35(5):417–23.
62. Salazar-Martinez E, Willett WC, Ascherio A, Manson JE, Leitzmann MF, Stampfer
MJ, et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern
Med. 2004 Jan 6;140(1):1–8.
63. Agardh EE, Carlsson S, Ahlbom A, Efendic S, Grill V, Hammar N, et al. Coffee
consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and
women. J Intern Med. 2004 Jun;255(6):645–52.
64. Mueller BA, Daling JR, Moore DE, Weiss NS, Spadoni LR, Stadel BV, et al.
Appendectomy and the risk of tubal infertility. N Engl J Med. 1986 Dec
11;315(24):1506–8.
65. Jose-Miller AB, Boyden JW, Frey KA. Infertility. Am Fam Physician. 2007 Mar
15;75(6):849–56.
66. Yuan S, Qiu Y, Xu Y, Wang H. Human papillomavirus infection and female
infertility: a systematic review and meta-analysis. Reprod Biomed Online. 2020
Feb;40(2):229–37.
67. Donnez J, Dolmans M-M. Uterine fibroid management: from the present to the
future. Hum Reprod Update. 2016;22(6):665–86.
68. American Society for Reproductive Medicine. (2015). Fibroids and fertility.
Retrieved February 2020, from http://www.fertilityanswers.com/wpcontent/uploads/2016/04/fibroids-and-fertility.pdf/.
69. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis
and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North
Am. 2012 Dec;39(4):535–49.
70. American Society for Reproductive Medicine. (2012). Third-party reproduction
(sperm, egg, and embryo donation and surrogacy): A guide for patients. Retrieved
February 2020, from https://www.reproductivefacts.org/globalassets/rf/news-andpublications/bookletsfact-sheets/english-fact-sheets-and-info-booklets/thirdparty_reproduction_booklet_web.pdf.
71. Sunderam S, Kissin DM, Zhang Y, Folger SG, Boulet SL, Warner L, et al. Assisted
Reproductive Technology Surveillance - United States, 2016. Morb Mortal Wkly
Rep Surveill Summ Wash DC 2002. 2019 Apr 26;68(4):1–23.
72. American Society for Reproductive Medicine. (2015). Assisted reproductive
technologies: A guide for patients. Retrieved January 2020, from
http://www.fertilityanswers.com/wp-content/uploads/2016/04/assistedreproductive-technologies-booklet.pdf.

153

73. Adamson GD, de Mouzon J, Chambers GM, Zegers-Hochschild F, Mansour R,
Ishihara O, et al. International Committee for Monitoring Assisted Reproductive
Technology: world report on assisted reproductive technology, 2011. Fertil Steril.
2018 Nov;110(6):1067–80.
74. Chandra A, Copen CE, Stephen EH. Infertility service use in the United States: data
from the National Survey of Family Growth, 1982-2010. Natl Health Stat Rep.
2014 Jan 22;(73):1–21.
75. Pinar MH, Gibbins K, He M, Kostadinov S, Silver R. Early Pregnancy Losses:
Review of Nomenclature, Histopathology, and Possible Etiologies. Fetal Pediatr
Pathol. 2018 May 4;37(3):191–209.
76. Pandya PP, Snijders RJ, Psara N, Hilbert L, Nicolaides KH. The prevalence of nonviable pregnancy at 10-13 weeks of gestation. Ultrasound Obstet Gynecol Off J Int
Soc Ultrasound Obstet Gynecol. 1996 Mar;7(3):170–3.
77. Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, Schlatterer JP, Canfield RE, et
al. Incidence of early loss of pregnancy. N Engl J Med. 1988 Jul 28;319(4):189–
94.
78. Rossen LM, Ahrens KA, Branum AM. Trends in Risk of Pregnancy Loss Among US
Women, 1990-2011. Paediatr Perinat Epidemiol. 2018;32(1):19–29.
79. Agenor A, Bhattacharya S. Infertility and miscarriage: common pathways in
manifestation and management. Womens Health Lond Engl. 2015 Jul;11(4):527–
41.
80. Wong LF, Schliep KC, Silver RM, Mumford SL, Perkins NJ, Ye A, et al. The effect
of a very short interpregnancy interval and pregnancy outcomes following a
previous pregnancy loss. Am J Obstet Gynecol. 2015 Mar;212(3):375.e1-11.
81. Magnus MC, Wilcox AJ, Morken N-H, Weinberg CR, Håberg SE. Role of maternal
age and pregnancy history in risk of miscarriage: prospective register based study.
BMJ. 2019 20;364:l869.
82. Rasti S, Ghasemi FS, Abdoli A, Piroozmand A, Mousavi SGA, Fakhrie-Kashan Z.
ToRCH “co-infections” are associated with increased risk of abortion in pregnant
women. Congenit Anom. 2016 Mar;56(2):73–8.
83. Larsen EC, Christiansen OB, Kolte AM, Macklon N. New insights into mechanisms
behind miscarriage. BMC Med. 2013 Dec;11(1):154.
84. Chan YY, Jayaprakasan K, Tan A, Thornton JG, Coomarasamy A, Raine-Fenning
NJ. Reproductive outcomes in women with congenital uterine anomalies: a
systematic review. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet
Gynecol. 2011 Oct;38(4):371–82.

154

85. World Health Organization.Tobacco. July 2019 [cited 2020 January; Available from:
https://www.who.int/news-room/fact-sheets/detail/tobacco.
86. Fronczak A, Polańska K, Makowiec-Dabrowska T, Kaleta D. [Smoking among
women--strategies for fighting the tobacco epidemic]. Przegl Lek.
2012;69(10):1103–7.
87. Creamer MR, Wang TW, Babb S, Cullen KA, Day H, Willis G, et al. Tobacco
Product Use and Cessation Indicators Among Adults — United States, 2018.
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1013–9.
88. Tong VT, Dietz PM, Morrow B, D’Angelo DV, Farr SL, Rockhill KM, et al. Trends
in smoking before, during, and after pregnancy--Pregnancy Risk Assessment
Monitoring System, United States, 40 sites, 2000-2010. Morb Mortal Wkly Rep
Surveill Summ Wash DC 2002. 2013 Nov 8;62(6):1–19.
89. Kondracki AJ. Prevalence and patterns of cigarette smoking before and during early
and late pregnancy according to maternal characteristics: the first national data
based on the 2003 birth certificate revision, United States, 2016. Reprod Health.
2019 Dec;16(1):142.
90. Homa DM, Neff LJ, King BA, Caraballo RS, Bunnell RE, Babb SD, et al. Vital
signs: disparities in nonsmokers’ exposure to secondhand smoke--United States,
1999-2012. MMWR Morb Mortal Wkly Rep. 2015 Feb 6;64(4):103–8.
91. Xu X, Bishop EE, Kennedy SM, Simpson SA, Pechacek TF. Annual healthcare
spending attributable to cigarette smoking: an update. Am J Prev Med. 2015
Mar;48(3):326–33.
92. Centers for Disease Control and Prevention. State Tobacco Activities Tracking &
Evaluation (STATE) System. State Highlights. Kentucky. (Behavior Risk Factor
Surveillance System) 2017 [accessed 2019 September 5].
93. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco
smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum.
2004;83:1–1438.
94. Jacob P, Benowitz NL, Destaillats H, Gundel L, Hang B, Martins-Green M, et al.
Thirdhand Smoke: New Evidence, Challenges, and Future Directions. Chem Res
Toxicol. 2017 17;30(1):270–94.
95. Martins-Green M, Adhami N, Frankos M, Valdez M, Goodwin B, Lyubovitsky J, et
al. Cigarette smoke toxins deposited on surfaces: implications for human health.
PloS One. 2014;9(1):e86391.
96. Douglas CE, Henson R, Drope J, Wender RC. The American Cancer Society public
health statement on eliminating combustible tobacco use in the United States. CA
Cancer J Clin. 2018;68(4):240–5.
155

97. Jaakkola MS, Jaakkola JJ. Assessment of exposure to environmental tobacco smoke.
Eur Respir J. 1997 Oct;10(10):2384–97.
98. Hanke W, Kalinka J, Florek E, Sobala W. Passive smoking and pregnancy outcome
in central Poland. Hum Exp Toxicol. 1999 Apr;18(4):265–71.
99. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of
self-reported smoking: a review and meta-analysis. Am J Public Health. 1994
Jul;84(7):1086–93.
100. World Health Organization & Centers for Disease Control (U.S.). (2011). Tobacco
questions for surveys: a subset of key questions from the Global Adult Tobacco
Survey (GATS): global tobacco surveillance system. World Health Organization.
https://apps.who.int/iris/handle/10665/87331.
101. Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G. Methods for
quantification of exposure to cigarette smoking and environmental tobacco smoke:
focus on developmental toxicology. Ther Drug Monit. 2009 Feb;31(1):14–30.
102. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure.
Epidemiol Rev. 1996;18(2):188–204.
103. Bramer SL, Kallungal BA. Clinical considerations in study designs that use
cotinine as a biomarker. Biomark Biochem Indic Expo Response Susceptibility
Chem. 2003 Aug;8(3–4):187–203.
104. Benowitz NL, Schultz KE, Haller CA, Wu AHB, Dains KM, Jacob P. Prevalence
of smoking assessed biochemically in an urban public hospital: a rationale for
routine cotinine screening. Am J Epidemiol. 2009 Oct 1;170(7):885–91.
105. Campo L, Polledri E, Bechtold P, Gatti G, Ranzi A, Lauriola P, et al. Determinants
of active and environmental exposure to tobacco smoke and upper reference value
of urinary cotinine in not exposed individuals. Environ Res. 2016 Jul;148:154–63.
106. Zenzes MT, Reed TE, Wang P, Klein J. Cotinine, a major metabolite of nicotine, is
detectable in follicular fluids of passive smokers in in vitro fertilization therapy.
Fertil Steril. 1996 Oct;66(4):614–9.
107. Budani MC, Tiboni GM. Ovotoxicity of cigarette smoke: A systematic review of
the literature. Reprod Toxicol Elmsford N. 2017 Sep;72:164–81.
108. Dechanet C, Anahory T, Mathieu Daude JC, Quantin X, Reyftmann L, Hamamah
S, et al. Effects of cigarette smoking on reproduction. Hum Reprod Update. 2011
Feb;17(1):76–95.
109. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects
of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol RBE.
2012 Jun 29;10:49.

156

110. Zenzes MT. Smoking and reproduction: gene damage to human gametes and
embryos. Hum Reprod Update. 2000 Apr;6(2):122–31.
111. Shiverick KT, Salafia C. Cigarette smoking and pregnancy I: ovarian, uterine and
placental effects. Placenta. 1999 May;20(4):265–72.
112. Pryor WA, Stone K. Oxidants in Cigarette Smoke Radicals, Hydrogen Peroxide,
Peroxynitrate, and Peroxynitrite. Ann N Y Acad Sci. 1993 May;686(1 Tobacco
Smoki):12–27.
113. Das S, Chattopadhyay R, Ghosh S, Ghosh S, Goswami SK, Chakravarty BN, et al.
Reactive oxygen species level in follicular fluid--embryo quality marker in IVF?
Hum Reprod Oxf Engl. 2006 Sep;21(9):2403–7.
114. Agarwal A, Majzoub A. Role of Antioxidants in Assisted Reproductive
Techniques. World J Mens Health. 2017 Aug;35(2):77–93.
115. Khan HM, Khan MY, Minhas LA. Effect of passive tobacco smoking on fertility
of female mice. J Coll Physicians Surg--Pak JCPSP. 2008 Nov;18(11):708–12.
116. Mai Z, Lei M, Yu B, Du H, Liu J. The effects of cigarette smoke extract on
ovulation, oocyte morphology and ovarian gene expression in mice. PloS One.
2014;9(4):e95945.
117. Gannon AM, Stampfli MR, Foster WG. Cigarette smoke exposure leads to follicle
loss via an alternative ovarian cell death pathway in a mouse model. Toxicol Sci
Off J Soc Toxicol. 2012 Jan;125(1):274–84.
118. Bordel R, Laschke MW, Menger MD, Vollmar B. Nicotine does not affect
vascularization but inhibits growth of freely transplanted ovarian follicles by
inducing granulosa cell apoptosis. Hum Reprod Oxf Engl. 2006 Mar;21(3):610–7.
119. Tsai-Turton M, Nakamura BN, Luderer U. Induction of apoptosis by 9,10dimethyl-1,2-benzanthracene in cultured preovulatory rat follicles is preceded by a
rise in reactive oxygen species and is prevented by glutathione. Biol Reprod. 2007
Sep;77(3):442–51.
120. Tuttle AM, Stämpfli M, Foster WG. Cigarette smoke causes follicle loss in mice
ovaries at concentrations representative of human exposure. Hum Reprod Oxf
Engl. 2009 Jun;24(6):1452–9.
121. Plante BJ, Cooper GS, Baird DD, Steiner AZ. The impact of smoking on
antimüllerian hormone levels in women aged 38 to 50 years. Menopause N Y N.
2010 Jun;17(3):571–6.
122. Benedict MD, Missmer SA, Vahratian A, Berry KF, Vitonis AF, Cramer DW, et
al. Secondhand tobacco smoke exposure is associated with increased risk of failed

157

implantation and reduced IVF success. Hum Reprod Oxf Engl. 2011
Sep;26(9):2525–31.
123. Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted
reproductive technology treatment. Hum Reprod Oxf Engl. 2002
Dec;17(12):3220–3.
124. Neal MS, Hughes EG, Holloway AC, Foster WG. Sidestream smoking is equally
as damaging as mainstream smoking on IVF outcomes. Hum Reprod Oxf Engl.
2005 Sep;20(9):2531–5.
125. Baird DD, Wilcox AJ. Cigarette smoking associated with delayed conception.
JAMA. 1985 May 24;253(20):2979–83.
126. Radin RG, Hatch EE, Rothman KJ, Mikkelsen EM, Sorensen HT, Riis AH, et al.
Active and passive smoking and fecundability in Danish pregnancy planners. Fertil
Steril. 2014 Jul;102(1):183-191.e2.
127. Sapra KJ, Barr DB, Maisog JM, Sundaram R, Buck Louis GM. Time-to-Pregnancy
Associated With Couples’ Use of Tobacco Products. Nicotine Tob Res Off J Soc
Res Nicotine Tob. 2016 Nov;18(11):2154–61.
128. Laurent SL, Thompson SJ, Addy C, Garrison CZ, Moore EE. An epidemiologic
study of smoking and primary infertility in women. Fertil Steril. 1992
Mar;57(3):565–72.
129. Hyland A, Piazza K, Hovey KM, Tindle HA, Manson JE, Messina C, et al.
Associations between lifetime tobacco exposure with infertility and age at natural
menopause: the Women’s Health Initiative Observational Study. Tob Control.
2016 Nov;25(6):706–14.
130. Augood C, Duckitt K, Templeton AA. Smoking and female infertility: a systematic
review and meta-analysis. Hum Reprod Oxf Engl. 1998 Jun;13(6):1532–9.
131. Hughes EG, Brennan BG. Does cigarette smoking impair natural or assisted
fecundity? Fertil Steril. 1996 Nov;66(5):679–89.
132. Van Voorhis BJ, Dawson JD, Stovall DW, Sparks AE, Syrop CH. The effects of
smoking on ovarian function and fertility during assisted reproduction cycles.
Obstet Gynecol. 1996 Nov;88(5):785–91.
133. Freour T, Masson D, Mirallie S, Jean M, Bach K, Dejoie T, et al. Active smoking
compromises IVF outcome and affects ovarian reserve. Reprod Biomed Online.
2008 Jan;16(1):96–102.
134. Hull MG, North K, Taylor H, Farrow A, Ford WC. Delayed conception and active
and passive smoking. The Avon Longitudinal Study of Pregnancy and Childhood
Study Team. Fertil Steril. 2000 Oct;74(4):725–33.

158

135. Wesselink AK, Hatch EE, Rothman KJ, Mikkelsen EM, Aschengrau A, Wise LA.
Prospective study of cigarette smoking and fecundability. Hum Reprod Oxf Engl.
2019 Mar 1;34(3):558–67.
136. Feichtinger W, Papalambrou K, Poehl M, Krischker U, Neumann K. Smoking and
in vitro fertilization: a meta-analysis. J Assist Reprod Genet. 1997
Nov;14(10):596–9.
137. Waylen AL, Metwally M, Jones GL, Wilkinson AJ, Ledger WL. Effects of
cigarette smoking upon clinical outcomes of assisted reproduction: a metaanalysis. Hum Reprod Update. 2009 Feb;15(1):31–44.
138. Budani MC, Fensore S, Di Marzio M, Tiboni GM. Cigarette smoking impairs
clinical outcomes of assisted reproductive technologies: A meta-analysis of the
literature. Reprod Toxicol Elmsford N. 2018 Sep;80:49–59.
139. Meeker JD, Missmer SA, Cramer DW, Hauser R. Maternal exposure to secondhand tobacco smoke and pregnancy outcome among couples undergoing assisted
reproduction. Hum Reprod Oxf Engl. 2007 Feb;22(2):337–45.
140. Meeker JD, Missmer SA, Vitonis AF, Cramer DW, Hauser R. Risk of spontaneous
abortion in women with childhood exposure to parental cigarette smoke. Am J
Epidemiol. 2007 Sep 1;166(5):571–5.
141. Armstrong BG, McDonald AD, Sloan M. Cigarette, alcohol, and coffee
consumption and spontaneous abortion. Am J Public Health. 1992 Jan;82(1):85–7.
142. Ness RB, Grisso JA, Hirschinger N, Markovic N, Shaw LM, Day NL, et al.
Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J Med. 1999
Feb 4;340(5):333–9.
143. Mishra GD, Dobson AJ, Schofield MJ. Cigarette smoking, menstrual symptoms
and miscarriage among young women. Aust N Z J Public Health. 2000
Aug;24(4):413–20.
144. Nielsen A, Hannibal CG, Lindekilde BE, Tolstrup J, Frederiksen K, Munk C, et al.
Maternal smoking predicts the risk of spontaneous abortion. Acta Obstet Gynecol
Scand. 2006;85(9):1057–65.
145. Hyland A, Piazza KM, Hovey KM, Ockene JK, Andrews CA, Rivard C, et al.
Associations of lifetime active and passive smoking with spontaneous abortion,
stillbirth and tubal ectopic pregnancy: a cross-sectional analysis of historical data
from the Women’s Health Initiative. Tob Control. 2015 Jul;24(4):328–35.
146. Lintsen AME, Pasker-de Jong PCM, de Boer EJ, Burger CW, Jansen CAM, Braat
DDM, et al. Effects of subfertility cause, smoking and body weight on the success
rate of IVF. Hum Reprod Oxf Engl. 2005 Jul;20(7):1867–75.

159

147. Rockhill K, Tong VT, Boulet SL, Zhang Y, Jamieson DJ, Kissin DM. Smoking
and Clinical Outcomes of Assisted Reproductive Technologies. J Womens Health.
2019 Mar;28(3):314–22.
148. Pineles BL, Park E, Samet JM. Systematic review and meta-analysis of
miscarriage and maternal exposure to tobacco smoke during pregnancy. Am J
Epidemiol. 2014 Apr 1;179(7):807–23.
149. Ahlborg GJ, Bodin L. Tobacco smoke exposure and pregnancy outcome among
working women. A prospective study at prenatal care centers in Orebro County,
Sweden. Am J Epidemiol. 1991 Feb 15;133(4):338–47.
150. Windham GC, Swan SH, Fenster L. Parental cigarette smoking and the risk of
spontaneous abortion. Am J Epidemiol. 1992 Jun 15;135(12):1394–403.
151. George L, Granath F, Johansson ALV, Anneren G, Cnattingius S. Environmental
tobacco smoke and risk of spontaneous abortion. Epidemiol Camb Mass. 2006
Sep;17(5):500–5.
152. Windham GC, Von Behren J, Waller K, Fenster L. Exposure to environmental and
mainstream tobacco smoke and risk of spontaneous abortion. Am J Epidemiol.
1999 Feb 1;149(3):243–7.
153. Salmasi G, Grady R, Jones J, McDonald SD, Knowledge Synthesis Group.
Environmental tobacco smoke exposure and perinatal outcomes: a systematic
review and meta-analyses. Acta Obstet Gynecol Scand. 2010;89(4):423–41.
154. Leonardi-Bee J, Britton J, Venn A. Secondhand smoke and adverse fetal outcomes
in nonsmoking pregnant women: a meta-analysis. Pediatrics. 2011
Apr;127(4):734–41.
155. Sim E, Lack N, Wang C-J, Long H, Westwood I, Fullam E, et al. Arylamine Nacetyltransferases: structural and functional implications of polymorphisms.
Toxicology. 2008 Dec 30;254(3):170–83.
156. Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to
infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012
Jan;13(1):31–41.
157. Wang Y, Zhang Q, Zhang M, Wang C. NAT2 slow acetylation genotypes
contribute to asthma risk among Caucasians: evidence from 946 cases and 1,091
controls. Mol Biol Rep. 2014 Mar;41(3):1849–55.
158. Gu J, Liang D, Wang Y, Lu C, Wu X. Effects of N-acetyl transferase 1 and 2
polymorphisms on bladder cancer risk in Caucasians. Mutat Res. 2005 Mar
7;581(1–2):97–104.

160

159. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and
haplotype on urinary bladder cancer risk. Oncogene. 2006 Mar;25(11):1649–58.
160. Sanderson S, Salanti G, Higgins J. Joint effects of the N-acetyltransferase 1 and 2
(NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literaturebased systematic HuGE review and evidence synthesis. Am J Epidemiol. 2007 Oct
1;166(7):741–51.
161. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, et al.
Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled
analysis of genotype-based studies. Cancer Epidemiol Biomark Prev Publ Am
Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2001 Dec;10(12):1249–52.
162. Zhang J, Qiu L-X, Wang Z-H, Wang J-L, He S-S, Hu X-C. NAT2 polymorphisms
combining with smoking associated with breast cancer susceptibility: a metaanalysis. Breast Cancer Res Treat. 2010 Oct;123(3):877–83.
163. Millikan RC, Pittman GS, Newman B, Tse CK, Selmin O, Rockhill B, et al.
Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer
Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev
Oncol. 1998 May;7(5):371–8.
164. Nöthlings U, Yamamoto JF, Wilkens LR, Murphy SP, Park S-Y, Henderson BE, et
al. Meat and heterocyclic amine intake, smoking, NAT1 and NAT2
polymorphisms, and colorectal cancer risk in the multiethnic cohort study. Cancer
Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev
Oncol. 2009 Jul;18(7):2098–106.
165. Voutsinas J, Wilkens LR, Franke A, Vogt TM, Yokochi LA, Decker R, et al.
Heterocyclic amine intake, smoking, cytochrome P450 1A2 and N-acetylation
phenotypes, and risk of colorectal adenoma in a multiethnic population. Gut. 2013
Mar;62(3):416–22.
166. Nyberg F, Hou SM, Hemminki K, Lambert B, Pershagen G. Glutathione Stransferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to
tobacco smoke in nonsmoking and smoking lung cancer patients and population
controls. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res
Cosponsored Am Soc Prev Oncol. 1998 Oct;7(10):875–83.
167. Tian F, Zhang Y, Ren Y, Shen L, Wu W, Zhou B. N-Acetyltransferase 2 (NAT2)
gene polymorphism and exposure to smoking in lung cancer of Chinese males.
Med Oncol Northwood Lond Engl. 2014 Aug;31(8):90.
168. Nakago S. Association between endometriosis and N-acetyl transferase 2
polymorphisms in a UK population. Mol Hum Reprod. 2001 Nov 1;7(11):1079–
83.

161

169. Bischoff FZ, Marquez-Do D, Dang D, Carson SA, Buster JE, Simpson JL. NAT2
and GSTM1 DNA polymorphisms: increased GSTM1 (active) genotypes in
endometriosis. Fertil Steril. 2002 Feb;77:S17.
170. Wei Z, Zhang M, Zhang X, Yi M, Xia X, Fang X. NAT2 gene polymorphisms and
endometriosis risk: A PRISMA-compliant meta-analysis. PloS One.
2019;14(12):e0227043.
171. Fayez D, Saliminejad K, Irani S, Kamali K, Memariani T, Khorram Khorshid HR.
Arylamine N-acetyltransferase 2 Polymorphisms and the Risk of Endometriosis.
Avicenna J Med Biotechnol. 2018 Sep;10(3):163–7.
172. Yarosh SL, Kokhtenko EV, Churnosov MI, Ataman AV, Solodilova MA,
Polonikov AV. Synergism between the N-acetyltransferase 2 gene and oxidant
exposure increases the risk of idiopathic male infertility. Reprod Biomed Online.
2014 Sep;29(3):362–9.
173. Nohr EA, Liew Z. How to investigate and adjust for selection bias in cohort
studies. Acta Obstet Gynecol Scand. 2018 Apr;97(4):407–16.
174. Hernán MA, Robins JM. Causal inference: What if. Boca Raton: Chapman &
Hill/CRC.; 2020.
175. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J
Epidemiol Community Health. 2006 Jul;60(7):578–86.
176. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection
bias. Epidemiol Camb Mass. 2004 Sep;15(5):615–25.
177. Howe CJ, Cole SR, Lau B, Napravnik S, Eron JJ. Selection Bias Due to Loss to
Follow Up in Cohort Studies. Epidemiol Camb Mass. 2016 Jan;27(1):91–7.
178. Sterzik K, Strehler E, De Santo M, Trumpp N, Abt M, Rosenbusch B, et al.
Influence of smoking on fertility in women attending an in vitro fertilization
program. Fertil Steril. 1996 Apr;65(4):810–4.
179. Wright KP, Trimarchi JR, Allsworth J, Keefe D. The effect of female tobacco
smoking on IVF outcomes. Hum Reprod Oxf Engl. 2006 Nov;21(11):2930–4.
180. Cinar O, Dilbaz S, Terzioglu F, Karahalil B, Yucel C, Turk R, et al. Does cigarette
smoking really have detrimental effects on outcomes of IVF? Eur J Obstet Gynecol
Reprod Biol. 2014 Mar;174:106–10.
181. Crha I, Hruba D, Fiala J, Ventruba P, Zakova J, Petrenko M. The outcome of
infertility treatment by in-vitro fertilisation in smoking and non-smoking women.
Cent Eur J Public Health. 2001 May;9(2):64–8.

162

182. Elenbogen A, Lipitz S, Mashiach S, Dor J, Levran D, Ben-Rafael Z. The effect of
smoking on the outcome of in-vitro fertilization--embryo transfer. Hum Reprod
Oxf Engl. 1991 Feb;6(2):242–4.
183. El-Nemr A, Al-Shawaf T, Sabatini L, Wilson C, Lower AM, Grudzinskas JG.
Effect of smoking on ovarian reserve and ovarian stimulation in in-vitro
fertilization and embryo transfer. Hum Reprod Oxf Engl. 1998 Aug;13(8):2192–8.
184. Florack EI, Zielhuis GA, Rolland R. Cigarette smoking, alcohol consumption, and
caffeine intake and fecundability. Prev Med. 1994 Mar;23(2):175–80.
185. Baba S, Noda H, Nakayama M, Waguri M, Mitsuda N, Iso H. Risk factors of early
spontaneous abortions among Japanese: a matched case-control study. Hum
Reprod. 2011 Feb 1;26(2):466–72.
186. Wisborg K, Kesmodel U, Henriksen TB, Hedegaard M, Secher NJ. A prospective
study of maternal smoking and spontaneous abortion. Acta Obstet Gynecol Scand.
2003 Oct;82(10):936–41.

163

APPENDIX A - LOUSSI Supplemental Smoking Questionnaire

LOUSSI SUPPLEMENTAL SMOKING QUESTIONNAIRE
LIFETIME EXPOSURE TO TOBACCO SMOKE
INSTRUCTIONS
Dear Participant:
Thank you for taking the time to answer this questionnaire. This form should take 5 to 10
minutes to complete. Your answers will be used for research purposes only. Your doctor
will not know the answers you have marked. Information gained from this study will
help scientists and doctors understand the effect of smoking and secondhand smoke on
fertility.
This packet contains three questionnaires.
Please choose ONE questionnaire to complete, depending on whether you are a
current smoker, former smoker, or nonsmoker. Leave the other two questionnaires
blank.

CURRENT SMOKERS: Please answer Questionnaire 1. You are considered a
current smoker if you currently smoke at least 1 cigarette/week, or if you recently quit
(less than 1 month ago)
FORMER SMOKERS: Please answer Questionnaire 2. You are considered a former
smoker if you quit more than 1 month ago and used to smoke at least 1 cigarette/week.
NONSMOKERS: Please answer Questionnaire 3. You are considered a nonsmoker if
you have never smoked more than 1 cigarette/week.

Please place questionnaire in the envelope provided and return it to the study
personnel or place it inside the designated LOUSSI Study dropbox when you are
finished.

Thank you very much for your time!
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QUESTIONNAIRE 1 (FOR CURRENT SMOKERS)
Answer this questionnaire if you currently smoke at least 1 cigarette/week,
or if you quit smoking less than 1 month ago.
Smoking History
1. How many years have you been smoking (at least 1 cigarette/week)? _____
years
(If you have smoked on and off, please add up the total number of years
you smoked.)

2. On the average, how many cigarettes (or packs) do you now smoke per day?
___ cigarettes/day or ____ packs/day
(If you quit less than 1 month ago, please indicate how much you used to
smoke before you quit.)

Secondhand Smoke

3. Think about your home when you were growing up (less than 18 years old).
On average, how often were you exposed to secondhand smoke inside your
home? (For example, how often did your parents, guardians, or siblings smoke
inside the home?)
Never
Rarely
Often
Every day
(less than once/week)
(1-6 days/week)
4. Think about your home in the past year. How often have you been exposed
to secondhand smoke inside your home?
Never
Rarely
Often
Every day
(less than once/week)
(1-6 days/week)
5. Think about other places you go on a regular basis. (For example, a friend or
relative’s house, your workplace, bars or restaurants, in your car or someone
else’s car, etc.) In the past year, how often have you been exposed to
secondhand smoke inside other places besides your home?
Never
Rarely
Often
Every day
(less than once/week)
(1-6 days/week)
Please see back
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6.

Does anyone else living in your home smoke cigarettes, cigars or a pipe?
☐ Yes
☐ No
If you answered “Yes”, how many other people living in your home smoke these
tobacco products?
____Enter number
What is your relationship with the smoker(s)? (Check all that apply)
____Spouse or partner
____Other

Other sources of nicotine

7. Please check whether you have used any of the following in the past week:
_____ Nicotine patches
_____ Nicorette gum or similar
_____ E-cigarettes
_____ Smokeless tobacco or chewing tobacco
_____ Other source of nicotine: ______________
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QUESTIONNAIRE 2 (FOR FORMER SMOKERS)
Answer this questionnaire if you used to smoke at least 1 cigarette/week and quit at
least 1 month ago.
Past Smoking
1. When is the last time you smoked a cigarette? (Month, Year) ____,______
2. How many years did you smoke at least 1 cigarette/week? ____years
(If you smoked on and off, please add up the total number of years you smoked.)

3. On the average, how many cigarettes (or packs) did you used to smoke per
day?
___ cigarettes/day or ____ packs/day
Secondhand Smoke

4. Think about your home when you were growing up (less than 18 years old).
On average, how often were you exposed to secondhand smoke inside your
home? (For example, how often did your parents, guardians, or siblings smoke
inside the home?)
Never
Rarely
Often
Every day
(less than once/week)
(1-6 days/week)
5. Think about your home in the past year. How often have you been exposed
to secondhand smoke inside your home?
Never
Rarely
Often
Every day
(less than once/week)
(1-6 days/week)
6. Think about other places you go on a regular basis. (For example, a friend or
relative’s house, your workplace, bars or restaurants, in your car or someone
else’s car, etc.) In the past year, how often have you been exposed to
secondhand smoke inside other places besides your home?
Never
Rarely
Often
Every day
(less than once/week)
(1-6 days/week)
Please see
back
7.

Does anyone living in your home smoke cigarettes, cigars or a pipe?
☐ Yes
☐ No
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If you answered “Yes”, how many people living in your home smoke these tobacco
products?
____Enter number
What is your relationship with the smoker(s)? (check all that apply)
____Spouse or partner
____Other

Other sources of nicotine

8. Please check whether you have used any of the following in the past week:
_____ Nicotine patches
_____ Nicorette gum or similar
_____ E-cigarettes
_____ Smokeless tobacco or chewing tobacco
_____ Other source of nicotine: ______________
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QUESTIONNAIRE 3 (FOR NONSMOKERS)
Answer this if you have never smoked more than 1 cigarette/week
The goal of this questionnaire is to determine how much exposure to secondhand smoke
you have had in your lifetime.
Secondhand Smoke

1. Think about your home when you were growing up (less than 18 years old).
On average, how often were you exposed to secondhand smoke inside your
home? (For example, how often did your parents, guardians, or siblings smoke
inside your home?)
Never

Rarely
(less than once/week)

Often
(1-6 days/week)

Every day

2. Think about your home in the past year. How often have you been exposed
to secondhand smoke inside your home?
Never

Rarely
(less than once/week)

Often
(1-6 days/week)

Every day

3. Think about other places you go on a regular basis. (For example, a friend or
relative’s house, your workplace, bars or restaurants, in your car or someone
else’s car, etc.) In the past year, how often have you been exposed to
secondhand smoke inside other places besides your home?
Never

Rarely
Often
Every day
(less than once/week)
(1-6 days/week)
4. Does anyone living in your home smoke cigarettes, cigars or a pipe?
☐ Yes
☐ No
If you answered “Yes”, how many people living in your home smoke these
tobacco products?
____Enter number
What is your relationship with the smoker(s)? (check all that apply)
____Spouse or partner
____Other
Please see
back
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Other sources of nicotine

5. Please check whether you have used any of the following in the past week:
_____ Nicotine patches
_____ Nicorette gum or similar
_____ E-cigarettes
_____ Smokeless tobacco or chewing tobacco
_____ Other source of nicotine: ______________
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APPENDIX B - Medical Record Data Extraction Form

DATA COLLECTION FORM
Number:

Subject Identification

Date of first visit (MM/YY):________________

type of exercise: _________________

Date of study enrollment (MM/YY):________

Hours per exercise time: _______________

Age (years) at enrollment: ________________

Routine exposure to
chemicals(Yes/no):______

Height: (feet, inches): ______feet_____inches
Weight: _________pounds or __________ kg

If yes, list here:
________________________

Body mass index: _________________kg/m2

Diet restrictions: ____________________

Total number of previous pregnancies: _____

Meals/day: ________________________

Regular periods (yes/no): ________________

Current tobacco use (yes/no): ________

Average menstrual cycle length: _______days

Packs/day ________________________

Age at first period: _________________years

for how many years? ___________

Sexually transmitted infections: _____(yes/no)

Ever smoked 100 cigarettes? ________

If yes, list:___________________________

Alcohol (yes/no) ________________

“Social History” Section:

Alcoholic drinks/week___________

Occupation: __________________________

Caffeine (yes/no) __________________

Married/single: _______________________

Caffeinated drinks/day__________

Partner/no partner? ___________________
Length of time with current partner: _______

Drugs (e.g. marijuana) (yes/no) _______
Ancestry or Race _________________

Routine exercise (yes/no): ____________

Consistent ovulation (yes/no)________

times/week: _____________________
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Clinical measurements and records from patient visits:
These will be updated as patient is followed up during the study period. A date (MM/YY) will be
included for all measurements.

Blood Pressure (date of enrollment): ____________

Date: (MM/YY)

__________________

Weight (at date of enrollment): ____________

Date: (MM/YY)

__________________
Height: ___________
BMI (at date of enrollment) __________

Anti-Mullerian hormone level (1): ____________ Date: (MM/YY) __________________
Anti-Mullerian hormone level (2): ____________ Date: (MM/YY) __________________

Antral follicle count (1): ____________________ Date: (MM/YY) ___________________
Antral follicle count (2): ____________________ Date: (MM/YY) ___________________

Infertility diagnosis/diagnoses: (More than one line is provided for multiple infertility diagnoses)
How long has the couple been trying to conceive at baseline? _________years
__________months
Consistent ovulation? ________yes

__________no

__________unknown

Patient’s Infertility Diagnoses (e.g., male factor, PCOS, fibroids, adhesions, tubal obstructions,
etc.):
_____________________

Date of diagnosis (MM/YY) _______________

_____________________

Date of diagnosis (MM/YY) _______________

_____________________

Date of diagnosis (MM/YY) _______________

Any diagnosis of PCOS (past or current?)

YES/NO

Comments on infertility diagnosis:

Fertility treatments and interventions, and outcomes (This form may be
photocopied if necessary)
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IVF (1) : Date of IVF procedure (MM/YY): _____________
ICSI (Intracytoplasmic sperm injection?)

YES/NO

Donor egg used? YES/NO
Type of ovarian stimulation (circle): ORAL

INJECTABLE

BOTH

Oocyte yield (the number of oocytes retrieved following ovarian stimulation):
_____________
Number of zygotes created ______________
Number of embryos implanted _____________
Outcome of procedure (clinical pregnancy: yes/no) __________________

IVF (2) : Date of IVF procedure (MM/YY): _____________
ICSI (Intracytoplasmic sperm injection?)

YES/NO

Donor egg used? YES/NO
Type of ovarian stimulation (circle): ORAL

INJECTABLE

BOTH

Oocyte yield (the number of oocytes retrieved following ovarian stimulation):
_____________
Number of zygotes created ______________
Number of embryos implanted______________
Outcome of procedure (ongoing pregnancy: yes/no) __________________

List other fertility interventions, date of treatment, and outcomes below:
Examples: Ovulation induction (OI) + timed intercourse, OI + IUI (intrauterine insemination),
surgical interventions
1. Intervention: _____________________
Date (MM/YY)________________________
Type of ovarian stimulation (circle): ORAL

INJECTABLE

BOTH

Outcome of procedure (ongoing pregnancy: yes/no) __________________
2. Intervention: _____________________
Date (MM/YY)________________________
Type of ovarian stimulation (circle): ORAL

INJECTABLE

BOTH

Outcome of procedure (ongoing pregnancy: yes/no) __________________
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Did this patient become pregnant during the follow-up period (3 years from signing consent
form)?
YES/NO

If YES, list estimated month and year of
LMP (MM/YY):_______________ or
Conception (MM/YY):_________ or
Due date (MM/YY):___________
Pregnancy outcome (circle on)
(1) Live birth
(2) Early pregnancy loss or Miscarriage
(3) Ectopic pregnancy
(4) Molar pregnancy
(5) Stillbirth or fetal death

Birthweight _________________

IF YES, what was the treatment or intervention that resulted in ongoing pregnancy? (or did she
conceive without assistance?)

_______________________________________
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APPENDIX C - Recontact Questionnaire

Call script and Data Entry Form

Participant

ID____________________________
Instructions: Call participants at least 24 hours after sending introductory email. Using
phone numbers provided on informed consent form.
If it goes to voicemail:
Hello, my name is _______________ and I am calling from the University of Louisville
school of public health.
WE hope you received the email that we sent to you. In the past 18 months, you
participated in a fertility study at the U of L fertility clinic. To jog your memory, it was
called the LOUSSI study, and you answered a short questionnaire and provided a urine
sample. I am calling today to ask if you are still trying to conceive or if you have already
conceived. This will take less than 5 minutes of your time. We will try to call you again
in the next week. You can also call us at 502-852-4063 and leave us a voicemail with
your name, phone number and most convenient time to call. Thank you very much again
for your time.
If someone answers:
Hello, my name is _______________ and I am calling from the University of Louisville
school of public health. May I please speak with _________________?
Hello, I’m the calling from the LOUSSI study that you participated in, at the U of L
fertility clinic. You answered a short smoking questionnaire and provided a urine
sample. At your enrollment you gave us permission to contact you again and I am calling
today to ask you a few follow-up questions. This will take less than 5 minutes of your
time. Is now a good time?
If they say no- now is not a good time:
“Okay, no problem. When is a better time?” ____________________
Or, Would you prefer us to send you an email with the questions? (get email
address).
Email address: _______________________________
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If they agree to talk:
1. Have you conceived since enrollment in the LOUSSI study? (YES or NO)
(if No, ask questions on this page)
(if Yes, ask questions on the back)
2. Are you still trying to conceive? (YES or NO)
(if NO, ask #3 and 4)
3.

How many months did you continue to try after being seen at the clinic?
______months

4. Are you doing anything now to prevent pregnancy? (such as taking birth control
pills?) (Y/N)
Thank you so much for your time! We really appreciate your participation
in the study. Goodbye!

FOR THOSE WHO HAVE CONCEIVED:
5. How many times have you conceived since enrollment? __ times
6. (Let’s talk about the first time you became pregnant—if they have become
pregnant more than once.) How did you become pregnant?
a. Did you conceive ‘naturally’? (Yes/no)
If not, how did you conceive?
b. Using ovulation induction? _________
c. Using intrauterine insemination? ____________
d. Using IVF or ICSI? __________

If yes- Did you use donor eggs? ______

7. When did you become pregnant—in other words, what was the date of the last
menstrual period before your pregnancy? _________
(if they don’t remember LMP, ask for due date.)
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8. Are you still pregnant now? (Y or N)
If No: 8a. What the pregnancy outcome? (live birth, miscarriage, ectopic pregnancy,
stillbirth, other)

Thank you so much for your time! We really appreciate your participation in the
study. Goodbye!
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APPENDIX D - Supplemental Tables

S Table 1: Characteristic of Women by Current Smoking among non-MAR Users
(N=130)
Current Smoker
N=43
31.00
(27.00-34.00)

P - value

Age in years,
median (Q1-Q3)

Nonsmoker
N=87
32.00
(27.00-36.00)

BMI (kg/m2)
median (Q1-Q3)

30.44
(24.58-36.78)

30.64
(25.93-34.65)

0.82

BMI kg/m2, n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)
Gravidity, n (%)
0
1
>=2
Regular Period, n (%)
No
Yes

0.23

0.83
24(27.59)

10(23.26)

19(21.84)
44(50.57)

9(20.93)
24(55.81)
0.38

37(42.53)
16(18.39)
34(39.08)

14(32.56)
12(27.91)
17(39.53)
0.71

30(34.48)
57(65.52)

17(39.53)
26(60.47)

Average Cycle Length
(days), median (Q1-Q3)

28.00
(27.00-30.00)

30.00
(28.75-45.00)

<0.001

Age of Menarche, in
years, median (Q1-Q3)

13.00
(12.00-14.00)

12.00
(11.00-13.00)

0.23

Previous STD, n (%)
No
Yes
Marital Status, n (%)
No
Yes

0.03
57(65.52)
30(34.48)

18(43.90)
23(56.10)
<0.001

28(32.18)
59(67.82)
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30(69.77)
13(30.23)

Exercise, n (%)

0.18
No
Yes

36(43.90)
46(56.10)

23(58.97)
16(41.03)

Alcohol Use, n (%)

0.07
No
Yes

60(68.97)
27(31.03)

22(51.16)
21(48.84)

Caffeine Use, n (%)

0.49
No
Yes

18(21.18)
67(78.82)

6(14.29)
36(85.71)

Race, n (%)

0.021
Other
Black

60(68.97)
27(31.03)

20(46.51)
23(53.49)

AMH (ng/mL),
median (Q1-Q3)

2.60
(0.92-5.09)

2.48
(1.67-6.05)

0.39

Length of Infertility,
years median (Q1-Q3)

2.08
(1.50-4.63)

2.00
(1.38-5.00)

0.90

NAT2 Acetylator Status,
n (%)
Rapid
Slow
Pregnant, n (%)
No
Yes
Pregnancy Outcome,
n (%)
Live Birth
Miscarriage

0.53
44(58.67)
31(41.33)

26(66.67)
13(33.33)
0.97

67(77.01)
20(22.99)

34(79.07)
9(20.93)
0.021

13(81.25)
3(18.75)

2(25.00)
6(75.00)

Total Follow-up Time in
years, median (Q1-Q3)

8.00(4.00-15.00)

8.00(2.00-15.50)

0.58

Cotinine Levels mg/dL,
median (Q1-Q3)

0.50(0.00-4.38)

100(100-100)

< 0.001

Cotinine Categories,
n (%)
0 mg/dL
<100 mg/dL
100mg/dL

< 0.001
38(46.34)
44(53.66)
0(0.00)
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0(0.00)
2(4.76)
40(95.24)

S Table 2: Characteristic of Women by Current Smoking among MAR Users
(N=93)

Age (years)
median (Q1-Q3)
BMI, (mean ± SD),
(kg/m2)
BMI kg/m2, n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

Nonsmoker
N=81
33.00
(29.25-37.00)

Current Smoker
N=11
36.00
(34.50-38.50)

P - value

29.01 ± 6.14

30.83 ± 4.98

0.35

0.06

0.43
22(26.83)

1(9.09)

30(36.59)
30(36.59)

4(36.36)
6(54.55)

Gravidity, n (%)

0.07
0
1
>=2

37(45.12)
22(26.83)
23(28.05)

5(45.45)
0(0.00)
6(54.55)

Regular Period, n (%)
No
Yes

0.16
28(34.15)
54(65.85)

1(9.09)
10(90.91)

Average Cycle Length
(days), median (Q1-Q3)

29.00
(28.00-30.00)

28.50
(28.00-29.00)

0.62

Age of Menarche, in
years, median (Q1-Q3)

13.00
(12.00-14.00)

13.00
(11.50-13.00)

0.37

Previous STD, n (%)
No
Yes
Marital Status, n (%)
No
Yes
Exercise, n (%)

1
50(61.73)
31(38.27)

7(63.64)
4(36.36)
0.01

18(21.95)
64(78.05)

7(63.64)
4(36.36)
0.75
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No
Yes

31(38.75)
49(61.25)

5(45.45)
6(54.55)

Alcohol Use, n (%)

0.34
No
Yes

37(45.12)
45(54.88)

7(63.64)
4(36.36)

Caffeine Use, n (%)

1
No
Yes

16(19.51)
66(80.49)

2(18.18)
9(81.82)

Race, n (%)

0.21
Other
Black

68(82.93)
14(17.07)

7(63.64)
4(36.36)

AMH (ng/mL), median
(Q1-Q3)

2.44
(1.38-4.99)

2.30
(1.35-3.16)

0.66

Length of Infertility,
years median (Q1-Q3)

1.46
(0.94-4.33)

2.50
(1.58-7.00)

0.06

NAT2 Acetylator
Status, n (%)

0.51
Rapid
Slow

40(57.14)
30(42.86)

7(70.00)
3(30.00)

Pregnant, n (%)

1

No
Yes
Pregnancy Outcome,
n (%)
Live Birth
Miscarriage

34(41.46)
48(58.54)

5(45.45)
6(54.55)
0.39

24(57.14)
18(42.86)

2(33.33)
4(66.67)

Total Follow-up Time,
years, median (Q1-Q3)

5.00
(3.00-12.00)

7.00
(3.50-8.00)

0.85

Cotinine Levels, mg/dL
median (Q1-Q3)

0.00
(0.00-2.00)

100
(100-100)

<0.001

Cotinine mg/dL, n (%)
0
<100
100

<0.001
44(56.41)
34(43.59)
0(0.00)
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0(0.00)
0(0.00)
10(100.00)

S Table 3: Characteristics of Nonsmoking Women Stratified by Recent SHS
Exposure Measured With Urinary Cotinine among MAR Users (N=78)

Age, years
(mean ± SD)
BMI, kg/m2
(mean ± SD)
BMI kg/m2, n (%)
<25 (Underweight
and Normal)
25 - 29.9
(Overweight)
≥ 30 (Obese)

Cotinine = 0
mg/dL
N=44
33.66 ± 5.26

0 < Cotinine ≤
4mg/dL
N=19
32.89 ± 4.32

4 < Cotinine ≤
47 mg/dL
N=15
31.67 ± 5.30

P-value

27.77 ± 6.19

30.18 ± 4.39

32.06 ± 7.25

0.05

0.44
15(34.09)

3(15.79)

3(20.00)

15(34.09)

8(42.11)

4(26.67)

14(31.82)

8(42.11)

8(53.33)

Gravidity, n (%)
0
1
>=2
Regular Period,
n (%)
No
Yes

0.42

0.011
17(38.64)
11(25.00)
16(36.36)

14(73.68)
2(10.53)
3(15.79)

3(20.00)
8(53.33)
4(26.67)
0.40

12(27.27)
32(72.73)

8(42.11)
11(57.89)

6(40.00)
9(60.00)

Average Cycle
Length
(days), median
(Q1-Q3)

28.50
(28.00-30.00)

29.00
(28.00-29.88)

28.50
(26.50-29.75)

0.84

Age of Menarche,
in years, median
(Q1-Q3)

13.00
(12.00-14.00)

12.50
(11.25-13.75)

12.00
(12.00-13.50)

0.89

Previous STD,
n (%)

0.73
No
Yes

27(61.36)
17(38.64)

12(66.67)
6(33.33)
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8(53.33)
7(46.67)

Marital Status,
n (%)

0.32

No
Yes
Exercise, n (%)
No
Yes
Alcohol Use,
n (%)
No
Yes
Caffeine Use,
n (%)
No
Yes
Race, n (%)
White
Black
Other

7(15.91)
37(84.09)

5(26.32)
14(73.68)

5(33.33)
10(66.67)

32(72.73)
6(13.64)
6(13.64)

12(63.16)
5(26.32)
2(10.53)

10(66.67)
3(20.00)
2(13.33)

AMH
(ng/mL), median
(Q1-Q3)

2.31
(1.10-4.50)

3.23
(1.34-5.26)

2.52
(1.87-4.44)

0.73

Length of
Infertility, years
median (Q1-Q3)

1.04
(0.88-3.33)

1.50
(1.19-5.50)

2.21
(0.81-5.06)

0.72

0.57
14(33.33)
28(66.67)

9(47.37)
10(52.63)

6(40.00)
9(60.00)
0.45

17(38.64)
27(61.36)

10(52.63)
9(47.37)

8(53.33)
7(46.67)
1

9(20.45)
35(79.55)

3(15.79)
16(84.21)

3(20.00)
12(80.00)
0.81

Treatment
Cycles, n (%)
1
2
3 and more
NAT2 Acetylator
Status, n (%)
Rapid
Slow
Pregnant, n (%)
No
Yes
Pregnancy
Outcome, n (%)

0.04
17(38.64)
12(27.27)
15(34.09)

7(36.84)
4(21.05)
8(42.11)

10(66.67)
5(33.33)
0(0.00)
0.40

25(64.10)
14(35.90)

8(47.06)
9(52.94)

7(50.00)
7(50.00)
0.50

20(45.45)
24(54.55)

6(31.58)
13(68.42)

5(33.33)
10(66.67)
0.036
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Live Birth
Miscarriage
Total Follow-up
Time, years
median (Q1-Q3)

16(72.73)
6(27.27)

5(50.00)
5(50.00)

2(22.22)
7(77.78)

6.00
(3.00-15.00)

6.00
(4.00-13.00)

3.00
(2.00-10.50)

0.17

S Table 4: Characteristics of Nonsmoking Women Stratified by Recent SHS
Exposure Measured with Urinary Cotinine among non-MAR Users (N=82)

Age, years
(mean ± SD)
BMI, kg/m2
(mean ± SD)
BMI kg/m2, n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)
Gravidity, n (%)
0
1
>=2
Regular Period, n (%)
No
Yes

Cotinine = 0
mg/dL
N=38
33.47 ± 5.12

0 < Cotinine
≤ 4mg/dL
N=23
30.87 ± 6.06

4 < Cotinine
≤ 47 mg/dL
N=21
31.00 ± 5.82

P-value

27.49
(23.89-32.44)

35.51
(27.61-41.33)

30.64
(24.19-36.11)

0.02

0.13

0.24
11(28.95)

4(17.39)

6(28.57)

12(31.58)
15(39.47)

3(13.04)
16(69.57)

4(19.05)
11(52.38)
0.02

13(34.21)
8(21.05)
17(44.74)

15(65.22)
5(21.74)
3(13.04)

7(33.33)
2(9.52)
12(57.14)
0.41

13(34.21)
25(65.79)

11(47.83)
12(52.17)

6(28.57)
15(71.43)

Average Cycle Length
(days), median (Q1-Q3)

28.00
(27.0-30.0)

28.00
(27.0-28.0)

29.00
(27.5-30.0)

0.52

Age of Menarche, in
years, median (Q1-Q3)

13(12-14)

12(11-13.5)

13(12-14)

0.43

Previous STD, n (%)

1
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No
Yes
Marital Status, n (%)
No
Yes
Routine Exercise, n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
White
Black
Other

25(65.79)
13(34.21)

15(65.22)
8(34.78)

14(66.67)
7(33.33)

15(39.47)
10(26.32)
13(34.21)

9(39.13)
7(30.43)
7(30.43)

8(38.10)
8(38.10)
5(23.81)

AMH
(ng/mL), median (Q1Q3)

1.98
(3.78-9.71)

3.28
(0.93-5.85)

2.87
(1.04-6.93)

0.41

Length of Infertility,
years median (Q1-Q3)

2.00
(1.50-4.00)

2.08
(1.50-3.38)

2.50
(1.19-5.75)

0.96

0.15
14(36.84)
24(63.16)

4(17.39)
19(82.61)

9(42.86)
12(57.14)
0.04

13(35.14)
24(64.86)

7(33.33)
14(66.67)

13(68.42)
6(31.58)
0.64

28(73.68)
10(26.32)

16(69.57)
7(30.43)

13(61.90)
8(38.10)
0.56

10(26.32)
28(73.68)

3(13.04)
20(86.96)

4(21.05)
15(78.95)
0.89

NAT2 Acetylator
Status, n (%)

0.04
Rapid
Slow

22(64.71)
12(35.29)

15(71.43)
6(28.57)

7(35.00)
13(65.00)

Pregnant, n (%)
No
Yes
Pregnancy Outcome,
n (%)
Live Birth
Miscarriage
Total Follow-up Time,
years median (Q1-Q3)

0.89
29(76.32)
9(23.68)

17(73.91)
6(26.09)

17(80.95)
4(19.05)
1

5(71.43)
2(28.57)

4(80.00)
1(20.00)

3(100.00)
0(0.00)

11.00
(7.00-16.00)

4.00
(3.00-14.5)

5.00
(3.00-9.00)
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0.04

S Table 5: Characteristics of Nonsmoking Women Stratified by SHS Exposure
Measured from SSQ among MAR Users (N=82)

Age, years
(mean ± SD)
BMI, kg/m2
(mean ± SD)
BMI Category kg/m2,
n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)
Gravidity, n (%)
0
1
>=2
Regular Period, n (%)
No
Yes

No and Low
exposure
(score=2,3)
N=62
32.44 ± 5.15

Med and High
exposure (score
≥4)
N=20
34.2 ± 5.04

P-value

28.22 ± 5.58

31.47 ± 7.22

0.04

0.18

0.65
17(27.42)

5(25.00)

24(38.71)
21(33.87)

6(30.00)
9(45.00)
0.85

29(46.77)
16(25.81)
17(27.42)

8(40.00)
6(30.00)
6(30.00)
0.36

19(30.65)
43(69.35)

9(45.00)
11(55.00)

Average Cycle Length
(days), median (Q1-Q3)

29.00
(28.00-30.00)

28.00
(26.25-30.00)

0.43

Age of Menarche, in years,
median (Q1-Q3)

13.00
(12.00-14.00)

12.00
(12.00-13.00)

0.14

Previous STD, n (%)

1
No
Yes

38(62.30)
23(37.70)

12(60.00)
8(40.00)

Marital Status, n (%)

0.03
No
Yes

10(16.13)
52(83.87)

8(40.00)
12(60.00)

Exercise, n (%)

1
No

23(38.33)
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8(40.00)

Yes

37(61.67)

12(60.00)

Alcohol Use, n (%)

0.45
No
Yes

26(41.94)
36(58.06)

11(55.00)
9(45.00)

Caffeine Use, n (%)

1
No
Yes

12(19.35)
50(80.65)

4(20.00)
16(80.00)

Race, n (%)

0.63
White
Black
Other

44(70.97)
10(16.13)
8(12.90)

12(60.00)
4(20.00)
4(20.00)

AMH
(ng/mL), median (Q1-Q3)

2.44
(1.34-4.98)

2.40
(1.55-5.47)

0.86

Length of Infertility, years
median (Q1-Q3)

1.02
(0.31-2.77)

2.52
(0.77-7.00)

0.04

Treatment Cycles, n (%)

0.27

1
2
3 and more
NAT2 Acetylator Status,
n (%)
Rapid
Slow
Pregnant, n (%)
No
Yes
Pregnancy Outcome, n (%)
Live Birth
Miscarriage

25(40.32)
16(25.81)
21(33.87)

10(50.00)
7(35.00)
3(15.00)
0.27

32(61.54)
20(38.46)

8(44.44)
10(55.56)
0.53

24(38.71)
38(62.30)

10(50.00)
10(50.00)
0.01

22(68.75)
10(31.25)

2(20.00)
8(80.00)

Total Follow-up Time,
years median (Q1-Q3)

5.00(3.00-12.00)

5.50(3.75-12.25)

0.55

Cotinine Levels, mg/dL
median (Q1-Q3)

0.00(0.00-1.00)

1.25(0.00-15.63)

0.03

Cotinine mg/dL, n (%)

0.01
0
<4

35(60.34)
16(27.59)
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9(45.00)
2(10.00)

>= 4

7(12.07)

9(45.00)

S Table 6: Characteristics of Nonsmoking Women Stratified by SHS Exposure
Measured from SSQ among non-MAR Users (N=87)

Age, years
(mean ± SD)
BMI, kg/m2
median (Q1-Q3)

No and Low
exposure (score=2,3)
N=50
33.16 ± 5.72

Med and High
exposure (score ≥4)
N=37
30.73 ± 5.23

P-value

30.45
(24.75-35.02)

29.04
(24.14-37.25)

1

BMI kg/m2, n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)
Gravidity, n (%)
0
1
>=2
Regular Period, n (%)
No
Yes
Average Cycle Length
(days), median (Q1-Q3)

17(34.00)
33(66.00)
28.00
(26.00-29.25)

13(35.14)
24(64.86)
28.00
(28.00-30.00)

Age of Menarche, in years,
median (Q1-Q3)

12.00
(11.75-14.00)

13.00
(12.00-14.00)

0.045

0.93
13(26.00)

11(29.73)

11(22.00)
26(52.00)

8(21.62)
18(48.65)
0.61

19(38.00)
10(20.00)
21(42.00)

18(48.65)
6(16.22)
13(35.14)
1

Previous STD, n (%)

0.34

0.95

0.74
No
Yes

34(68.00)
16(32.00)

23(62.16)
14(37.84)

Marital Status, n (%)

0.23
No
Yes

13(26.00)
37(74.00)
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15(40.54)
22(59.46)

Exercise, n (%)

0.16
No
Yes

17(36.17)
30(63.83)

19(54.29)
16(45.71)

Alcohol Use, n (%)

1
No
Yes

34(68.00)
16(32.00)

26(70.27)
11(29.73)

Caffeine Use, n (%)

1
No
Yes

10(20.41)
39(79.59)

8(22.22)
28(77.78)

Race, n (%)

0.02
White
Black
Other

19(38.00)
11(22.00)
20(40.00)

16(43.24)
16(43.24)
5(13.51)

AMH (ng/mL),
median (Q1-Q3)

2.48
(0.81-3.84)

2.67
(0.99-6.28)

0.52

Length of Infertility, years
median (Q1-Q3)

2.00
(1.04-4.00)

3.00
(1.03-5.00)

0.73

NAT2 Acetylator Status,
n (%)
Rapid
Slow
Pregnant, n (%)
No
Yes
Pregnancy Outcome,
n (%)
Live Birth
Miscarriage

0.79
23(56.10)
18(43.90)

21(61.76)
13(38.24)
0.99

38(76.00)
12(24.00)

29(78.38)
8(21.62)
1

7(77.78)
2(22.22)

6(85.71)
1(14.29)

Total Follow-up Time,
years median (Q1-Q3)

9.00
(4.25-10.48)

5.00
(3.00-13.00)

0.13

Cotinine Levels, mg/dL
median (Q1-Q3)

0.00
(0.00-1.00)

4.00
(0.50-9.10)

<0.001

Cotinine mg/dL, n (%)
0
<4
>= 4

<0.001
30(63.83)
10(21.28)
7(14.89)
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8(22.86)
9(25.71)
18(51.43)

S Table 7: Characteristics of Women that used ART Measured Using the 3-level
Combined Effect Variable among MAR users (N=93)

Age, years
median (Q1-Q3)
BMI, kg/m2
(mean ± SD)
BMI Category,
kg/m2, n (%)
<25 (Underweight
and Normal)
25 - 29.9
(Overweight)
≥ 30 (Obese)
Gravidity, n (%)
0
1
>=2
Regular Period,
n (%)
No
Yes

Nonsmokers
with Low SHS
N=62
33.00
(29.00-37.00)

Nonsmokers
with High SHS
N=20
35.00
(31.00-38.25)

Smokers

Pvalue

N=11
36.00
(34.50-38.50)

0.07

28.22 ± 5.58

31.47 ± 7.22

30.83 ± 4.98

0.07

0.61
17(27.42)

5(25.00)

1(9.09)

24(38.71)

6(30.00)

4(36.36)

21(33.87)

9(45.00)

6(54.55)
0.22

29(46.77)
16(25.81)
17(27.42)

8(40.00)
6(30.00)
6(30.00)

5(45.45)
0(0.00)
6(54.55)
0.12

19(30.65)
43(69.35)

9(45.00)
11(55.00)

1(9.09)
10(90.91)

Average Cycle
Length (days),
median (Q1-Q3)

29.00
(28.00-30.00)

28.00
(26.25-30.00)

28.50
(28.00-29.00)

0.63

Age of Menarche,
years, median (Q1Q3)

13.00
(12.00-14.00)

12.00
(12.00-13.00)

13.00
(11.50-13.00)

0.19

Previous STD,
n (%)

1
No
Yes

38(62.30)
23(37.70)

12(60.00)
8(40.00)
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7(63.64)
4(36.36)

Marital Status,
n (%)

0.002
No
Yes

10(16.13)
52(83.87)

8(40.00)
12(60.00)

7(63.64)
4(36.36)

Exercise, n (%)

0.91

No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Black
Other

23(38.33)
37(61.67)

8(40.00)
12(60.00)

5(45.45)
6(54.55)

10(16.13)
52(83.87)

4(20.00)
16(80.00)

4(36.36)
7(63.64)

AMH
(ng/mL), median
(Q1-Q3)

2.44
(1.34-4.98)

2.40
(1.55-5.47)

2.30
(1.35-3.16)

0.89

Length of Infertility,
years median (Q1Q3)

1.21
(0.94-2.94)

2.75
(0.94-7.00)

2.50
(1.58-7.00)

0.02

0.31
26(41.94)
36(58.06)

11(55.00)
9(45.00)

7(63.64)
4(36.36)
1

12(19.35)
50(80.65)

4(20.00)
16(80.00)

2(18.18)
9(81.82)
0.29

Treatment Cycles,
n (%)
1
2
3 and more
NAT2 Acetylator
Status, n (%)
Rapid
Slow

0.39
25(40.32)
16(25.81)
21(33.87)

10(50.00)
7(35.00)
3(15.00)

3(27.27)
3(27.27)
5(45.45)
0.33

32(61.54)
20(38.46)

8(44.44)
10(55.56)

7(70.00)
3(30.00)

Pregnant, n (%)

0.66
No
Yes

Pregnancy
Outcome, n (%)
Live Birth
Miscarriage

24(38.71)
38(61.29)

10(50.00)
10(50.00)

5(45.45)
6(54.55)
0.01

22(68.75)
10(31.25)

2(20.00)
8(80.00)
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2(33.33)
4(66.67)

Total Follow-up
Time, years median
(Q1-Q3)

5.00
(12.00-3.00)

5.50
(12.25-3.75)

7.00
(8.00-3.50)

0.81

Cotinine Levels,
mg/dL median (Q1Q3)

0.00
(0.00-1.00)

1.25
(0.00-15.63)

100.00
(100.0-100.0)

<0.001

Cotinine mg/dL, n
(%)
0
<4
>= 4

<0.001
35(60.34)
23(39.66)
0(0.00)

9(45.00)
11(55.00)
0(0.00)

0(0.00)
0(0.00)
10(100.00)

S Table 8: Characteristics of Women that used ART Measured Using the 3-level
Combined Effect Variable among non-MAR Users (N=130)
Nonsmokers
with high SHS
N=37
31.00
(26.00-35.00)

Smokers

P - value

Age, years
median (Q1-Q3)

Nonsmokers
with low SHS
N=50
34.00
(29.00-37.75)

N=43
31.00
(27.00-34.00-)

0.07

BMI, kg/m2
median (Q1-Q3)

30.45
(24.75-35.02)

29.04
(24.14-37.25)

30.64
(25.93-34.65)

BMI, kg/m2, n (%)
<25 (Underweight
and Normal)
25 - 29.9
(Overweight)
≥ 30 (Obese)
Gravidity, n (%)
0
1
>=2
Regular Period,
n (%)
No

0.97

0.97
13(26.00)

11(29.73)

10(23.26)

11(22.00)

8(21.62)

9(20.93)

26(52.00)

18(48.65)

24(55.81)
0.59

19(38.00)
10(20.00)
21(42.00)

18(48.65)
6(16.22)
13(35.14)

14(32.56)
12(27.91)
17(39.53)
0.85

17(34.00)

13(35.14)
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17(39.53)

Yes

33(66.00)

24(64.86)

26(60.47)

Average Cycle
Length (days),
median (Q1-Q3)

28.00
(26.00-29.25)

28.00
(28.00-30.00)

30.00
(28.75-31.25)

0.001

Age of Menarche,
years, median (Q1Q3)

12.00
(11.75-14.00)

13.00
(12.00-14.00)

12.00
(11.00-13.00)

0.47

Previous STD,
n (%)

0.06
No
Yes

34(68.00)
16(32.00)

23(62.16)
14(37.84)

18(43.90)
23(56.10)

Marital Status,
n (%)

<0.001
No
Yes

13(26.00)
37(74.00)

15(40.54)
22(59.46)

30(69.77)
13(30.23)

Exercise, n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Black
Other
AMH
(ng/mL), median
(Q1-Q3)
Length of
Infertility, years
median (Q1-Q3)
NAT2 Acetylator
Status, n (%)
Rapid
Slow
Pregnant, n (%)

0.08
17(36.17)
30(63.83)

19(54.29)
16(45.71)

23(58.97)
16(41.03)
0.14

34(68.00)
16(32.00)

26(70.27)
11(29.73)

22(51.16)
21(48.84)
0.63

10(20.41)
39(79.59)

8(22.22)
28(77.78)

6(14.29)
36(85.71)
0.006

11(22.00)
39(78.00)
2.48
(0.81-3.84)

16(43.24)
21(56.76)
2.67
(0.99-6.28)

23(53.49)
20(46.51)
2.48
(1.67-6.05)

2.00
(1.50-4.00)

3.00
(1.33-5.00)

2.00
(1.38-5.00)

0.57

0.93

0.62
23(56.10)
18(43.90)

21(61.76)
13(38.24)

26(66.67)
13(33.33)
0.93
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No
38(76.00)
Yes
12(24.00)
Pregnancy Outcome, n (%)
Live Birth
7(77.78)
Miscarriage
2(22.22)

29(78.38)
8(21.62)

34(79.07)
9(20.93)
0.04

6(85.71)
1(14.29)

2(25.00)
6(75.00)

Total Follow-up
Time, years median
(Q1-Q3)

9.00
(4.25-16.00)

5.00
(3.00-13.00)

8.00
(2.00-15.50)

0.29

Cotinine Levels,
mg/dL median (Q1Q3)

0.00
(0.00-1.00)

4.00
(0.50-9.10)

100.00
(100.0-100.0)

< 0.001

Cotinine mg/dL, n
(%)
0
<4
>= 4

< 0.001
30(63.83)
17(36.17)
0(0.00)

8(22.86)
27(77.14)
0(0.00)

0(0.00)
2(4.76)
40(95.24)

S Table 9: Characteristics of Women from Group 1 Stratified by Type of Follow-up
(None vs Medical Records) (N=95)
No Follow Up
N=21
Age, years,
(mean ± SD)

30.95 ± 7.28

Medical Record
(MR)
N=74
32.35 ± 5.17

BMI, kg/m2, median
(Q1-Q3)

32.20
(29.35-42.89)

30.32
(26.59-35.97)

BMI kg/m2, n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

P-value

0.11

0.42

0.89
3(15.00)

14(18.92)

5(25.00)
12(60.00)

21(28.38)
39(52.70)

Gravidity, n (%)

0.71
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0
1
>=2
Regular Period, n (%)
No
Yes

6(28.57)
7(33.33)
8(38.10)

29(39.19)
21(28.38)
24(32.43)
0.24

11(52.38)
10(47.62)

26(35.14)
48(64.86)

Average Cycle Length,
days, median (Q1-Q3)

28
(26.50-29.75)

29.00
(28.00-30.00)

0.29

Age of Menarche,
(years) median(Q1-Q3)

12(11-13)

12(12-14)

0.11

Previous STD, n (%)

0.70

No
Yes
Marital Status, n (%)
No
Yes
Routine Exercise, n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Black
Other

14(70.00)
6(30.00)

46(62.16)
28(37.84)

10(47.62)
11(52.38)

48(64.86)
26(35.14)

AMH (ng/mL),
median (Q1-Q3)

1.85
(0.67-3.79)

2.77
(1.13-5.45)

0.33

Length of Infertility,
years, median(Q1-Q3)

3.50
(1.50-4.25)

2.00
(1.19-5.00)

0.42

0.31
9(45.00)
11(55.00)

22(29.73)
52(70.27)
0.40

11(57.89)
8(42.11)

31(43.66)
40(56.34)
0.74

11(52.38)
10(47.62)

44(59.46)
30(40.54)
0.39

3(15.00)
17(85.00)

19(25.68)
55(74.32)
0.24

NAT2 Acetylator
Status, n (%)

0.91
Rapid
Slow

9(47.37)
10(52.63)
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34(52.31)
31(47.69)

Pregnant, n (%)

<0.001

No
Yes
Pregnancy Outcome,
n (%)
Miscarriage
Live Birth

21(100.00)
0(0.00)

47(63.51)
27(36.49)

0(0.00)
0(0.00)

12(57.14)
9(42.86)

Cotinine mg/dL,
median (Q1-Q3)

28.00
(2.00-100)

4.00
(1.00-19.75)

Cotinine mg/dL, n (%)
0
<100
100

0.13

0.04
4(19.05)
7(33.33)
10(47.62)

13(18.06)
44(61.11)
15(20.83)

Current, Active Smoker, n (%)
No
11(52.38)
Yes
10(47.62)

0.04
58(78.38)
16(21.62)

Self-reported SHS Exposure, n (%)
Low
8(38.10)
High
13(61.90)

0.35
39(52.70)
35(47.30)

S Table 10: Characteristics of Women from Group 2 Stratified by Type of Followup (None vs Medical Records vs Personal) (N=162)
No Follow Up
N=7

Medical
Record (MR)
only N=35

Personal only
N=120

P-value

Age, years,
median (Q1-Q3)

29.50
(26.00-37.50)

33.00
(26.00-34.00)

33.00
(28.00-37.00)

0.45

BMI, kg/m2, median
(Q1-Q3)

22.80
(20.39-32.73)

28.72
(25.16-34.30)

28.54
(23.62-34.39)

0.58

BMI kg/m2, n (%)

0.25
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<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

4(66.67)

8(22.86)

39(32.50)

0(0.00)
2(33.33)

12(34.29)
15(42.86)

30(25.00)
51(42.50)

Gravidity, n (%)

0.57
0
1
>=2

Regular Period, n (%)
No
Yes

1(16.67)
1(16.67)
4(66.67)

17(48.57)
7(20.00)
11(31.43)

51(42.50)
23(19.17)
46(38.33)
0.36

3(50.00)
3(50.00)

9(25.71)
26(74.29)

43(35.83)
77(64.17)

Average Cycle
Length, days, median
(Q1-Q3)

28.0
(28.00-29.00)

28.5
(28.00-30.00)

28.7
(27.00-30.00)

0.78

Age of Menarche,
(years) median(Q1-Q3)

12
(11.25-12.75)

13
(11.00-13.00)

12.5
(11.00-14.00)

0.75

Previous STD, n (%)
No
Yes
Marital Status, n (%)
No
Yes
Routine Exercise,
n (%)
No
Yes
Alcohol Use, n (%)
No
Yes
Caffeine Use, n (%)
No
Yes
Race, n (%)
Black
Other
AMH (ng/mL),
median (Q1-Q3)

0.04
3(50.00)
3(50.00)

27(77.14)
8(22.86)

63(54.31)
53(45.69)
0.74

2(33.33)
4(66.67)

16(45.71)
19(54.29)

47(39.17)
73(60.83)
0.05

2(33.33)
4(66.67)

16(45.71)
19(54.29)

47(39.17)
73(60.83)
0.03

5(83.33)
1(16.67)

25(71.43)
10(28.57)

60(50.00)
60(50.00)
0.7

0(0.00)
6(100.00)

6(18.18)
27(81.82)

20(16.81)
99(83.19)
0.10

2(33.33)
4(66.67)

27(77.14)
8(22.86)

83(69.17)
37(30.83)

3.85
(3.06-4.65)

2.17
(1.47-3.99)

2.49
(1.27-4.99)
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0.7

Length of Infertility,
years, median(Q1-Q3)
NAT2 Acetylator
Status, n (%)
Rapid
Slow
Pregnant, n (%)
No
Yes
Pregnancy Outcome,
n (%)
Miscarriage
Live Birth
Cotinine mg/dL,
median (Q1-Q3)

1.00
(0.83-1.17)

2.00
(1.00-5.00)

2.00
(1.00-4.88)

0.10

0.1
7(100.00)
0(0.00)

16(45.71)
8(22.86)

76(63.33)
17(14.17)
0.21

7(100.00)
0(0.00)

21(60.00)
14(40.00)

77(64.17)
43(35.83)

0(0.00)
0(0.00)

6(45.15)
7(53.85)

23(58.97)
16(41.03)

0.12

100
(27.3-100)

16.0
(0.00-100)

0.00
(0.00-32.3)

0.52

1(16.67)
1(16.67)
4(66.67)

11(35.48)
10(32.26)
10(32.26)

60(52.63)
27(23.68)
27(23.68)

Cotinine mg/dL,
n (%)
0
<100
100
Current, Active
Smoker, n (%)

<0.001
0.03
0.17

No
Yes
Self-reported SHS
Exposure, n (%)
Low
High

3(42.86)
4(57.14)

25(71.43)
10(28.57)

90(75.00)
30(25.00)
0.10

1(14.29)
6(85.71)

15(42.86)
20(57.14)
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63(52.50)
57(47.50)

S Table 11: Characteristics of Women from Group 2 Stratified by Type of Followup (Medical Records vs Personal) (N=95)

Age, years,
median (Q1-Q3)
BMI, kg/m2, median
(Q1-Q3)
BMI kg/m2, n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)

Medical Record
only N=35
33.00
(26.00-34.00)

Personal only
N=120
33.00
(28.00-37.00)

P-value

28.72
(25.16-34.30)

28.54
(23.62-34.39)

0.71

0.23

0.43
8(22.86)

39(32.50)

12(34.29)
15(42.86)

30(25.00)
51(42.50)

Gravidity, n (%)

0.75
0
1
>=2

17(48.57)
7(20.00)
11(31.43)

51(42.50)
23(19.17)
46(38.33)

Regular Period, n (%)

0.36
No
Yes

9(25.71)
26(74.29)

43(35.83)
77(64.17)

Average Cycle Length,
days, median (Q1-Q3)

28.50
(28.00-30.00)

28.50
(27.00-30.00)

0.5

Age of Menarche,
(years) median(Q1-Q3)

13.00
(11.00-13.00)

12.50
(11.00-14.00)

0.6

Previous STD, n (%)

0.03
No
Yes

27(77.14)
8(22.86)

63(54.31)
53(45.69)

Marital Status, n (%)

0.62
No
Yes

16(45.71)
19(54.29)

47(39.17)
73(60.83)

Routine Exercise, n (%)

0.03
No
Yes

21(61.76)
13(38.24)

44(39.29)
68(60.71)

Alcohol Use, n (%)

0.04
No

25(71.43)
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60(50.00)

Yes

10(28.57)

60(50.00)

Caffeine Use, n (%)

0.8
No
Yes

6(18.18)
27(81.82)

20(16.81)
99(83.19)

Race, n (%)

0.48
Black
Other

27(77.14)
8(22.86)

83(69.17)
37(30.83)

AMH (ng/mL),
median (Q1-Q3)

2.17
(1.47-3.99)

2.49
(1.27-4.99)

0.52

Length of Infertility, years,
median(Q1-Q3)

2.00
(1.00-4.67)

1.5
(0.56-4.00)

0.3

Treatment Cycles, n (%)
0
1
2 and more
NAT2 Acetylator Status,
n (%)
Rapid
Slow
Pregnant, n (%)
No
Yes
Pregnancy Outcome, n (%)
Miscarriage
Live Birth
Cotinine mg/dL, median
(Q1-Q3)

0.17
16(45.71)
8(22.86)
11(31.43)

76(63.33)
17(14.17)
27(22.50)
0.94

20(66.67)
10(33.33)

65(63.73)
37(36.27)
0.8

21(60.00)
14(40.00)

77(64.17)
43(35.83)
0.63

6(46.15)
7(53.85)

23(58.97)
16(41.03)

16.00
(0.00-100)

0.00
(0.00-100)

Cotinine mg/dL, n (%)

0.08

0.23
0
<100
100

1(16.67)
1(16.67)
4(66.67)

71(48.97)
37(25.52)
37(25.52)

Current, Active Smoker,
n (%)
No
Yes

0.84
25(71.43)
10(28.57)
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90(75.00)
30(25.00)

Self-reported SHS Exposure, n (%)
Low
15(42.86)
High
20(57.14)

0.42
63(54.31)
57(47.50)

S Table 12: Characteristics of Women from Group 2 Stratified by Type of Followup (None vs Any) (N=95)
No Follow-Up

Age, years,
median (Q1-Q3)

N=7
29.50
(26.00-37.50)

MR and Personal
Follow-up
N=155
33.00
(27.00-37.00)

BMI, kg/m2, median
(Q1-Q3)

22.8
(20.39-32.73)

28.54
(23.80-34.42)

BMI kg/m2, n (%)
<25 (Underweight and
Normal)
25 - 29.9 (Overweight)
≥ 30 (Obese)
Gravidity, n (%)
0
1
>=2
Regular Period, n (%)
No
Yes

P-value

0.34

0.69

0.15
4(66.67)

47(30.32)

0(0.00)
2(33.33)

42(27.10)
66(42.58)
0.25

1(16.67)
1(16.67)
4(66.67)

68(43.87)
30(19.35)
57(36.77)
0.42

3(50.00)
3(50.00)

52(33.55)
103(66.45)

Average Cycle Length,
days, median (Q1-Q3)

28.00
(28.00-29.00)

28.50
(28.00-30.00)

0.91

Age of Menarche,
(years) median(Q1-Q3)

12.00
(11.25-12.75)

13.00
(11.0-14.0)

0.57

Previous STD, n (%)

0.69
No
Yes

3(50.00)
3(50.00)

Marital Status, n (%)

90(59.6)
61(40.4)
1
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No
Yes

2(33.33)
4(66.67)

63(40.65)
92(59.35)

Routine Exercise, n (%)

1
No
Yes

2(50.00)
2(50.00)

65(44.52)
81(55.48)

Alcohol Use, n (%)

0.23
No
Yes

5(83.33)
1(16.67)

85(54.84)
70(45.16)

Caffeine Use, n (%)

0.59
No
Yes

0(0.00)
6(100.00)

26(17.11)
126(82.89)

Race, n (%)

0.07
Black
Other

2(33.33)
4(66.67)

110(70.97)
45(29.03)

AMH (ng/mL),
median (Q1-Q3)

3.85
(3.06-3.85)

2.48
(1.33-4.94)

0.59

Length of Infertility, years,
median(Q1-Q3)

0.83
(0.04-1.08)

1.75
(0.67-4.00)

0.04

NAT2 Acetylator Status,
n (%)
Rapid
Slow
Pregnant, n (%)
No
Yes
Cotinine mg/dL,
median (Q1-Q3)

0.1
6(100.00)
0(0.00)

85(64.39)
47(35.61)
0.05

7(100.00)
0(0.00)

98(63.23)
57(36.77)

100
(27.25-100)

0.50
(0.00-100)

Cotinine mg/dL, n (%)

0.05

0.1
0
<100
100

1(16.67)
1(16.67)
4(66.67)

71(48.97)
37(25.52)
37(25.52)

Current, Active Smoker,
n (%)

0.09
No
Yes

3(42.86)
4(57.14)
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115(74.19)
40(25.81)

Self-reported SHS
Exposure, n (%)

0.12
Low
High

1(14.29)
6(85.71)
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78(50.32)
77(49.68)
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